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SUMMARY 
 
A. Behavioral analysis of P301L tau transgenic mice 
 
Background: Of all forms of human dementias, Alzheimer’s disease (AD) is the most 
prevalent. It is characterized by extracellular β-amyloid-containing (Aβ) plaques, intracellular 
neurofibrillary tangles (NFT) composed of hyperphosphorylated tau aggregates, reduced 
synaptic density and neuronal loss, which leads to a progressive deterioration of memory 
and other cognitive functions. NFT are also abundant, in the absence of amyloid plaques, in 
additional neurodegenerative diseases such as frontotemporal dementia with Parkinsonism 
linked to chromosome 17 (FTDP-17), where mutations have been identified in the tau gene, 
establishing that tau dysfunction alone can cause neurodegeneration and lead to dementia.  
 
Results: The transgenic mice used in my study overexpress the FTDP-17 associated 
mutation P301L of tau and form tau aggregates in many brain areas including the hippocam-
pus and the amygdala, both of which are characterized by NFT formation in the human dis-
ease state. To detect early signs of tau aggregate-associated changes, I investigated in a 
first set of experiments behavioral alterations and cognitive deficits in six months old trans-
genic mice on a mixed background (B6D2F1) using an amygdala-specific test battery. At this 
age, NFT formation is initiated in the amygdala, a brain area involved in mediating effects of 
emotion (fear, exploration) on learning and memory and in the validation of primarily negative 
events. Next, to determine whether tau aggregation, in the absent of NFT formation, is suffi-
cient to cause deficits in hippocampus-dependent behavior, I assessed in a second set of 
experiments six and eleven months old P301L mice backcrossed onto a C57Bl/6 background 
in a hippocampus-specific test battery.  
I found that P301L mice had anxiety levels not different from wild-types, but their exploratory 
behavior was significantly increased as evidenced by several tasks. The disinhibition of ex-
ploratory behavior was independent of the background of the mice and was even more pro-
nounced during aging, indicating that this effect is due to the presence of the tau transgene. 
Amygdala-specific tests revealed no impairment in the acquisition of a fear response to tone 
and context and in the acquisition and consolidation of a conditioned taste aversion (CTA). 
However, extinction of the CTA memory was significantly accelerated in the P301L mice. 
Next, I determined the distribution of P301L tau in more detail with special emphasis on brain 
areas shown to be involved in CTA. The aggregation pattern of tau was consistent with the 
behavioral outcome: Tau aggregates were present in the basolateral nucleus of the amyg-
dala (BLA), which has been shown to be essential for extinction of CTA memory, whereas 
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acquisition of a CTA is dependent on an intact central nucleus, where no tau aggregates 
were found.  
Moreover, tau aggregation, in the absence of overt NFT formation, caused deficits in spatial 
reference memory in the water maze at both ages tested. However, due to a floor effect as 
evidenced by a poor performance of the aged wild-type control group during the probe trial, a 
significant difference compared to the wild-type group was only seen at six months of age. 
No impairment was found in acquisition and reversal learning in the water maze and in spa-
tial working memory as assessed by spontaneous alternation behavior in the Y-maze.  
 
Significance: Together, these data suggest that expression of P301L tau in transgenic mice, 
not yet accompanied by massive NFT formation, causes selective behavioral deficits that are 
correlated with the regional distribution of tau aggregates in distinct subnuclei of the amyg-
dala. The correlation of NFT as a disease hallmark with the behavioral outcome is an impor-
tant measure of the validity of our transgenic mice as an animal model for the tau pathology 
in AD and related disorders. 
 
B. Role of different phospho-epitopes and cleavage sites in tau filament 
formation in tissue culture 
 
Background: Despite extensive research, the relationship between Aβ and tau and their 
relative contribution to the clinical features of AD is still unknown. Recently, our group dem-
onstrated pathological interactions between these two hallmarks. Using P301L mice stereo-
taxically injected with Aβ42 fibrils, enhanced NFT formation was achieved that was tightly cor-
related with the pathological phosphorylation of tau at the phospho-epitopes Ser-422 and 
AT100 (Thr-212/Ser-214) (Gotz et al., 2001b). Furthermore, using tau overexpressing human 
SH-SY5Y neuroblastoma cells exposed for five days to pre-aggregated Aβ42, tau-containing 
filaments formed and a decreased tau solubility was observed, both of which were prevented 
by mutating the Ser-422 phospho-epitope (Ferrari et al., 2003).  
 
Results: To confirm the previous in vitro findings and to map further phospho-epitopes 
and cleavage sites of tau involved in the Aβ-mediated decrease in tau solubility and tau fila-
ment formation, I generated several tau mutant and wild-type (wt) constructs and expressed 
them in SH-SY5Y neuroblastoma cells. 
Adding pre-aggregated Aβ42 to differentiated wt-tau overexpressing SH-SY5Y cells led to a 
more than 15-fold increase in Aβ-mediated tau insolubility compared to PBS-treated cells, 
whereas mutating distinct phospho-epitopes of tau with a proclaimed role in human disease 
(the AT8-epitope pSer-202/pThr-205, pThr-231 and pSer-422) prevented the decrease in tau 
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solubility, indicating an interplay of different epitopes in tau filament formation. In addition, 
truncation of the carboxy-terminal region of tau at the caspase cleavage-site (position 421) 
prevented the Aβ42-mediated decrease in tau solubility in our tissue culture system. This indi-
cates that truncation is not an initial step in filament formation, but rather a subsequent event. 
 
Significance: I could show that the Aβ-mediated increase in tau insolubility depends on the 
interplay of distinct phospho-epitopes of tau and not only on phosphorylation of the Ser-422 
epitope. This novel tau-overexpressing tissue culture system is a useful tool to study aspects 
of AD and related disorders. Further adaptation of the in vitro model, such as the use of an 
inducible expression system (which I have also initiated), is likely to provide mechanistic in-
sight into tauopathies and may allow the screening and validation of compounds designed to 
prevent filament formation. 
Zusammenfassung 
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ZUSAMMENFASSUNG 
 
A. Verhaltensanalyse von P301L Tau transgenen Mäusen 
 
Hintergrund: Die Alzheimerkrankheit (AD) ist die häufigste Demenzerkrankung beim 
Menschen. Sie ist gekennzeichnet durch extrazelluläre β-Amyloid (Aβ) Plaques, intrazelluläre 
neurofibrilläre Bündel (NFT), die im Wesentlichen aus dem hyperphosphoryliertem Protein 
Tau bestehen, und neuronalen Zell- und Synapsenverlust, welcher durch einen kontinuierli-
chen Verlust des Gedächtnisses und anderer kognitiver Funktionen klinisch begleitet ist. 
Neurofibrilläre Bündel ohne eine Amyloid-Pathologie lassen sich auch in weiteren neurode-
generativen Demenzerkrankungen finden, zu denen auch die mit Chromosom 17 assoziierte 
frontotemporale Demenz mit Parkinsonismus (FTDP-17) zählt. Die Identifizierung von Muta-
tionen im Tau-Gen bei FTDP-17 Patienten erbrachte den formellen Beweis, dass auch eine 
Fehlfunktion von Tau selbst zu Neurodegeneration und Demenz führen kann.  
 
Resultate: Die transgenen Mäuse, welche ich in meinen Studien untersucht habe, über-
exprimieren die FTDP-17 Taumutation P301L und zeigen filamentöse Ablagerungen des 
Tau-Proteins in vielen Hirnarealen, darunter im Hippocampus und in der Amygdala (Mandel-
kern). In diesen beiden Hirnarealen findet man beim Alzheimerpatienten sehr früh eine NFT-
Pathologie. Um frühe tauaggregatbedingte Verhaltensänderungen und kognitive Defizite 
aufzeigen zu können, habe ich sechs Monate alte Mäuse auf einem gemischten genetischen 
Hintergrund (B6D2F1) in einem ersten Set von Experimenten in einer Amygdala-spezifischen 
Testbatterie untersucht. In diesem Alter werden die ersten NFT in der Amygdala gebildet, ein 
Hirnareal, das die Steuerung von Emotionen (Angst, Exploration) reguliert und eine Verhal-
tensbewertung von vornehmlich negativen Ereignissen vornimmt. Als nächstes habe ich, um 
zu untersuchen ob Tau Aggregation ohne die Ausbildung von NFT ausreichend ist um Defizi-
te im Hippocampus-abhängigem Verhalten (Gedächtnistests) zu bewirken, in einem zweiten 
Set von Experimenten sechs und elf Monate alte P301L Mäuse, die wir auf den C57Bl/6 
Stamm zurückgekreuzt hatten, in einer Hippocampus-spezifischen Testbatterie untersucht. 
Ich konnte in verschiedenen Tests aufzeigen, dass P301L Mäuse eine kaum veränderte 
Ängstlichkeit verglichen mit Wildtyp-Mäusen besassen, wohl aber ein signifikant verstärktes 
Explorationsverhalten zeigten. Die Enthemmung des Explorationsverhaltens war unabhängig 
vom genetischen Hintergrund und verstärkte sich mit dem Alter, was darauf hindeutet, dass 
dieser Effekt auf das Tautransgen zurückzuführen ist. Amygdala-spezifische Tests zeigten 
keine Beeinträchtigung in der Angst-Konditionierung gegenüber Ton und Kontext und in der 
Erfassung und Konsolidierung einer Geschmacksaversion (CTA). Hingegen war die Extinkti-
on dieser konditionierten Geschmacksaversion in den transgenen Mäusen signifikant be-
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schleunigt. Anschliessend überprüfte ich die Verteilung von P301L Tau etwas eingehender 
mit dem Hauptaugenmerk auf Hirnareale, welche bei der CTA eine Rolle spielen. Das Ag-
gregationsmuster von Tau stimmte mit dem Verhalten überein: Tauaggregate waren im ba-
solateralen Nukleus der Amygdala präsent, der eine zentrale Bedeutung in der Extinktion 
des CTA-Gedächtnisses besitzt, während der Erwerb einer CTA von einem intakten zentra-
len Nukleus abhängig ist, wo keine Tauaggregate gefunden wurden. 
Überdies konnte ich zeigen, dass eine Tau Aggregation ohne augenfällige NFT-Bildung aus-
reichend war um Defizite im räumlichen Referenzgedächtnis (spatial reference memory) im 
Wasserlabyrinth bei beiden getesteten Altersstufen hervorzurufen. Aufgrund eines schlech-
ten Leistungsverhaltens der älteren Wildtyp-Kontrollgruppe während des Testdurchgangs 
konnte ein signifikanter Unterschied zu den Wildtyp Mäusen nur im Alter von sechs Monaten 
aufgezeigt werden. 
Keine Defizite wurden beim Erlernen und beim Umkehrlernen der Plattformposition im Was-
serlabyrinth aufgezeigt, ebenso im Y-Labyrinth, wo das räumliche Arbeitsgedächtnis (spatial 
working memory) über spontanes Alternationsverhalten getestet wurde.  
 
Signifikanz: Zusammengefasst deuten diese Daten daraufhin, dass die Expression von 
P301L Tau in den transgenen Mäusen zu einem Zeitpunkt, der noch nicht durch eine massi-
ve NFT Bildung gekennzeichnet ist, selektive Verhaltensdefizite hervorruft, die mit dem Ex-
pressionsmuster von Tau in unterschiedlichen Amygdalakernen übereinstimmen. Der Zu-
sammenhang zwischen NFT als einem Krankheitsmerkmal und dem Verhalten ist ein wichti-
ger Massstab für die Validierung unserer transgenen Mäuse als Tiermodel für die Taupatho-
logie bei Alzheimer und verwandten Erkrankungen. 
 
B. Funktion verschiedener Phosphoepitope und Spaltungsstellen bei der 
Bildung von Taufilamenten in Zellkultur 
 
Hintergrund: Trotz umfassender Forschungen ist der genaue Zusammenhang zwischen 
Aβ und Tau und der jeweilige Beitrag zur Pathologie immer noch unklar. Kürzlich hat unsere 
Gruppe einen pathophysiologischen Zusammenhang zwischen diesen zwei Proteinen de-
monstriert. Durch stereotaktische Injektionen von fibrillärem Aβ in die Hirne von P301L Tau 
transgenen Mäusen konnte eine verstärkte NFT-Bildung aufgezeigt werden, die mit einer 
Phosphorylierung der Tauepitope Ser-422 und AT100 (Thr-212/Ser-214) einher ging (Gotz et 
al., 2001b). Desweiteren konnte durch eine fünftägige Inkubation Tau überexprimierende 
humaner SH-SY5Y Neuroblastomzellen mit Aβ-Fibrillen die Bildung von Taufilamenten und 
eine verminderte Löslichkeit von Tau erzielt werden. Diese wurde durch die Mutation des 
Ser-422 Epitopes verhindert (Ferrari et al., 2003). 
Zusammenfassung 
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Resultate: Um die früheren in vitro Ergebnisse zu bestätigen und die Rolle von zusätzli-
chen Phosphorylierungs- und Spaltungsstellen von Tau in der Aβ-bedingten Unlöslichkeit 
von Tau und der Filamentbildung zu untersuchen, habe ich verschiedene Taumutanten und 
Wildtypkonstrukte erzeugt und diese in SH-SY5Y Neuroblastomzellen überexprimiert.  
Die Zugabe von Aβ-Fibrillen zu differenzierten Wildtyp Tau überexprimierenden SH-SY5Y 
Zellen führte zu einer mehr als 15-fachen Zunahme in der Aβ-bedingten Unlöslichkeit von 
Tau verglichen mit PBS behandelten Zellen, wohingegen durch Mutation unterschiedlicher 
Phosphoepitope von Tau mit einer bekannten Rolle bei der menschlichen Erkrankung (wie 
das AT8-Epitop pSer-202/pThr-205, pThr-231 und pSer-422) die Abnahme in der Löslichkeit 
von Tau verhindert wurde, was auf ein Zusammenspiel verschiedener Epitope in der Taufi-
lamentbildung hindeutet. Ähnlich wie bei den Phospho-Mutanten wurde durch das Entfernen 
des carboxy-terminalen Teils von Tau an der putativen Caspase-3 Schnittstelle (Position 
421) die Aβ bedingte Verringerung der Taulöslichkeit in unserem Zellkultursystem verhindert. 
Dies deutet daraufhin, dass der Spaltungsvorgang kein initialer Schritt in der Filamentbildung 
darstellt, sondern eher nach Bildung der Filamente erfolgt. 
 
Signifikanz: Ich konnte aufzeigen, dass der Aβ-bedingte Anstieg in der Unlöslichkeit von 
Tau vom Zusammenwirken mehrerer Phosphoepitope abhängig ist und nicht nur vom Ser-
422-Epitop alleine. Unser neues Tau-überexprimierendes Zellkultursystem stellt ein geeigne-
tes Werkzeug dar, um Aspekte von Alzheimer und verwandter Erkrankungen in vitro zu un-
tersuchen. Durch weitere Anpassungen dieses Models, zum Beispiel durch Einsatz eines 
induzierbaren Expressionssystems (das ich ebenfalls gestartet habe), dürfte es möglich sein, 
bessere Einblicke in die Entstehung von Tauopathien zu gewinnen und therapeutische An-
sätze und Präparate zu testen, um die Bildung von Taufilamenten zu verhindern. 
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1 INTRODUCTION 
 
1.1 Alzheimer’s Disease (AD) 
 
Of all forms of dementias, Alzheimer’s disease (AD) is the most prevalent one. This disease 
was first described by the German physician Alois Alzheimer almost 100 years ago 
(Alzheimer, 1907). In the last decades, the numbers of AD patients have risen, as the relative 
numbers of old people in the population have increased. Approximately 8 % of the people 
over 65 years are affected by AD. This number rises to about 30 % in people older than 85 
years (Hebert et al., 2003).  
AD is characterized by a well-defined neuropathological profile which includes extracellular 
β-amyloid-containing plaques, intracellular neurofibrillary tangles (NFT) of hyperphosphory-
lated tau protein, reduced synaptic density and neuronal loss in selected brain areas. The 
most severe neuropathological changes occur in the hippocampal formation, the association 
cortices and subcortical structures, including the amygdala and the nucleus basalis of 
Meynert (Arnold et al., 1991). AD is described by cognitive and memory deterioration, pro-
gressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms 
and behavioral disturbances (deterioration of language, visuospatial deficits, motor and sen-
sory abnormalities and gait disturbances) (Cummings, 2004). As the disease advances, pa-
tients become incontinent, bedridden and unable to feed themselves. The disease course 
ranges from 2 to 15 years from the onset of symptoms until death, which occurs typically 
from pneumonia, upper respiratory infections or nutritional disorders.  
 
 
1.2 Histopathology 
 
1.2.1 β-amyloid plaques and Aβ processing 
 
The major proteinaceous component of the extracellular plaques is a 40-42 amino acid poly-
peptide termed Aβ (Aβ40 and Aβ42), which is derived by proteolysis from the larger amyloid 
precursor protein APP (Glenner and Wong, 1984; Masters et al., 1985) (Fig. 1.1). APP un-
dergoes several endoproteolytic cleavage events. One of these events results from the activ-
ity of the membrane-associated α-secretase, which cleaves APP within the Aβ domain (Esch 
et al., 1990). This pathway is non-amyloidogenic, as this cleavage precludes the formation of 
Aβ. Alternatively, cleavage may occur in the endosomal-lysosomal pathway, first by the β-
secretase and then by the γ-secretase which together generates the Aβ-peptide. The latter 
involves an unusual form of proteolysis in which the protein is cleaved within the transmem- 
1 INTRODUCTION 
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Fig. 1.1 Schematic overview of APP processing. (A) APP is a type I integral membrane protein with a large extra- 
and a short intracellular domain. (B) Cleavage by α-secretase within the Aß domain leads to secretion of the 
soluble APPα and prevents the formation of Aß-fragments (non-amyloidogenic pathway). The C-terminal stub 
C83 is processed further by γ-secretase releasing the p3 peptide. (C) Cleavage of APP in the endosomal-
lysosomal pathway by ß-secretase enables the secretion of APPß. Processing of C99 by γ-secretase leads to the 
release of the Aß-peptides.  
 
 
brane domain. Further, the cleavage-site of the γ-secretase is critical as it dictates the length 
of the peptide, with Aβ40 being the most common species (around 90%), but Aβ42 the more 
fibrillogenic and neurotoxic species (Sisodia and St George-Hyslop, 2002). β-secretase activ-
ity has been attributed to a single protein, BACE, whereas γ-secretase activity was shown to 
depend on the presence of a total of four components: presenilin (PS), nicastrin, APH-1 and 
PEN-2 (Edbauer et al., 2003; Vassar et al., 1999).  
The precise physiological role of APP is still unknown, however, an involvement in the devel-
oping nervous system is likely. Furthermore, the transmembrane structure of APP indicates a 
role as either a receptor or a mediator of extracellular signalling (Kerr and Small, 2005), 
whereas the cytoplasmic domain may act as a transcription factor regulating gene expres-
sion (Cao and Sudhof, 2001). 
Likewise, the mechanism of Aβ toxicity is unclear, but it may involve aberrant microglial acti-
vation (Roher et al., 1996), induction of apoptosis (Loo et al., 1993), increased ER and oxida-
tive stress (Barnham et al., 2004; Behl et al., 1994; Nakagawa et al., 2000), activation of ion 
channels and disruption of intracellular calcium homeostasis (Mattson et al., 1992), leading 
to synaptic dysfunction.  
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1.2.2 Tau and NFTs 
 
The second histopathological hallmark of AD are the neurofibrillary lesions that are found in 
cell bodies and apical dendrites as NFT, in distal dendrites as neuropil threads, and in the 
abnormal neurites that are associated with some β-amyloid plaques (neuritic plaques). Their 
major proteinaceous components are abnormal filaments which are termed either straight 
(SF) or paired helical filaments (PHF) (Crowther and Wischik, 1985; Wischik et al., 1985). 
The core protein of these filaments is the microtubule-associated protein tau (Goedert et al., 
1988) that is widely expressed in the mammalian nervous system, but other non-neuronal 
cells, like astrocytes and oligodendrocytes, also express tau although at lower levels. The 
major function of tau is to regulate the stability and assembly of microtubules, and thus plays 
an important role in axonal transport and organization of the actin cytoskeleton. Additional 
functions have been assigned to tau in signal transduction and anchoring of phosphatases 
and kinases (Anderton et al., 2000; De et al., 2000; Ebneth et al., 1998; Flanagan et al., 
1997; Jenkins and Johnson, 1998; Lee and Rook, 1992; Maas et al., 2000; Morishima-
Kawashima and Kosik, 1996; Reszka et al., 1995; Sontag et al., 1999).  
In the adult human brain, six tau isoforms are produced by alternative mRNA splicing of ex-
ons 2, 3, and 10 from a single gene located on chromosome 17q21 (Goedert et al., 1988; 
Goedert et al., 1989) (Fig 1.2). They differ by the presence or absence of one or two short 
inserts in the amino-terminal half (exon 2 and 3), and have either three or four microtubule-
binding repeat motifs in the carboxy-terminal half (3R and 4R). At the protein level, the iso-
forms ranging from 352 to 441 amino acids, with apparent molecular weights between 45 to 
65 kDa on a SDS-PAGE. All six brain tau isoforms are found in neurofibrillary lesions of AD 
patients (Goedert et al., 1992). Tau mRNA splicing is developmentally regulated and in the 
fetal brain only the shortest 3R-tau isoform is expressed (Goedert et al., 1989). In addition, 
tau from fetal brain is phosphorylated at more sites than tau from adult brain, implying regula-
tion during brain maturation. In general, tau is a phosphoprotein already under physiological 
conditions. The sequence of the protein is rich in serines and threonines followed by prolines 
(so-called SP/TP sites), and in tyrosines (Chen et al., 2004a). In the course of the disease, 
tau becomes hyperphosphorylated, which means that the protein is phosphorylated to a 
higher degree at physiological sites, and at additional “pathological” sites (Augustinack et al., 
2002; Buee et al., 2000). Phosphorylation tends to dissociate tau from microtubules. Since 
this increases the soluble pool of tau it might be an important first step in the assembly of tau 
filaments (Buee et al., 2000; Chen et al., 2004a; Goedert et al., 1995; Gotz, 2001; Gotz et al., 
2004b; Lee et al., 2001; Lichtenberg et al., 1988; Schweers et al., 1994). Hyperphosphory-
lated tau also displays a reduced electrophoretic mobility due to its increased phosphoryla-
tion state and has a lower range of pI values, indicating a more negatively charged, acidic 
character than normal tau (Hanger et al., 1991; Ksiezak-Reding et al., 1990). 
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Fig. 1.2 Mutations in the tau gene and alternative splicing. (A) In FTDP-17, the majority of the exonic mutations 
are clustered around the microtubule-binding domain (exons 9-12). The intronic mutations are indicated by the 
predicted stem-loop pre-mRNA structure at the junction between exon 10 and the following intron. (B) In the adult 
human brain six tau isoforms are produced by alternative mRNA splicing of exons 2, 3 and 10. They differ by the 
presence or absence of one or two short inserts in the N-terminal part, and have either three or four microtubule-
binding repeat motifs in the C-terminal half.  
 
 
Furthermore, to aggregate into filaments, tau undergoes a shift from a natively unfolded or 
random coiled conformation to a more compact state and is relocalized from axonal to soma-
todendritic compartments (Mandelkow et al., 1996; Schweers et al., 1994). One of the first 
alterations, which is found already in pretangle neurons but persists in NFT-containing neu-
rons, is the folding of the amino terminal portion of the tau molecule which binds to the third 
microtubule-binding domain. This conformation is known as the “Alz50 state”, as it is specifi-
cally recognized by the monoclonal antibody Alz50 (Carmel et al., 1996). Another conforma-
tional change is revealed by the monoclonal antibody TG3 raised to PHFs from AD brain 
homogenates recognizing a conformation-dependent phospho-epitope of tau at position Thr-
231 (Jicha et al., 1997). Further alterations in the conformation of tau are detected during 
tangle evolution including various truncation events at both the amino- and carboxy termini 
(Binder et al., 2005). In addition, posttranslational modifications of tau other than phosphory-
lation were described as well, which may occur either before of after filament formation 
(Buee et al., 2000; Chen et al., 2004a).  
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1.3 AD-causing mutations 
 
The existence of early-onset familial forms of AD (FAD) allowed the identification of causa-
tive genes and key proteins, the elucidation of pathogenic mechanisms, and the develop-
ment of transgenic animal models (see below under 1.5). In FAD, pathogenic mutations have 
been identified in either the APP gene itself or in the genes encoding presenilin 1 and 2 as a 
part of the γ-secretase complex (Sherrington et al., 1995; Van Broeckhoven et al., 1992).  
The first missense mutation in FAD families was found in the APP gene of a British family in 
1991 (V717I, the so-called “London mutation”) (Goate et al., 1991). Since then, more than 20 
pathogenic mutations have been identified in the APP gene. Immediately upstream of the Aβ 
domain, the most famous mutation was discovered in a Swedish FAD family, consisting in a 
double base pair substitution (K670D/M671L “Swedish mutation”) (Mullan et al., 1992). The 
Swedish mutation leads to enhanced cleavage through β-secretase and thereby to increased 
Aβ formation, whereas the London mutation (and other pathogenic mutations at the same 
position) lead to an increased proportion of Aβ42 being produced and secreted.  
80% of FAD cases are caused by mutations in PS1 (> than 120) and PS2 (only 8 mutations 
to date). In FAD, most missense mutations in presenilins lead to an increased production of 
the more fibrillogenic Aβ42 over Aβ40 (Sinha and Lieberburg, 1999). 
Although FAD-mutations are estimated to account for less than 1% of the total number of AD 
cases (Delacourte et al., 2002), the histopathological hallmarks are indistinguishable when 
FAD is compared with sporadic AD (SAD). For these, a complex etiology has been reported 
that is due to environmental conditions and susceptibility genes. These genetic factors act as 
predisposing agents and increase the risk of getting the disease. However, of the two dozen 
genes identified until today, only the apolipoprotein E (ApoE) gene, a regulator of lipid me-
tabolism, has been confirmed unanimously as a risk gene and found to be associated with 
SAD (Rocchi et al., 2003). Further studies are required to confirm the definite role of other 
genes in AD. 
 
 
1.4 Therapeutic strategies and Anti-Aβ vaccination 
 
Currently, there is no cure for AD available. The main efforts in the development of treatment 
strategies for AD focus on the prevention of Aβ production and aggregation or downstream 
neurotoxic events. β- and γ-secretases are attractive drug targets of the pharmaceutical in-
dustry (Lahiri et al., 2003). However, a major problem in drug development arises from the 
finding that APP is not the only substrate of these secretases. Other approaches aim to block 
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the assembly of Aβ using β-sheet breakers (Soto et al., 1998) or lowering zinc levels, as zinc 
can form complexes with Aβ (Cherny et al., 2001).  
Since ApoE has been confirmed as a risk gene in SAD, it is reasonable to assume that lipids 
such as cholesterol are involved in the pathogenesis of AD. Recent epidemiological and bio-
chemical studies have strengthened this assumption by demonstrating an association be-
tween cholesterol and AD (Puglielli et al., 2003). Other available drugs like NMDA-
antagonists (memantine) or cholinesterase inhibitors (donepezil) only alleviate the symptoms 
but are ineffective against cognitive decline over time (Cummings, 2004).  
As transgenic animal models provided evidence that both active and passive Aβ immuniza-
tion can reduce cognitive dysfunction in APP transgenic mouse models without any side ef-
fects (Schenk et al., 1999), an immunization trial was initiated in humans. In 2001, a phase 
IIa clinical trial was started in a multicenter placebo-controlled double-blind design where 
patients received a pre-aggregated synthetic Aβ42 preparation (AN-1792 vaccine) (Schenk, 
2002). However, the clinical trial was halted in January 2002 when four patients who had 
received the vaccine developed signs of subacute meningoencephalitis (Check, 2002; Sen-
ior, 2002). 
A follow-up study from the Zurich center demonstrated that ~80% of their patients developed 
specific antibodies against Aβ which did not cross-react with human full-length APP. These 
antisera stained Aβ plaques on brain slices of APP transgenic mice and post-mortem brain 
sections from AD patients (Hock et al., 2002). The specific immune reaction against Aβ was 
still stable after one year. Moreover, this immune reaction showed a significant correlation 
with slowed cognitive decline (Hock et al., 2003). Together, these results indicate that vacci-
nation against Aβ might be a potential treatment for AD, provided that a safe treatment mo-
dality can be introduced. Concurrently, it is important to note that immunization against Aβ 
does not seem to remove NFT pathology as shown in postmortem studies of three vacci-
nated patients (Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2003). 
 
 
1.5 FTDP-17 and other tauopathies 
 
No mutations have been identified in the tau gene in AD until today. In addition to AD, NFT 
are also found in the presence of either no or only scant amyloid plaques in additional neu-
rodegenerative diseases, collectively termed tauopathies. They include diseases as diverse 
as Pick’s disease (PiD) (Delacourte et al., 1998; Hof et al., 1994), progressive supranuclear 
palsy (PSP) (Bergeron et al., 1997), corticobasal degeneration (CBD) (Bugiani et al., 1999), 
pallido-ponto-nigral degeneration (Yasuda et al., 1999), subcortical gliosis (Goedert et al., 
1999b), and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-
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17). In contrast to AD, where hyperphosphorylated tau forms filaments only in neurons, in 
PSP and CBD they also form abundantly in glial cells (Bergeron et al., 1997; Chin and Gold-
man, 1996; Komori, 1999).  
In 1998, exonic and intronic mutations were identified in the tau gene in patients with FTDP-
17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998), establishing that tau dys-
function alone can cause neurodegeneration and lead to dementia. Most mutations identified 
so far are located in or near the microtubule-binding region in the carboxy-terminal half of the 
tau protein, suggesting that it is a hot spot of disease-causing mutations (Fig. 1.2). Mutations 
in exons 9 and 11-13 (such as G272V or R406W) affect all six tau isoforms. By contrast, mu-
tations in exon 10 (such as P301L) only affect 4R tau isoforms. In vitro studies have demon-
strated that the majority of the exonic mutations disrupt tau-microtubule interactions, reduc-
ing the ability of tau to promote microtubule assembly (D'Souza et al., 1999; Goedert et al., 
1999a; Hasegawa et al., 1998; Nacharaju et al., 1999).  
The intronic mutations are located close to the splice-donor site of the intron that follows the 
alternatively spliced exon 10, all destabilizing a potential stem-loop structure which is in-
volved in regulating the alternative splicing of exon 10 (Fig. 1.2). This causes a more fre-
quent usage of the 5' splice site and an increased proportion of tau transcripts that include 
exon 10, thereby disrupting the normal balance between three-repeat and four-repeat tau 
isoform expression (4R>3R) (Grover et al., 1999; Hutton et al., 1998; Poorkaj et al., 1998; 
Spillantini et al., 1998; Varani et al., 1999).  
Depending on the brain area affected by neuronal loss, the clinical phenotype in FTDP-17 
patients can differ with variable cognitive and behavioral features (Kramer et al., 2003). Of-
ten, the clinical feature of FTDP-17 includes initial personality changes, disinhibition, loss of 
initiative or apathy and psychiatric manifestations, as well as stereotypical behavior (Neary et 
al., 1998). Neuropsychological changes include short-term memory, attention and concentra-
tion (Bird et al., 1999; Mirra et al., 1999; Reed et al., 1997; Sumi et al., 1992; van Swieten et 
al., 1999). 
 
 
1.6 Animal models of tauopathies 
 
1.6.1 APP transgenic mouse models 
 
Several APP and PS transgenic mouse models have been generated over the past several 
years (for review, see (Ashe, 2001; Gotz et al., 2004b)). In the APP single transgenic mice a 
role for Aβ could be demonstrated in progressive plaque formation, synaptic loss, gliosis and 
memory deficits which progressed with ageing. Transgenic co-expression of mutant prese-
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nilins and mutant APP enhanced the histopathological and behavioral phenotype compared 
with APP single transgenic mice. These models are suited to test therapeutic strategies 
aimed at reducing Aβ levels and behavioral impairment associated with Aβ (see also 1.4). 
However, although these models contributed enormously to a better understanding of the 
pathogenesis of AD, they have their limitations. They do not show massive nerve cell death, 
with the exception of some motor neurons, nor do they develop NFT, the second hallmark of 
AD. To address the role of NFT-formation tau transgenic models has been developed. 
 
1.6.2 Tau transgenic mouse models 
 
The first tau transgenic model was established in 1995 (Table 1.1), by expressing the longest 
human 4R brain tau isoform, without a pathogenic mutation, under control of the hThy1 pro-
moter for neuronal expression (Gotz et al., 1995). Despite the lack of NFT pathology, these 
mice modeled aspects of human AD, such as somatodendritic localization and tau hyper-
phosphorylation and, therefore, represented an early pre-NFT phenotype. The use of 
stronger promoters to drive transgene expression caused a more pronounced phenotype 
(Ishihara et al., 1999; Probst et al., 2000; Spittaels et al., 1999). However, despite the de-
creased solubility of tau as the mice became older, NFT did not form, unless the mice 
reached a very old age (Ishihara et al., 2001). Taken together, these findings demonstrated 
that overexpression of human wild-type tau can lead to an axonopathy resulting in nerve cell 
dysfunction and amyotrophy (Gotz, 2001; Gotz et al., 2004b).  
With the identification of mutations in tau, several groups created transgenic models express-
ing different tau mutations (Table 1.1). NFT formation was achieved both in neurons (Allen et 
al., 2002; Gotz et al., 2001a; Lewis et al., 2000; Tanemura et al., 2001; Tatebayashi et al., 
2002) and in glial cells of transgenic mice (Forman et al., 2005; Gotz et al., 2001c; Higuchi et 
al., 2002). The P301L mutation was one of the first FTDP-17 mutations which had been iden-
tified in human patients (Hutton et al., 1998). This mutation was shown in vitro to cause both 
an accelerated aggregation of tau into filaments and a marked reduction in the ability of tau 
to promote microtubule assembly (Barghorn et al., 2000; Hasegawa et al., 1998; Nacharaju 
et al., 1999). The P301L mutation is also quite frequent (Sobrido et al., 2003), and therefore, 
this made it a fitting choice to be expressed in transgenic mice.  
When a human tau isoform lacking the two amino-terminal inserts was expressed together 
with the P301L mutation under control of the murine PrP promoter, 90% of the mice devel-
oped severe motor and behavioral disturbances by 10 months of age (Lewis et al., 2000). 
Importantly, NFT were identified in brain and spinal cord, and motor neurons were reduced 
twofold in spinal cord. The same mutation was expressed using the longest human tau iso-  
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Table 1.1: List of tau transgenic mouse models 
muta-
tion 
strain name 
(genetic 
background) 
pro-
moter 
tau 
isoform 
Neurological characteristics Refer-ence 
wild-
type 
ALZ7 
(B6D2F1) 
hThy1 4R-tau (2N) 
Early pre-NFT phenotype: Somatodendritic localization 
and hyperphosphorylation of tau, but no NFT. 
(Gotz et al., 
1995) 
wild-
type 
TG23 
(C57Bl/6 x 
CBA-F2) 
mHMG-
CoAR 
3R-tau 
(0N) 
Early pre-NFT phenotype: Somatodendritic localization 
and hyperphosphorylation of tau, but no NFT. 
(Brion et al., 
1999) 
wild-
type 
htau44 
(B6D2F1) 
mPrP 3R-tau (0N) 
Accumulation of intraneuronal filamentous inclusions of 
insoluble, hyperphosphorylated tau, profound astrocytosis 
and axonal degeneration, but no NFT. 
(Ishihara et 
al., 1999) 
wild-
type 
htau40 
(FVB) 
mThy1.2 4R-tau (2N) 
Axonal degeneration in brain and spinal cord, astrogliosis 
and ubiquitination in accumulated proteins of dilated ax-
ons. 
(Spittaels et 
al., 1999) 
wild-
type 
ALZ17 
(B6D2F1) 
mThy1.2 4R-tau (2N) 
Somatodendritic staining for hyperphosphorylated tau, and 
prominent axonopathy. 
(Probst et al., 
2000) 
wild-
type Tα1-3RT 
Tα1 
α-tubulin 
3R-tau 
(0,1,2N) 
Age-dependent accumulation of filamentous tau aggre-
gates in oligodendrocytes and, to a lesser extent, astro-
cytes that was Gallyas and thioflavin-S positive. Neuronal 
tau abnormalities also occurred. 
(Higuchi et 
al., 2002) 
wild-
type 
GFAP/tau 
(C57Bl/6 x 
C3H) 
mGFAP 4R-tau (1N) 
Age-dependent accumulation of abnormally phosphory-
lated, ubiquitinated, and filamentous insoluble tau protein 
in astrocytes that was Gallyas and thioflavin-S positive. 
Mild blood-brain barrier disruption, induction of low-
molecular-weight HSPs and focal neuronal degeneration. 
(Forman et 
al., 2005) 
P301L 
JNPL3 
(Swiss Web-
ster) 
mPrP 3R-tau (2N) 
NFT identified in brain and spinal cord; motor neurons 
reduced 2-fold in spinal cord. Progressive motor distur-
bances by 10 months of age. 
(Lewis et al., 
2000) 
P301L 
pR5 
(B6D2F1 + 
C57Bl/6) 
mThy1.2 4R-tau (2N) 
Numerous abnormal, tau-reactive nerve cell bodies and 
dendrites; large numbers of pathologically enlarged axons 
containing NFT- and tau-reactive spheroids. Neuronal 
lesions similar to FTDP-17. 
(Gotz et al., 
2001a) 
G272V 
pR3 
(B6D2F1) 
mPrP-
TA 
4R-tau 
(2N) 
Filaments in murine oligodendrocytes, associated with tau
phosphorylation at AT8 epitope Ser-202/Thr-205 in vivo. 
In the spinal cord, fibrillary inclusions identified by thiofla-
vin-S in oligodendrocytes and motor neurons. 
(Gotz et al., 
2001c) 
V337M 
Tg214 
(B6SYL) 
mPDGF 4R-tau (2N) 
Neurons of irregular shape in hippocampus were immuno-
reactive for paired helical filament-associated tau, and 
showed signs of atrophic cell death. 
(Tanemura et 
al., 2001) 
R406W (B6SYL) CaMKII 4R-tau (2N) 
Accumulation of insoluble tau in aged mice. Congophilic 
hyperphosphorylated tau inclusions only in forebrain neu-
rons of aged mice. 
(Tatebayashi 
et al., 2002)
P301S 
2541 
(C57BL/6 × 
CBA) 
mThy1.2 4R-tau (0N) 
Massive NFT formation. Perchloric-acid soluble tau phos-
phorylated at many phospho-epitopes of tau (but not the 
AT100 epitope Ser-214); sarkosyl-insoluble tau strongly 
immunoreactive with all antibodies, including AT100. 
(Allen et al., 
2002) 
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form which contains both amino-terminal inserts. The mThy1.2 promoter was chosen instead 
of the PrP promoter, which may account for different expression patterns in these mice (pR5-
line) (Gotz et al., 2001a). As above, NFT were identified by Gallyas silver staining and thiofla-
vin-S fluorescent microscopy. In addition, tau filaments were revealed by immuno-electron 
microscopy of sarcosyl extracts using phospho tau-specific antibodies. Subsequent studies 
showed an upregulation of glyoxalase I, a critical player in the detoxification of dicarbonyl 
compounds (Chen et al., 2004b) and a mitochondrial dysfunction (David et al., 2005) in these 
P301L mice. Due to low expression levels in motor neurons of the spinal cord, no motor phe-
notype was observed, which would affect behavioral testing. 
 
1.6.3 Additional transgenic animal models for tauopathies 
 
In addition to transgenic mice, a variety of animal models of tauopathies have been used to 
provide additional insight into the mechanism of tau dysfunction. These models include the 
nematode Caenorhabditis elegans (Kraemer et al., 2003), the fruit fly Drosophila 
melanogaster (Jackson et al., 2002; Shulman and Feany, 2003; Wittmann et al., 2001), and 
the sea lamprey (Hall et al., 2001; Hall et al., 2002). Furthermore, Xenopus oocytes, in which 
most of the M-phase regulators during mitosis have been discovered, were used to investi-
gate the relationship between tau phosphorylation and mitosis (Delobel et al., 2002). Each of 
these models offers its unique advantages like powerful genetics (easily genetically manipu-
lations), simple and fast breeding, large screenings for pharmacological compounds and well 
characterized neurons (Gotz et al., 2004b; Lee et al., 2005). However, these phylogenetically 
lower species have a brain anatomy much different from humans, making interpretation of 
the findings and direct comparisons difficult.  
 
 
1.7 Relationship between Aβ- and tau pathology 
 
The pathogenic relationship of the two major lesions of AD, Aβ-plaques and NFT, and their 
relative contribution to the clinical features of AD is one of the most crucial and controversial 
topics in AD research. Patients bearing APP mutations develop both hallmarks, whereas tau 
mutation carriers only develop NFT, providing evidence that Aβ can induce NFT formation 
but that the opposite has not been established. These led to the proposition of the amyloid 
cascade hypothesis (Hardy and Higgins, 1992), which claims that (at least in familial AD) β-
amyloid causes or enhances the NFT pathology. Although this concept at first sight seems 
consistent, it is difficult to combine it with the highly puzzling finding that plaques and NFT 
are neuroanatomically separated. NFT develop in specific sites of the brain and spread in a 
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predictable, non-random manner across it. Six stages of disease progression based on the 
tau pathology have been distinguished (Braak and Braak, 1991, 1995): the transentorhinal 
stages I-II representing clinically silent cases; the limbic stages III-IV of incipient AD; and the 
neocortical stages V-VI of fully developed AD. A comparative study of Aβ-associated pathol-
ogy defined five phases which differ strikingly from the NFT-stages. Further, Aβ-deposition 
expands anterogradely into regions that receive neuronal projections from regions already 
exhibiting Aβ (Thal et al., 2002).  
Numerous correlation studies failed to demonstrate a clear relationship between the severity 
of dementia and Aβ deposition in human AD brains whereas correlation between NFT num-
bers and severity of dementia has been reported (Arriagada et al., 1992; Bierer et al., 1995; 
Crystal et al., 1988; Nagy et al., 1996). It was shown that total NFT counts in specific brain 
areas such as the entorhinal and frontal cortex, as well as neuron numbers in the CA1 region 
of the hippocampus were the best predictors of cognitive deficits in brain aging and AD 
(Giannakopoulos et al., 2003).  
Recently, however, a synergistic interaction between the APP- and the tau-related pathology, 
despite the different spatiotemporal distribution of plaques and NFT, could be proposed 
(Delacourte et al., 1999; Delacourte et al., 2002). It was also shown that whenever Aβ ag-
gregates were detected, tau pathology was found, at least in the entorhinal cortex. The op-
posite was not true because cases were found with advanced tau pathology, with no trace of 
Aβ aggregates (Delacourte et al., 2002).  
 
1.7.1  Relationship between Aβ and tau pathology addressed in trans-
genic mice 
 
To test the role of Aβ in tau pathogenesis, our group previously addressed this issue, using 
the P301L tau transgenic mouse model (pR5-line), by stereotaxically injecting pre-
aggregated β-amyloid fibrils into the somatosensory cortex and the hippocampus (CA1) of 
these mice (Gotz et al., 2001b). This stereotaxic approach caused a fivefold increase in the 
numbers of NFT in the amygdala of P301L mice, but not in wild-type tau transgenic or control 
mice. NFT formation was associated with the pathological phosphorylation of tau at the epi-
topes Thr-212/Ser-214 (AT100) and Ser-422 (pS422). Furthermore, mitochondria from 
P301L mice displayed an increased vulnerability towards Aβ insult, suggesting a synergistic 
action of tau and Aβ pathology on the mitochondria (David et al., 2005). 
An alternative approach was pursued by intercrossing Aβ-producing APP-mutant mice 
(Tg2576 mice overexpressing the APPSWE mutation) with P301L tau transgenic mice (JNPL3-
line) (breeding approach) (Lewis et al., 2001). Double transgenic mice showed a more than 
sevenfold increase in NFT numbers in the olfactory bulb, the entorhinal cortex and the amyg-
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dala compared to P301L single transgenic mice. In contrast, plaque formation was unaf-
fected by the presence of the tau mutation compared to APPSWE single transgenic mice.  
Later on, a triple transgenic mouse model (3×Tg) harboring the APPSWE mutation, the P301L 
tau (4R0N) mutation and the PS1M146V mutation was generated (Oddo et al., 2003). These 
mice develop synaptic dysfunction, including LTP deficits, which manifests in an age-related 
manner, but before plaque and tangle pathology. The authors also claim that extracellular Aβ 
deposits appear prior to tau pathology, however, a causal relationship can not be established 
by this approach.  
Together, these data established an interaction between APP/Aβ and tau by significantly 
accelerating the NFT formation in P301L mice. However, the discovery that the injection of 
Aβ-fibrils was not capable of inducing NFT formation in wild-type tau transgenic mice (which 
develop no NFT) imply that at least in the mouse model Aβ can not induce NFT formation de 
novo. Together with the findings from human tauopathies which are associated with NFT 
formation, but lack β-amyloid pathology, these would imply that other factors than Aβ induce 
NFT formation in the brain, but that Aβ has the ability to significantly accelerate the disease 
progress.  
 
1.7.2  Relationship between Aβ and tau pathology addressed in the cell 
culture 
 
Based on the in vivo data of the tau transgenic mice, our group established a cellular system 
using the human SH-SY5Y neuroblastoma cell line (Gotz et al., 2004a). Both four-repeat 
wild-type and P301L mutant human tau were stably overexpressed in these cells. Addition of 
extracellular pre-aggregated Aβ42-peptides for five days caused the development of numer-
ous AD-like tau filaments (Ferrari et al., 2003). Mutating the Ser-422 phospho-epitope of tau 
(which was hyperphosphorylated in P301L tau transgenic mice after β-amyloid injections 
(Gotz et al., 2001b), prevented both the Aβ42-mediated decrease in solubility and the genera-
tion of tau filaments in tissue culture, suggesting a pivotal role of this Ser-422 epitope in fibril-
logenesis. Furthermore, stable reference genes were identified in this tissue culture system 
using custom-made gene arrays (Hoerndli et al., 2004), enabling the subsequent identifica-
tion of genes involved in the regulation of molecular and cellular processes of tau aggrega-
tion. 
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1.8 Aims of the study 
 
1.8.1  Behavioral analysis of P301L tau transgenic mice 
 
Transgenic mouse models of human diseases are well suited to provide insight into the un-
derlying biochemical mechanisms and to assist in the development of treatment strategies 
(see above). In addition to reproducing the histopathological hallmarks of the human disease, 
correlation of these hallmarks with the behavioral outcome is an important measure of the 
validity and experimental use of any animal model. Therefore, the first part of my thesis con-
sisted in the analysis of P301L tau transgenic mice (pR5-line) in several behavioral tasks to 
define the behavioral phenotype of these FTDP-17 tau mutant mice as a model for the tau 
pathology in AD and related disorders and to correlate the behavioral outcome with the ex-
pression pattern of the tau transgene. 
In a first study I analyzed the mice in several amygdala-dependent tasks as expression lev-
els of tau were high in the amygdala and as NFT formation was initiated in this brain region 
(Gotz et al., 2001b; Pennanen et al., 2004). The amygdala is involved in mediating effects of 
emotion (fear, exploration) on learning and memory and in the validation of primarily negative 
events. 
P301L tau aggregates were also found in the hippocampus, yet, unlike the amygdala, NFT 
developed in the hippocampus only at high age (>18 months). In a follow-up study, to deter-
mine whether tau aggregation is sufficient to cause deficits in hippocampus-dependent be-
havior, the P301L mice were investigated also in a hippocampus-specific test battery 
(Pennanen et al., 2005).  
 
1.8.2  Role of different phospho-epitopes and cleavage sites in tau fila-
ment formation in tissue culture 
 
To further map phospho-epitopes and cleavage sites of tau involved in filament formation, I 
generated, in the second part of my thesis, different tau mutant constructs and expressed 
them in human SH-SY5Y neuroblastoma cells. Upon treatment of differentiated tau-bearing 
SH-SY5Y cells with aggregated β-amyloid peptides (Aβ42) and subsequent sequential extrac-
tion using buffers with increasing ionic strengths, the β-amyloid-induced decrease in tau 
solubility was determined. 
To further validate and improve the in vitro model, an inducible expression system, the Tet-
on system, was chosen, which allows high levels of gene expression in a time- and concen-
tration dependent manner. Using a bi-directional (pBI) Tet response vector, expression of 
both tau and APP was achieved from the same plasmid. This system may eventually help to 
address several questions regarding the relationship between Aβ and tau.  
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2 MATERIALS AND METHODS 
 
2.1 Behavioral analysis of P301L tau transgenic mice 
 
2.1.1 Animals 
 
The transgenic mice used in this study express the human pathogenic mutation P301L of tau 
together with the longest human brain tau isoform (htau40) under control of the neuron-
specific mThy1.2 promoter. Pronuclear injections were done into C57Bl/6 x DBA/2 F2 oo-
cytes to obtain founder animals that were backcrossed with C57Bl/6 and B6D2F1 mice to 
establish transgenic lines (Gotz et al., 2001a). Line pR5-183 expressed mutant human tau in 
many brain areas, however, NFT formation was mainly confined to the amygdala (Gotz et al., 
2001a).  
For the first study, wild-type (wt) and P301L mice on a B6D2F1 background were sequen-
tially analyzed in two sets which were balanced for the genotype and subjected to an amyg-
dala-dependent test-battery starting at 6 months of age when NFT began to form in the 
amygdala. Data were pooled, as no statistically significant differences were found between 
sets.  
For the second study, where the mice were tested in a hippocampus-dependent test battery, 
by an initial breeding with a 50% C57Bl/6 background (P301L/B6D2F1 strain), and by back-
crossing five times (N5) with C57Bl/6 mice, animals were obtained with a calculated > 98% 
C57Bl/6 background. Transgenic mice and littermate controls were tested in two groups at 5 
to 6.5 months and 10 to 11 months of age, respectively.  
For all studies only male mice were used. The group-housed mice were transferred to indi-
vidual cages prior to testing and kept under an inverted 12 hour light/dark cycle with a room 
temperature of 22°C. Food pellets and water were available ad libitum unless otherwise no-
ted. 30 min before each test session, the mice were transferred to the behavioral room. 
 
2.1.2 P301L tau mouse genotyping 
 
2.1.2.1 Mouse tail lysis 
 
2 mm of mouse tail were cut and incubated in 20 µl digestion buffer (50 mM Tris pH 8.0, 20 
mM NaCl, 1 mM EDTA pH 8.0, 1% SDS) at 1400 rpm in a thermomixer (Vaudaux-Eppendorf 
AG, Schonenbuch, Switzerland) for 40 min at 55°C, supplemented with 2 µl proteinase K (20 
mg/ml). Proteinase K digestion was terminated through denaturation by adding 178 µl double 
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deionised water (ddH2O) and incubating the tail lysate at 99°C for 5 min at 500 rpm in the 
thermomixer. 
 
2.1.2.2 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction technique is a method to amplify DNA-sequences of interest 
(Mullis, 1990), by using two specific primers which are complementary to the two strands and 
define the sequence to be amplified. Three major steps are involved: First, denaturation of 
the DNA to single strands at 95°C. Second, annealing of the primers to their complementary 
sequence on the DNA. Optimal annealing temperatures are ~ 5 to 10°C lower than the Tm 
values of the primers. The Primers should be designed in such a way that an annealing tem-
perature of 55 – 65°C is allowed. Third, elongation of the DNA-strand by using a heat stable 
DNA polymerase adding nucleotides (dNTPs) to the 3’-ends of the primer sequences at 
72°C. By repeating these steps several times the DNA sequence of interest is amplified ex-
ponentially. 
Transgenic P301L tau mice were screened with oligonucleotides tau-I (5'-GGA GTT CGA 
AGT GAT GGA AG-3') (Pos 18-37, →, 20 bp) and tau-K (5'-GGT TTT TGC TGG AAT CCT 
GG-3') (Pos 506-525, ←, 20 bp) to obtain an amplified product of ~500 bp. Briefly, 0.5 µl of 
the tail lysate was added to PCR mix (9.5 µl H2O, 1.25 µl PCR buffer, 0.25 µl 10 mM dNTP, 
0.5 µl oligo tau I/K mixture (0.2 µM), 0.5 µl Red Taq genomic DNA polymerase (Sigma, 
Fluka, Buchs, Switzerland)). Using a GeneAmp PCR system 9700 machine (Applied Biosys-
tem, Rotkreuz, Switzerland), the reaction was heated to 95°C for 2 min before a series of 35 
cycles was initiated (40 sec at 95°C, 60 sec at 64°C, 1 min at 72°C), then kept at 72°C for 7 
min and cooled to 4°C. 
 
2.1.2.3 Agarose gel electrophoresis 
 
Analysis or separation of PCR products and digested DNA-fragments was carried out using 
agarose gel electrophoresis. (TAE-Buffer: 40 mM Tris-acetate, 1 mM EDTA; Gel-loading 
buffer: 0.25 % bromphenol blue, 0.25 % xylene cyanol FF, 30 % glycerol). An electrical field 
is used to drag the negatively charged DNA molecules (due to their phosphate groups) 
through a gel matrix. The migration rate of linear DNA depends mainly on its size and the 
shorter the DNA molecule the faster it moves through the gel. DNA-fragments were visual-
ized by adding ethidium bromide which intercalates bases of DNA. When exposed to UV-
light, ethidium bromide fluorescence a red-orange color.  
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2.1.3 Histology 
 
Mice were perfused transcardially under deep anesthesia with a mixture of 2% xylazine and 
10% ketamine (15 µl/g body weight) (Streuli-Pharma, Uznach, Switzerland). For that, the 
thorax was opened to expose the heart and major vessels. A cannula was inserted through 
the left ventricle into the ascending aorta. Right away, the right atrium was punctured with a 
sharp hook, to allow the efflux of return circulation. To remove the blood, mice were initially 
perfused with 0.9% NaCl for 5 min until the liver turned beige-yellow, followed by fixation with 
4% paraformaldehyde (PFA) in phosphate buffered saline (PBS: 10 x buffer: 80 g NaCl, 2 g 
KCl, 17.8 g Na2HPO4-2H2O and 2.4 g KH2PO4 in 1l H2O, adjusted to pH 7.4). Brains were 
then removed, postfixed in the same fixative solution overnight and washed 3 x with 1 x PBS 
for 24 h. The brains were then dehydrated in an ascending series of ethanol (70%, 96%, 
100%; each 3 h, by changing every hour), left overnight in xylol, subsequently immersed in 
liquid paraffin at 60°C for 5 h and finally embedded in paraffin. 
Immunohistochemistry was done on coronal 4-µm thin paraffin sections and brain areas were 
mapped based on the mouse atlas by Paxinos (Paxinos, 1997). To allow antibodies to pene-
trate fixed tissue embedded in paraffin, sections were dewaxed in xylol (3 x) and rehydrated 
in a descending series of ethanol (2 x 100%, 1 x 96%, 1 x 70%) and 2 x in ddH2O (5 min 
each). For signal enhancement, sections were microwave treated in citrate-buffer pH 5.8 at 
70°C for 15 minutes. Sections were blocked in PBS containing 4% BSA (Bovine serum al-
bumin) or milk and 5% goat serum. Incubation with the primary antibody was done in 50% 
blocking buffer overnight at 4°C or for 1 h at RT. After washing 3 x with PBS sections were 
incubated with the secondary antibody in 50% blocking buffer for 1 h at RT. The immu-
nostained sections were washed again and then flat-embedded between glass slides and 
coverslips with the anti-fading reagent Mowiol (Clariant, Frankfurt am Main, Germany). 
For determining the expression pattern of human P301L tau in our mice, the human tau-
specific antibody HT7 (Innogenetics Inc, diluted 1:200) and the phosphorylation-dependent 
anti-tau antibody CP13 (Dr. Peter Davies, diluted 1:200) directed against phosphorylated 
S202/T205 were used. For the peroxidase/DAB stainings, secondary antibodies were ob-
tained from Vector Laboratories (Vectastain ABC kits PK-6101 and PK-6102). 
 
2.1.4 Amygdala-dependent test battery 
 
2.1.4.1 Motor coordination on the Rotarod 
 
The body weight was determined at 6 and 8 months of age. To test locomotor coordination, 
the accelerating Rotarod (Udo Basile, Milan, Italy) (Fig. 2.1) was used which consists of a 
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rotating drum with a diameter of 3 cm covered with knurled Perspex to provide an adequate 
grip. The mice were first placed on the rod at the lowest speed of 4 rpm for 2 minutes. Only 
then the rod was switched to acceleration mode and the time on the rod was recorded for up 
to 5 minutes when the speed reached the maximum of 40 rpm. Mice were assessed daily in 
two trials on three consecutive days, with an intertrial interval of at least 3 h. 
 
 
Fig. 2.1 The accelerating Rotarod: The mice are placed on a rotating drum at the lowest speed. Only then the rod 
is switched to acceleration mode and the time on the rod is recorded (max. 5 min).  
 
 
2.1.4.2 Open-field test 
 
The open-field test analyzes spontaneous locomotor activity, exploratory behavior, and 
anomalies of locomotion patterns. Mice were placed at the border of a dimly lit (50 lux) circu-
lar arena (diameter of 150 cm) for 10 min followed by a second session on the following day. 
The arena was divided into an outer zone (within 7 cm of the wall), an inner zone (inner circle 
with a diameter of 110 cm), and an intermediate zone (Fig. 2.2A). Locomotor activity was 
assessed by measuring the total distance traveled and the total number of zone transitions. 
Thigmotaxis, i.e. moving along the wall, was quantified by measuring the time spent in the 
outer zone. To determine measures of anxiety and exploratory behavior, the following pa-
rameters were assessed: number of visits to the inner zone, average distance to the inner 
zone, and the number of activity state changes. Three activity states were distinguished: pro-
gression (periods with a locomotion speed above the progression threshold of 0.085 m/s and 
a minimal distance moved exceeding 0.05 m), resting (periods lasting at least 2 seconds with 
a speed below 0.025 m/s) and scanning (periods meeting neither resting nor progression 
criteria).  
 
2.1.4.3 Light-dark (L/D) test 
 
Unconditioned anxiety-like behavior was tested in the light-dark (L/D) test. The mice were  
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Fig. 2.2 To test levels of spontaneous locomotor activity, anxiety-like behavior and exploration two tests were 
performed. (A) In the open-field test, the mice were released at the border of a dimly lit circular arena which was 
divided into an outer zone (home zone; within 7 cm of the wall), an inner zone (exploration zone; inner circle with 
a diameter of 110 cm), and an intermediate zone. (B) For the light-dark test the mice were placed into the light 
compartment of the L/D box (average light intensity of 700 lux). A dark compartment was attached opposite to the 
releasing site with an opening facing the center of the illuminated part.  
 
 
placed into the 30 cm x 20 cm area of a Perspex L/D box that was illuminated with an aver-
age of 700 lux. A dark compartment of 15 cm x 20 cm was attached opposite to the releasing 
site with an opening facing the center of the illuminated part (Fig. 2.2B). Movements were 
tracked in the illuminated part over a 5 minutes trial. Anxiety was measured by the latency to 
enter the dark compartment and the time spent in it. Exploration was defined by the number 
of rearings in the illuminated part, and the percentage of visited tiles / total of 36 tiles (5 x 3.3 
cm) entered with all four paws defined as exploration index. 
 
2.1.4.4 Fear conditioning 
 
The conditioning chamber consisted of a gray opaque box (16.5 x 25 cm) with a grid floor 
through which shocks could be delivered (0.15 mA) as the unconditioned stimulus (US). The 
chamber was placed into a dimly lit sound-attenuating box with a speaker on top delivering a 
92 dB / 2000 Hz tone as the conditioned stimulus (CS). Two measures were used to quantify 
freezing as the conditioned reaction: A grid of photobeams (1 x 1 cm) detected the inactivity 
of the mice, which was defined as no photobeam breaks during at least 2 seconds. Freezing  
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Fig. 2.3 Schematic flowchart illustrating the basic fear conditioning process. (A) For conditioning, a 1-min adapta-
tion period (baseline) was followed by three identical conditioning trials, each trial consisting of 30 seconds CS 
presentation, with the US being applied during the last two seconds of the CS, separated by intertrial intervals of 
30 seconds. (B) To evaluate context conditioning, mice were placed for two minutes in the conditioning chamber. 
To evaluate conditioning to tone, the physical characteristics of the chamber were changed. Each mouse was 
then placed for two minutes into this new chamber, and the CS was presented throughout the second minute. 
 
 
was also detected manually while observing the animal and was defined as no movement 
except for respiration (as defined and applied by the experimenter). The two measures corre-
lated well with each other. However, the manually detected measurement was finally used 
due to technical problems with the photobeams during cue testing: Sawdust was used in the 
new environment and unfortunately, from time to time, the photobeams were concealed, 
which caused a higher, inappropriate measurement of inactivity.  
During the conditioning session, a 1-min adaptation period in the box was followed by three 
identical conditioning trials, each trial consisting of 30 seconds CS presentation, with the US 
being applied during the last two seconds of the CS, separated by an intertrial interval of 30 
seconds (Fig. 2.3A). Retrieval tests for context conditioning and, two hours later, for condi-
tioning to tone were carried out 24 h and 15 days after the conditioning session by recording 
freezing as mentioned above. To evaluate context conditioning, mice were placed for two 
minutes in the conditioning chamber. To evaluate conditioning to tone, the physical charac-
teristics of the chamber were changed (shape, light, smell, and bedding material). Each 
mouse was then placed for two minutes into this new chamber, and the CS was presented 
throughout the second minute (Fig. 2.3B). 
 
2.1.4.5 Conditioned taste aversion test (CTA) 
 
For the first four days of the experiment, water-deprived mice were adapted to obtain water 
only during two daily drinking sessions, a morning session lasting 20 min and an afternoon 
B: Context + tone testing (24h + 15 days after conditioning)
Context conditioning (120s) Altered context (60s) Tone conditioning (60s tone)
with the altered context
2 h
A: Conditioning (4min) 
US (2s) US (2s) US (2s) 
CS (30s) CS (30s) CS (30s)ITI (30s) ITI (30s) ITI (30s)baseline (60s) 
ITI = Inter - trial interval       CS = conditioned stimulus = tone       US = Unconditioned stimulus = shock 
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session lasting 10 min, with a 4 h intertrial interval. Water was presented in two 15 ml bottles 
that were weighed before and after the test to measure fluid intake. During the morning ses-
sion on the conditioning day, mice were only allowed to drink a 0.5% saccharin solution (CS) 
(saccharin sodium salt hydrate, Fluka Chemie, Buchs, Switzerland) from one bottle. 40 min 
later, the mice were injected i.p. with a 0.14 M LiCl solution (at 2% of body weight) as the 
nausea-inducing agent (US).  
Two days after conditioning, during the 20-min morning session all mice could drink either 
tap water from one bottle or the 0.5% saccharin solution from another bottle (two-bottle 
choice test). The percentage of saccharin consumption per total fluid intake was calculated. 
Extinction was determined by repeating the choice tests 3 days after conditioning, and on 
three consecutive days, beginning one week after conditioning. The mice of the second set 
were analyzed in three additional choice tests starting 5 weeks following conditioning. 
To determine whether P301L mice were able to discriminate basic taste qualities, a separate 
group of water-deprived naive mice was adapted to the drinking schedule as described 
above. Then, the mice were tested for their natural preference for a sweet taste in a choice 
test, where one bottle was filled with a 0.5% saccharin solution and the second with tap wa-
ter. Finally, to determine the natural aversion towards a bitter taste, a choice test between a 
0.02% quinine solution (quinine hydrochloride dihydrate, Fluka, Buchs, Switzerland) and wa-
ter was carried out. 
 
Water-
deprivation
Saccharin-
solution
LiCl-
injection Choice trial ?           ?
 
Fig. 2.4 Conditioned taste aversion test (CTA). On the conditioning day, water-deprived mice were allowed to 
drink a saccharin solution, before they were injected with LiCl as the nausea-inducing agent. Two days after con-
ditioning, the first choice trial was presented and the percentage of saccharin consumption was calculated. 
 
 
 
2.1.5 Hippocampus-dependent test battery 
 
2.1.5.1 Open-field and elevated O-maze 
 
In the second study, mice with a calculated > 98% C57Bl/6 background were tested. To iden-
tify potential effects of backcrossing on exploratory behavior, anxiety and locomotor activity, 
the mice were again assessed in the open field, together with the elevated O-maze. 
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The arena for the open-field test varied from the arena in the first study. Here, the mice were 
placed at the border of a dimly lit (50 lux) square arena (50 cm x 50 cm) and allowed to ex-
plore the arena freely for 30 min (Fig. 2.5A). The arena was divided into an outer (home) 
zone (within 7 cm of the wall), an inner (exploration) zone (inner square of 24 cm x 24 cm) 
and an intermediate zone. Locomotor activity was assessed by measuring the total distance 
moved and the total number of zone transitions. Thigmotaxis, i.e. moving along the wall, was 
quantified by measuring the time spent in the outer zone. To determine measures of anxiety 
and exploratory behavior, the following parameters were assessed: time spent in the inner 
zone, number of visits to the inner zone and the distance traveled in the inner zone.  
The elevated O-maze is a runway (diameter 46 cm, width 5.5 cm) elevated to a height of 40 
cm above floor level (Fig. 2.5B). It is comprised of two opposing open and two opposing 
closed sectors. The mice were placed into a closed sector and allowed to explore the maze 
freely for 5 min. The following parameters were assessed: Percentage of time spent in open 
sectors, percentage of entries into open sectors compared to total entries, total numbers of 
head dips, percentage of protected head dips, the total distance moved and the total num-
bers of zone transitions. 
 
A B
 
Fig. 2.5 Open-field and O-maze: (A) In the open-field arena, the mice were placed at the border of a dimly lit 
square arena (50 cm x 50 cm) which is divided into an outer (home) zone (within 7 cm of the wall), an inner (ex-
ploration) zone (inner square of 24 cm x 24 cm) and an intermediate zone. (B) The elevated O-maze is a runway 
elevated to a height of 40 cm above floor level. It is comprised of two opposing open and two opposing closed 
sectors and the mice were placed into one of the closed sectors. In both tasks, the mice are allowed to freely 
explore the arena.  
 
 
2.1.5.2 Y-maze 
 
To determine spontaneous alternation behavior (measure of spatial working memory), the 
mice were tested in a Y-maze with 40 cm long, 10 cm wide and 20 cm high arms. Each 
mouse received one trial during which it was placed at the end of one of the three arms and 
allowed to explore the maze for 5 min. Alternations and total numbers of arm entries were 
recorded. Spontaneous alternation, expressed as percentage, refers to the ratio of arm choi- 
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Fig. 2.6 Y-maze paradigm: To test spontaneous alternation behavior, mice were placed at the end of one of the 
three arms and allowed to explore the maze for 5 min. 
 
 
ces differing from the previous two choices, to the total number of arm entries. Arm entry was 
considered to be completed when the hind paws of the mouse had been completely placed 
in the arm. 
 
2.1.5.3 Morris Water Maze 
 
To measure spatial reference memory, place navigation in the Morris water maze (MWM) 
was conducted (Morris et al., 1982). Mice were trained in a circular pool of 150 cm diameter 
made of white Plexiglas, filled with water (24-26°C) and made opaque by adding a white non-
toxic paint (Acusol OP 301, Christ Chemie AG, Aesch, Switzerland). Distant visual cues for 
navigation were provided around the pool. A wire mesh platform (14 x 14 cm) was hidden 0.5 
cm below the water surface with a pool perimeter distance of 35 cm. To avoid visual orienta-
tion prior to release, mice were transferred in a white plastic cup from their cages to the pool 
and released with the cup opening towards the wall of the pool. Eight symmetrically placed 
starting positions at the pool perimeter were varied in a predetermined but not sequential 
order. Mice were allowed to swim for a maximum of 120 s or until they had found the plat-
form. Finding the platform was defined as staying on the grid for at least 3 s. After removal, 
mice were placed under an infrared lamp and allowed to warm up and dry off. 
The test was divided into two phases, an acquisition phase (18 trials, six/day) followed by a 
reversal phase during which the platform was moved to the opposite corner (12 trials, 
six/day) (Fig. 2.7). Intertrial intervals varied from 30 to 90 min. The first 60 s of trial 19 (first 
reversal trial) was used as probe trial for spatial retention. The following parameters were 
analyzed both during acquisition and reversal learning: Escape latency, swim speed, time  
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Fig. 2.7 Goal position and starting points in the Morris Water Maze: The figure shows one example out of the four 
different versions of the protocol. Goal positions are distributed over all four quadrants of the pool and are 
matched for the genotype, because spontaneous preference for one quadrant can not be excluded. Start points 
are spread in a pseudo-random manner in such a way that all points are used at a similar frequency. The mice 
perform 30 trials, 6 per day during 5 days. During the first 18 trials (acquisition phase) they are trained with the 
hidden platform in a constant position. For the reversal phase (the remaining 12 trials) the platform is moved to 
the opposite corner (figure adapted from D.P.Wolfer). 
 
 
floating, wall hugging (thigmotaxis), swim path and the percentage of non-floating time in the 
current goal quadrant.  
For data analysis of these parameters, trials were averaged into blocks of two trials. A se-
cond set of variables was used to assess spatial retention during the probe trial: Percentage 
of time spent in the former goal quadrant (with a chance level of 25%), percentage of time in 
a circular target zone comprising one-eighth of the pool (chance level of 12.5%) and the 
number of crossings over the former platform location (annulus crossing). These variables 
were compared with the average for the adjacent left and right quadrants. The opposite 
quadrant was not considered because it contained the new goal. 
An automated software algorithm was used to classify trials according to the predominant 
swimming strategy. Seven categories were defined: floating, wall hugging, random swim-
ming, scanning, chaining, focal searching and direct swims (Balschun et al., 2003). Each trial 
was categorized according to the predominant strategy. The number of trials falling into each 
category was computed for each mouse. 
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2.1.6 Video tracking and data analysis 
 
All paths were tracked with an electronic imaging system (EthoVision 2.3, Noldus Information 
Technology, Wageningen, The Netherlands) at a frequency of 4.2 Hz and a spatial resolution 
of 256 x 256 pixels. Raw data were transferred to the Wintrack 2.4 software for off-line 
analysis (Wolfer et al., 2001). For statistical analysis, the SPSS software was used. Be-
tween-group comparisons were analyzed using a one-way analysis of variance (ANOVA) or 
a two-way ANOVA with repeated measures. Significant effects were analyzed post hoc using 
the Dunnett’s test and Fisher’s PLSD (protected least significant difference) for pair-wise 
comparison. All data are represented as mean ± SEM with a statistical significance given at p 
< 0.05. 
 
 
2.2 Role of different phospho-epitopes and cleavage sites in tau 
filament formation in tissue culture 
 
2.2.1 Phospho-epitope mapping: Site-directed mutagenesis 
 
The longest human 4-repeat tau isoform, htau40, was cloned into the SpeΙ-site of the 
pRc/RSV expression vector (Invitrogen, Basel, Switzerland). Site-directed mutagenesis 
(Quick Change Kit, Stratagene, La Jolla CA, USA) following the manufacturer’s instructions 
was performed to generate tau mutants with the following sense primers (Microsynth, Bal-
gach, Switzerland): 
AT8 (epitope S202/T205 of tau mutated to S202A/T205A): 5’-CAG CCC CGG CGC CCC 
AGG CGC TCC CGG CAG-3’; 
AT100 (epitope T212/S214 of tau mutated to T212A/S214A): 5’-GCC GCT CCC GCG CCC 
CGG CCC TTC CAA CCC-3’; 
T231 (epitope pT231 of tau mutated to T231A): 5’-TGG CAG TGG TCC GTG CTC CAC CCA 
AGT CGC-3’. 
 
Tau Mutagenesis PCR: 
5 µl of 10x reaction buffer 
1 µl of 10mM dNTP 
0.5 µl DNA-template (20 ng/µl) 
1.25 µl tau primer forward (10 ng/µl) 
1.25 µl tau primer reverse (10 ng/µl) 
41 µl ddH2O to a final volume of 50 µl 
Then add 
1 µl of PfuTurbo DNA polymerase (2.5 U/µl) 
95°C for 30 sec 
 
95°C 30 sec 
55°C 60 sec 
68°C 12 minutes 18 cycles 
 
68°C for 12 minutes 
4°C ∞ 
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2.2.2 Cleavage site mapping: ∆421 truncated tau 
 
Generation of the tau ∆1-421 truncation mutant was done by a three-way ligation procedure. 
The pRc/RSV expression vector bearing htau40 was digested with the restriction enzymes 
BstEII (a unique restriction site in tau at position 951) and XbaI (no cleavage site in tau, cuts 
the RSV vector in the polylinker ~ 150 bp downstream / 3’ of the tau insert) (New England 
Biolabs, Bioconcept, Allschwil, Switzerland) (Fig. 2.8A). This yielded two fragments of ~ 4600 
bp and ~ 530 bp, respectively (Fig. 2.8B). Concurrently, a PCR product was created with the 
RSV-htau40 vector as template and the two following primers (Microsynth, Balgach, Switzer-
land) (Fig. 2.8C): 
Forward primer (28 bp): Tau BstEII F, contains the tau segment from bp 924-951 just before 
the BstEII restriction site: 5’-GTC TAC AAA CCA GTT GAC CTG AGC AAG G-3’. 
Reverse primer (35 bp): Tau 421 XbaI R, sense strain contains aa 418-421, followed by a 
stop codon, the XbaI restriction site and aa 425-428:  
 
 
2.2.3 Transformation of chemical competent E. coli cells 
 
To transform chemically competent E. coli cells, 1 ng/µl of plasmid DNA or an aliquot of a 
ligation reaction were added to 50 µl of E. coli cells and incubated on ice for 20 min. Follow-
ing a heat shock for 45 sec at 42°C the cells were chilled on ice for additional 2 min. After 
adding 950 µl of preheated (42°C) LB-medium (Luria-Bertani medium: 10 g Bacto-Tryptone, 
5 g Bacto-yeast extract and 10 g NaCl per 1l H2O adjusted to pH 7.0), the cells were incu-
bated on a shaker at 37°C for 1 hour. After transformation bacteria were plated on LB-agar 
plates (15 g of Bacto-agar added to 1l of LB-medium) containing the appropriate antibiotic 
(Ampicillin) and incubated overnight at 37°C. 
The next day, single colonies were picked and incubated overnight in 100 ml (for Maxipreps) 
or in 6 ml (for Minipreps) LB-medium (+ Ampicillin 1:1000) in a bacteria-shaker at 37°C. 
Transformed bacteria were stored in glycerol (0.3 ml of sterile 100% glycerol to 1.7 ml of bac-
terial culture) and kept at –80°C. 
5’-C GAC ATG GTA GAC TAG TCT AGA CTC GCC ACG CTA G-3’  Sense sequence 
 
5’-G CTG TAC CAT CTG ATC AGA TCT GAG CGG TGC GAT C-3’  Anti-sense sequence  
         418  419   420   421 STOP XbaI-site  425  426   427   428     
Tau 421 XbaIR 
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Fig. 2.8 Generation of ∆421 truncated tau: (A) The RSV-htau40 vector was digested with BstEII and XbaI. (B) 
Two fragments were obtained of the size of ~ 4600 bp and ~ 530 bp, respectively. (C) A PCR fragment with the 
tau sequence terminated at codon 421 was constructed with the RSV-htau40 vector as template and two specially 
created primers. (D) Fragments 1 and 3 were ligated, resulting in ∆421 truncated tau. 
 
 
2.2.4 Isolation of plasmid DNA from E.coli cultures 
 
Plasmid DNA isolation from E. coli cultures was done using the GenElute Plasmid Maxiprep 
and/or Miniprep Kit (Sigma Aldrich, Buchs, Switzerland). The principle of plasmid isolation is 
based on an alkaline-SDS lysis procedure followed by adsorption of the DNA onto silica in 
the presence of high salts. Contaminants were removed by a simple spin-wash step. Finally, 
the bound DNA was eluted in 10 mM Tris-HCl buffer (1 M Tris: 121,14 g tris(hydroxymethyl)- 
aminomethane in 1l H2O, pH 8.0). 
If required an ethanol precipitation procedure was used to concentrate the eluted DNA. Add-
ing ethanol depletes its hydration shell and exposes the negatively charged phosphate 
groups in the backbone of the DNA, so that positively charged ions (e.g. Na+) bind and a pre-
cipitate can form. To one volume of DNA solution, 1/10 volume of 3 M NaOAc (pH 5.2) and 
2.5 volumes of 100% ethanol were added. DNA was precipitated for 30 min at –80°C, centri-
fuged for 30 min at 10’000 rpm at 4°C and washed with 70% ethanol. The DNA pellet was 
dried at room temperature and finally resuspended in elution buffer. 
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BstEIXba Xba
1 2
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Tau 421 
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3
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D
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2.2.5 Recovery of DNA fragments from agarose gels 
 
To isolate DNA-fragments of interest, the appropriate bands were cut out from agarose gels 
and were recovered using the QIAGEN gel extraction kit according to the manufacturer’s 
instructions (Qiagen, Hombrechtikon, Switzerland). To avoid interference of high EDTA con-
centrations with enzymatic reactions, a modified TAE-buffer was used for preparation and 
running of the gel (Modified TAE-Buffer: 40 mM Tris-acetate, 0.1 mM EDTA). 
 
2.2.6 Ligation 
 
Digested DNA or PCR fragments were ligated with a linearized vector using the enzyme T4 
DNA ligase (New England Biolabs, Bioconcept, Allschwil, Switzerland). The ligase catalyses 
the joining of two strands of DNA between the 5’-phosphate and the 3’-hydroxyl groups. The 
reaction was set up following the manufacturer’s instructions. In order to suppress self-
ligation of digested plasmid DNA, which contains complementary sticky ends or blunt ends, 
alkaline phosphatase was used to remove terminal 5’-phosphate groups before the ligation 
reaction was started. 
 
2.2.7 DNA cycle sequencing 
 
To confirm the presence of the mutated bases or absence of randomly introduced mutations, 
plasmids were sequenced using the dideoxy method developed by Sanger (Sanger et al., 
1977). In the cycle sequencing reaction all four dideoxynucleotides (A, T, G, C) labeled with 
different fluorescent dyes are added to an excess of deoxynucleotides. When one of the 
dideoxynucleotides is incorporated into the synthesized strain, the elongation is terminated 
because of the lack of the 3’-hydroxyl group. The products are then electrophoretically sepa-
rated in a capillary according to their molecular weight. Different wavelengths are used to 
excite each dye and thus to identify the sequence of the DNA. 
Sequencing was done with the ABI PRISM BigDye Terminator Cycle Sequencing Ready Re-
action Kit (Applied Biosystems, Foster City CA, USA): To 200-500 ng DNA-template, 3.2 
pmol of primer, 4 µl of Ready Rxn premix and 2 µl of BigDye sequencing buffer were added 
and filled up to a total volume of 20 µl with H2O. The following primers were used for se-
quencing (Microsynth, Balgach, Switzerland): 
 
Tau-G: 5'-ACC TCT GAT GCT AAG AGC AC-3' (Pos 187-206, →, 20 bp) 
Tau-O: 5'-CCA ATG CCT GCT TC TTC AG-3' (Pos 308-326, ←, 19 bp) 
Tau-E: 5'-TGA AGA AGC AGG CAT TGG AG-3' (Pos 309-328, →, 20 bp) 
Tau-K: 5'-GGT TTT TGC TGG AAT CCT GG-3' (Pos 506-525, ←, 20 bp) 
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Tau-O232: 5'-AAG AAG GTG GCA GTG GTC CGT AC-3' (Pos 670-692, →, 23 bp) 
Tau-B: 5'-TGA CAT TCT CCA GGT CTG GC-3' (Pos 750-770, ←, 20 bp) 
Tau-F: 5'-AGA CTA TTT GCA CAC TGC CG-3' (Pos 909-928, ←, 20 bp) 
Tau-Q: 5'-TGA CCT CCA AGT GTG GCT C-3' (Pos 953-971, →, 19 bp) 
Tau-L: 5'-ATC TTC GAC TGG ACT CTG TC-3' (Pos 1042-1061, ←, 20 bp) 
 
The DNA cycle-sequencing reaction was carried out using the following program: 96°C for 
1min; 25 cycles (96°C for 10 s, 50°C for 5 s, 60°C for 4 min); hold at 4°C. DNA was precipi-
tated in 100% ethanol and washed with 70% ethanol. The air dried DNA pellet was resus-
pended in 20 µl HPLC-upgrade H2O. For the capillary gel run and detection of fluorescent 
dyes the ABI PRISM 310 Genetic analyzer (Applied Biosystems, Foster City CA, USA) was 
used. 
 
2.2.8 Cell culture 
 
Human SH-SY5Y neuroblastoma cells (DSMZ, Braunschweig, Germany; DSMZ No. ACC 
209) were grown in Dulbecco’s modified Eagle’s medium F-12 (DMEM: F-12) supplemented 
with 2 mM L-glutamine, 1% penicillin/streptomycin, 10% fetal calf serum (FCS) and 5% horse 
serum (HS) (GIBCO, Basel, Switzerland). HEK 293 cells (human embryonal kidney cells; 
LGC Promochem, Molsheim Cedex, France; ATCC No. CRL-1573) were cultured in DMEM 
medium (GIBCO, Basel, Switzerland) supplemented with 10% FCS. All cells were main-
tained at 37°C in a saturated humidity atmosphere containing 5% CO2.  
Transfections with either wild-type or mutant htau40 cDNA constructs were done using Li-
pofectAMINE 2000 (Invitrogen, Basel, Switzerland) or Metafectene (Biontex, Munich, Ger-
many) and clones selected with 125 µg/ml G418 (VWR International AG, Calbiochem, Lu-
cerne, Switzerland) for 30 days. To induce neuronal differentiation, cells were seeded on 
collagen type I-coated dishes (4 x 105 cells / 10 cm Petri dish) and sequentially treated for 5 
days with retinoic acid (RA, 20 µM; Sigma Aldrich, Buchs, Switzerland) in standard culture 
medium, followed by 5 days with brain-derived neurotrophic factor (BDNF; 50 ng/ml; Pepro-
tech, Lucerne, Switzerland) in serum-free medium (Encinas et al., 2000). These neuronally 
differentiated cells were cultured in serum-free medium with BDNF for another 5 days adding 
pre-aggregated Aβ42 (10 µM; Bachem, Bubendorf, Switzerland) or PBS. For that, Aβ42 was 
reconstituted in PBS at a calculated concentration of 220 µM and shaken at 1000 rpm for 24 
hours at 37°C. This fibril preparation contains a mixture of species such as Aβ-monomers 
and oligomers but also SDS-stable oligomers (Hartley et al., 1999). Suspensions of fibrillar 
Aβ42 preparations corresponding to 10 µM soluble peptide were added to the cultures for five 
days. Once Aβ42 had been added to the cells, the medium was not changed anymore.  
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2.2.9 Immunocytochemistry 
 
For immunocytochemistry, cells were grown on collagen-coated coverslips and fixed with 4% 
PFA for 30 min, followed by permeabilization with 0.3% Triton-X-100 for 10 min. Coverslips 
were blocked for 1h in 1x PBS containing 5% BSA and 2% goat serum. The first antibody 
was diluted in blocking buffer and cells were incubated for 1h in a humified chamber. After 
washing 2 x with PBS, cells were incubated with the according secondary antibody for an-
other hour. After washing with PBS and H2O, coverslips were mounted with Mowiol on mi-
croscope slides. Primary antibodies used for immunocytochemistry (IC) are listed in table 
2.1. Secondary antibodies were obtained from Jackson ImmunoResearch (Milan Analytica, 
LaRoche, Switzerland).  
 
2.2.10 MTT assay 
 
To measure the proliferation rate of SH-SY5Y cells, an MTT assay was performed. MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; Thiazolyl blue) (Sigma Aldrich, 
Buchs, Switzerland) is a water soluble tetrazolium salt that can be converted to insoluble 
purple formazan by cleavage of dehydrogenase enzymes of living cells. SH-SY5Y cells were 
plated on 12 well plates at a density of 4 x 104 cells / well and differentiated with RA and 
BDNF as described above. Cell density was measured at different time points over differen-
tiation (T0, T2d, T5d, T7d, and T9d) by adding MTT (0.5 mg/ml dissolved in phenol red free 
DMEM: F-12 medium) to each culture (1 ml / well) and incubating for 3 hours at 37°C. Sub-
sequently, medium was removed and the precipitated formazan was solubilized using 0.1 N 
HCl in 100% isopropanol. After 15 min shacking, the absorbance of the converted dye was 
measured at a wavelength of 595 nm using a Wallac Victor 2 (1420) Multi-label counter 
(PerkinElmer, Monza (Milan), Italy). Background absorbance was measured at 695 nm. 
 
2.2.11 Cell lysis and protein extraction 
 
The levels and solubility of tau protein were determined by extracting Aβ-treated and control 
cells using buffers with increasing ionic strength. The medium was exhausted and the cells 
were washed once with ice-cold PBS. Cells were scrapped and homogenized on ice with a 
Microlance 25 GA1 tip (BD Bioscience, Basel, Switzerland) in 150 µl RAB (high-salt reas-
sembly) buffer (0.1 M MES pH 7.2, 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 
1 mM PMSF, 0.1 mM EDTA), supplemented with a Complete EDTA-free protease inhibitor 
cocktail (1 tablet / 1 ml; 1:25) (Roche, Basel, Switzerland) and 1 mM PMSF. The cells were 
incubated for 20 min on ice, followed by centrifugation for 20 min at 10’000 g at 4°C. The 
supernatant was carefully removed (RAB fraction) and the RAB-insoluble pellet was extrac- 
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Table 2.1: Primary antibodies used for IC and WB 
Anti-
body Specificity Source IC WB 
APP C-
terminal 
Recognizes aa 676-695 on APP C-
terminus, α-rabbit 
Sigma Aldrich, Buchs, Swit-
zerland  1:2000 
AT100 
Phosphorylation-dependent human 
tau antibody against phosphorylated 
T212/S214, monoclonal α-mouse 
Innogenetics, Gent, Belgium 1:200  
AT8 
Phosphorylation-dependent human 
tau antibody against phosphorylated 
S202/T205, monoclonal α-mouse 
Innogenetics, Gent, Belgium 1:200  
CP13 
Phosphorylation-dependent human 
tau antibody against phosphorylated 
S202/T205, monoclonal α-mouse 
P. Davies, A. Einstein College 
of Med, New York, USA 1:200 1:50 
ET2 
Specific for exon 10 of tau (recog-
nizes only 4R-tau), monoclonal α-
mouse 
P. Davies, A. Einstein College 
of Med, New York, USA  1:25 
HT7 
Phosphorylation-independent human 
tau antibody, aa 159-163, monoclonal 
α-mouse 
Innogenetics, Gent, Belgium 1:200 1:500-1:1000 
Tau 5A6 
Phosphorylation-independent human 
tau antibody, aa 19-46, monoclonal α-
mouse 
Developmental Studies Hy-
bridoma Bank, Johnson, Uni-
versity of Iowa, Iowa City, 
USA 
1:300 1:1000 
Tau-133 N-terminal tau-specific antiserum (aa 1-16), α-rabbit 
M. Goedert, MRC Laboratory 
of Molecular Biology, Cam-
bridge, UK 
 1:200 
Tau-134 C-terminal tau-specific antiserum (aa 428-441), α-rabbit 
M. Goedert, MRC Laboratory 
of Molecular Biology, Cam-
bridge, UK 
 1:200 
Tau5 
Phosphorylation-independent human 
tau antibody, aa 200-220, monoclonal 
α-mouse 
Biosource, LucernaChem, 
Lucerne, Switzerland  
1:500-
1:1000 
Tau-C3 Specific for caspase-3 cleaved tau at aa 421, monoclonal α-mouse 
L. Binder, Northwestern Uni-
versity, Chicago, USA  1:500 
α-14-3-3 Recognize a mixture of GST-14-3-3 proteins, polyclonal α-rabbit Abcam Ltd., Cambridge, UK  1:1000 
α-GFP Anti green fluorescent protein, α-rabbit 
Biosource, LucernaChem, 
Lucerne, Switzerland  1:1000 
α-
RhoGDI Anti RhoGDI, polyclonal α-rabbit Abcam Ltd., Cambridge, UK  1:1000 
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ted in 150 µl RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 0.5% 
sodium deoxycholate SDO, 1% NP-40) with a Microlance 26 GA5/8 tip. After incubation for 
20 min on ice and centrifugation for 20 min at 10’000 g at 4°C, the supernatant was recov-
ered (RIPA fraction). The RIPA insoluble pellet was transferred with a pipette tip to a Beck-
man centrifuge tube. The pellet was extracted in 70% formic acid (FA) with a Microlance 26 
GA5/8 tip and incubated for 20 min on ice. The FA-solution was centrifuged for 30 min at 
50’000 g in an Optima TLX ultracentrifuge using a Beckmann TLA 120.2 rotor (Beckmann, 
Nyon, Switzerland) at 4°C. The supernatant was transferred onto a Millipore dialyze mem-
brane (Millipore, Volketswil, Switzerland) and dialyzed against 50 mM Tris (pH 7.4), 1 mM 
DTT (DiThioThreitol), and 0.1 mM PMSF for 1h at room temperature (FA fraction). All frac-
tions were stored at -80°C. 
 
2.2.12 Western Blot analysis 
 
Protein concentrations of the samples were determined with the DC Protein Assay (Bio-Rad, 
Reinach, Switzerland). Same amount of protein separated on 10-20% Tricine gels (Invitro-
gen, Basel, Switzerland) (10 x running buffer: 121 g TrisBase, 179 g Tricine, 10 g SDS per 1l 
H2O adjusted to pH 8.3) and then transferred onto nitrocellulose membranes (0.1 µm) 
(Schleicher & Schuell BioScience, Dassel, Germany) (10 x transfer buffer: 144,2 g Glycine 
and 30,4 g TrisBase per 1l H2O). The blots were blocked in TBS-Tween (TBST) containing 
5% non-fat milk for 1h and incubated with the primary antibody overnight at 4°C or for 2h at 
room temperature. Primary antibodies used for western blotting (WB) are listed in table 2.1. 
After three 5 min washes with TBST, the membranes were incubated with the appropriate 
secondary antibody conjugated to HRP (Horseradish Peroxidase) (Amersham Biosciences, 
Otelfingen, Switzerland) for 1h and washed afterwards with TBS at least three times. The 
blots were developed using ECL Western Blotting detection reagents (Amersham Biosci-
ences, Otelfingen, Switzerland) or SuperSignal West Femto Luminol / Enhancer Solution 
(Pierce, Perbio Science, Lausanne, Switzerland). Same exposure times were chosen for all 
blots. The films (X-OMAT LS, Kodak/Sigma, Buchs, Switzerland) were scanned and images 
were analyzed using the ImageJ analysis program developed at the National Institutes of 
Health (http://rsb.info.nih.gov/ij/). If needed, the blots were stripped for 30 min at 50°C 
using a Western Blot Stripping Buffer (2% SDS, 0.0625 M Tris and 0.1 M β-Mercapto-
ethanol) and reprobed. 
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2.2.13 Immunoprecipitation 
 
Immunoprecipitation was done using the Seize Primary Immunoprecipitation Kit (Pierce, 
Perbio Science, Lausanne, Switzerland) following the manufacturer’s instructions. Thereby, 
the purified antibody is immobilized directly onto an agarose gel column, where it can form 
an immune complex with the antigen of interest. After removal of non-bound material by 
washing, the bound antigen can be dissociated from the antibody and collected by centrifu-
gation. The advantage of this method is that it enables the reuse of primary antibody and 
results in purified antigen free of antibody contamination. 
 
2.2.14 Silver staining 
 
Silver staining allows the detection of most proteins on polyacrylamide gels. Thereby, the gel 
is impregnated with soluble silver ions and developed by treatment with formaldehyde, which 
reduces silver ions to form an insoluble brown precipitate of metallic silver. This reduction is 
promoted by proteins. A modified staining protocol from Blum et al. was used (Blum et al., 
1987). Protein fractions were run on a 10-20% Tricine gel. The gel was than fixed in 40% 
ethanol and 10% acetic acid overnight at 4°C. Following two washes in 30% ethanol and one 
wash in H2O, each for 20 min, the gel was sensitized in 0.02% sodium thiosulfate (Na2S2O3) 
for 1 min. The gel was washed 3 x 20 sec in H2O, incubated in ice-cold 0.1% silver nitrate 
(AgNO3) for 20 min at 4°C and washed again 3 x 20 sec in H2O. To develop the gel a solu-
tion containing 3% sodium carbonate (Na2CO3) and 0.05% formalin was used. If the devel-
oper turned yellow the solution was renewed. As soon as the staining was sufficient, it was 
terminated in 1% glycine for 10 min. Finally, the gel was washed 3 x 10 min and stored in 
H2O. 
 
2.2.15 Mass spectrometry analysis 
 
Since extraction of proteins from the gel is difficult, in-gel digestion of proteins with proteases 
(mostly trypsin) is used to generate peptide fragments. These peptide fragments were ana-
lyzed by matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry 
(MALDI-TOF / TOF). The mass spectra were further analyzed with the software Mascot (Ma-
trix Science, available at www.matrixscience.com) using a combined MS and MS/MS search. 
This search was carried out against the human UniProt complete proteome set database to 
identify proteins by comparing the peptide masses. Analysis was done at the Functional Ge-
nomics Center Zurich (FGCZ user centre) by Della David from the same laboratory.  
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2.2.16 Tet-system 
 
The Tet-system uses a transactivator which is expressed from a constitutive promoter (regu-
latory plasmid) to regulate the transcription of a gene of interest from a silent promoter (re-
sponse plasmid) (Fig. 2.9). In the Tet-On system the transactivator (rtTA) binds to a Tet-
response element (TRE) on the response plasmid and activates transcription in the presence 
of an inducer. The current inducer of choice is doxycycline (DOX) because of its low cost, 
commercial availability, and because it efficiently activates rtTA at doses that are well below 
cytotoxic levels. Transfected cells were treated for 24h with doxycycline (10 µg/ml). 
The regulator plasmid pUHD 29-1 that encodes the reverse-tetracycline-controlled transacti-
vator was obtained from Dr. Bujard (ZMBH, Heidelberg, Germany). The pBI Tet Vector (BD 
Biosciences Clontech, Palo Alto, CA, USA) is a response plasmid that can be used to ex-
press two genes of interest from one bidirectional promoter (Pbi-1), regulated by the rtTA pro-
tein. Pbi-1 contains a TRE element, which consists of seven copies of the 42-bp tet operator 
sequence (tetO). The TRE element is located between two minimal CMV promoters 
(CMVmin), which lack the enhancer that is part of the complete CMV promoter. Each of the 
two CMVmin-promoters controls the expression of two separate genes of interest (Fig. 2.9). 
 
PCMV rtetR AD
APPArctic TauTREPminCMV PminCMV
Dox
Transcription Transcription
B: with doxycycline
Regulator plasmid: TetOn
rtetR: Reverse Tet repressor protein
AD:    VP16 activation domain
APPArctic TauTREPminCMV PminCMV
A: without doxycycline
TRE: Tet Response element
 
Fig. 2.9 Tet-on-system: A regulator plasmid encodes the reverse-tetracycline-controlled transactivator (rtTA; con-
sisting of rtetR and AD) under the control of a constitutive promoter. As a response plasmid the pBI Tet vector is 
used which express two genes of interest (Tau and APPARC) each under the control of one minimal CMV pro-
moter. (B) Only in the presence of an inducer (doxycycline) the transactivator binds to a Tet-response element 
(TRE) located on the response plasmid and activates thereby transcription of the genes of interest. 
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2.2.16.1 β-galactosidase assay 
 
SH-SY5Y and HEK 293 cells were plated on 6 well plates at a density of 4 x 105 cells / well 
and co-transfected with the rtTA-plasmid and a pBI-GL control vector (BD Biosciences Clon-
tech, Palo Alto, CA, USA), which is a response plasmid that can be used to express 
luciferase and β-galactosidase. After 24h treatment with doxycycline (10 µg/ml) cells were 
washed in PBS and fixed for 15 min in 0.05% glutaraldehyde in PBS. After 3 x washing for 5 
min in PBS, they were stained in X-gal stain solution (1 mg/ml X-gal, 5 mM C6FeK3N6, 5 mM 
C6FeK4N6, 2 mM MgCl2, PBS pH 7.3) for 3 hours at 37°C.  
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3 RESULTS 
 
3.1 Behavioral analysis of P301L tau transgenic mice 
 
3.1.1 Amygdala-dependent test battery 
 
3.1.1.1 Expression pattern of P301L tau 
 
To determine the expression pattern of human P301L tau in more detail, with special empha-
sis on brain areas involved in the CTA task, frontal sections of four P301L tau expressing 
mice were analyzed by immunohistochemistry using the human tau-specific antibody HT7 
and the phosphorylation-dependent anti-tau antibody CP13 (Fig. 3.1). Expression of human 
tau was found in the motor, somatosensory and insular cortex (IC) and in the claustrum at 
position AP +1.1 mm. At AP –0.82, tau was present in cortical motor and somatosensory 
neurons and to a variable degree in the posterior part of the agranular insular cortex (AIP), in 
the anterior cortical amygdaloid nucleus (ACo) and different regions of the thalamus. At posi-
tion AP –1.34, expression was found in the cortex, in the basolateral (BLA) and the basome-
dial nucleus of the amygdala (BM), in the dorsal endopiriform nucleus (DEn) and in the ACo. 
No tau expression was found in the lateral nucleus (LA) and the central nucleus of the amyg-
dala (CE). HT7 staining revealed also a strong expression of human tau in the hippocampus 
(CA1, CA3 and dentate gyrus), whereas staining of these brain areas with the CP13 antibody 
was very weak. However, both antibodies strongly stained the posterior part of these hippo-
campal regions at position AP –2.92 (where human tau was also expressed in cortical neu-
rons), the posterior part of the basolateral amygdala, and to a variable degree neurons in the 
red nucleus (parvocellular part, RPC), the ventral tegmental area (VTA) and the posterome-
dial cortical amygdaloid nucleus (PMCo). At AP –4.60, tau was present in cortical neurons, 
especially in the lateral entorhinal cortex and the external cortex of the inferior colliculus 
(ECIC) and to a variable degree in the oral pontine reticular nucleus (PnO), the rostral perio-
livary region (RPO) and the reticulotegmental nucleus pons (RtTG). Particularly high levels of 
expression were found in the brain stem (AP –7.20), predominantly in the inferior olive (IO), 
the ambiguus nucleus (Amb), and in various parts of the reticular formation and medulla. In 
contrast to the tau expression in the BLA, IC and some thalamic nuclei, no expression was 
found in CTA-relevant areas such as the ventral posteromedial nucleus of the thalamus 
(VPM), the parabrachial nucleus (PBN) and the nucleus of the solitary tract (NTS). 
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Fig. 3.1 Expression pattern of tau in P301L tau transgenic mice. (A) Areas involved in CTA are shown in gray: IC, 
insular cortex; VPM, ventral posteromedial nucleus of the thalamus; LH, lateral hypothalamus; Am, amygdala; 
PbN, parabrachial nucleus and NTS, nucleus of the solitary tract. (B) Tau was expressed in the cortex, hippo-
campus and adjacent brain areas. (C) Higher magnification of tau expression in the IC and CL (claustrum), (D) 
the hippocampus, (E) the DEn (dorsal endopiriform nucleus), the BLA (basolateral nucleus) and BM (basomedial 
nucleus) of the amygdala, the Astr (amygdalostriatal transition area), but not in the lateral nucleus (LA) and the 
central nucleus of the amygdala (CE). (F) Tau was expressed in the brain stem. (G) Higher magnification of (F) 
shows high tau expression in motor neurons of the brain stem. (H) The amygdala of a wt mouse is shown as a 
negative control. The sections were stained with the human tau-specific antibody HT7 (B, D, F, G, H) and the 
phospho-tau specific antibody CP13 (C, E).  
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3.1.1.2 Weight reduction and motor coordination of P301L tau transgenic mice  
 
At 6 months of age when the experiments were initiated, body weights of wild-types (38.2 ± 
2.2 g) were significantly higher than that of P301L tau transgenic mice (33.0 ± 1.2 g; p < 
0.04) (wt: N=21; P301L: N=20). This difference was even more pronounced during the CTA 
task, where the mice were water-deprived (wt: 36.4 ± 1.2 g; P301L: 30.2 ± 0.8 g; p < 0.001) 
(Fig. 3.2). To test whether expression of the transgene affected locomotor coordination the 
accelerating Rotarod test was performed (N=11/group). P301L mice stayed significantly 
longer on the Rotarod than wt mice (wt: 124.3 ± 14.2 sec; P301L: 178.2 ± 17.5 sec; F (1,20) 
= 5.316, p < 0.032) and therefore reached a significantly higher average speed (wt: 18.7 ± 
2.0 rpm; P301L: 25.3 ± 2.3 rpm; F (1,20) = 4.647, p < 0.043) before slipping off the rod. 
However, when the data were normalized for weight (by calculating a weight coefficient), the 
differences between the two groups disappeared (F (1,20) = 0.364, p > 0.553), demonstra-
ting a correlation between weight and performance on the Rotarod (Fig. 3.3). 
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Fig. 3.2 Weight reduction of P301L mice. The weight of the P301L mice was significantly reduced at the onset of 
the experiment (p < 0.04) and, more pronounced, during the CTA task (p < 0.001). The values represent the 
mean ± SEM. 
 
 
3.1.1.3 Slightly increased exploration of P301L mice in the open-field and light-
dark test 
 
Levels of spontaneous locomotor activity, anxiety-like behavior and exploration were as-
sessed in the open-field and light-dark (L/D) tests. In the open-field test (N=21/group), no 
genotype effect was found for measures of locomotor activity [total distance traveled: F 
(1,40) = 2.587, p > 0.116; total number of zone transitions: F (1,40) = 0.003, p > 0.956]. Simi- 
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Fig. 3.3 Correlation between weight and performance on the Rotarod. (A) P301L mice stayed significantly longer 
on the Rotarod than wt mice. (B) However, when the data were normalized for weight (by calculating a weight 
coefficient), the differences between the two groups disappeared. The values represent the mean ± SEM. 
 
 
larly, no differences were found for measures of anxiety such as thigmotaxis (F (1,40) = 
0.119, p > 0.732), the time spent in the inner zone (F (1,40) = 0.473, p > 0.496), and the av-
erage distance to the inner zone (F (1,40) = 0.347, p > 0.559). Only for the total number of 
activity state changes a significant genotype effect was detected (F (1,40) = 6.469, p < 
0.015) (Fig. 3.4). 
No significant differences were found in the L/D test (wt: N=20; P301L: N=21) for measures 
of anxiety such as the latency to enter the dark compartment (F (1,39) = 0.082, p > 0.776) 
and the time spent in the dark compartment (F (1,39) = 0.040, p > 0.843). In contrast, addi-
tional parameters for exploration such as the number of rearings (F (1,39) = 4.624, p < 
0.038) and the exploration index (F (1,39) = 4.078, p < 0.050) were significantly increased in 
P301L tau transgenic mice (Fig. 3.5).  
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Fig. 3.4 No altered activity levels of P301L mice in the open-field test but slightly increased exploratory behavior. 
(A) Total distance moved; (B) average distance to exploration zone; and (C) total number of activity state 
changes. Values represent the mean ± SEM. 
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Fig. 3.5 No altered anxiety levels of P301L mice in the light-dark test but slightly increased exploratory behavior. 
(A) Latency to enter the dark compartment; (B) time spent in the dark compartment; (C) number of rearings; and 
(D) exploration index. Values represent the mean ± SEM. 
 
 
3.1.1.4 No altered fear conditioning in P301L mice 
 
To test the ability of P301L mice to acquire a conditioned fear response, freezing was re-
corded during the conditioning session as well as the retrieval sessions for conditioning to 
context or tone. During conditioning, freezing increased significantly in both groups after the 
first US has been delivered (F (7,273) = 38.022, p < 0.001; wt: N=21; P301L: N=20; Fig 
3.6A). Neither genotype nor genotype x interval significantly affected freezing during condi-
tioning (genotype: F (1,39) = 2.857, p > 0.099; genotype x interval: F (7,273) = 1.436, p > 
0.191), although freezing levels of transgenic mice consistently were below that of wt mice 
(Fig. 3.6A). 
During the retrieval test for context conditioning, no significant differences between trans-
genic and wt mice could be found 24 h (F (1,39) = 0.344, p > 0.561) (wt: N=21; P301L: 
N=20) as well as 15 days (F (1,19) = 0.242, p > 0.629) (wt: N=11; P301L: N=10) post-
conditioning (Fig. 3.6B). No significant genotype effect was observed in freezing during the 
retrieval test for conditioning to tone, neither at 24 h (F (1,39) = 0.013, p > 0.911) nor at 15 
days (F (1,19) = 0.068, p > 0.798) post-conditioning. Freezing significantly increased in re-
sponse to tone presentation (second minute of the test) in both groups (24h: F (3,117) = 
34.287, p < 0.001, 15d: F (3,57) = 112.458, p < 0.001) demonstrating that wt as well as 
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P301L mice learned to associate the tone with the US. Tone presentation elicited a similar 
increase of freezing in both groups (genotype x interval interaction: 24h: F (3,117) = 0.776, p 
> 0.510, 15d: F (3,57) = 0.512, p > 0.676) (Fig. 3.6C). 
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Fig. 3.6 No altered fear conditioning in P301L mice. (A) Genotype did not significantly affect freezing during con-
ditioning (p > 0.099). Base, baseline activity; CS, tone presentation; ITI, inter-trial interval. (B) In the context test, 
no significant differences between genotypes were detected, neither at 24 h (p > 0.561) nor at 15 days ( p > 
0.629) post-conditioning. (C) In the cue test, no significant differences between genotypes were detected, neither 
at 24 h ( p > 0.911) nor at 15 days (p > 0.798) post-conditioning. The values represent the mean ± SEM. 
 
3 RESULTS 
52 
3.1.1.5 Enhanced extinction of CTA in P301L mice 
 
To test the ability to develop a taste aversion, P301L mice and wild-type littermate controls 
(N=19/group) were exposed to the novel taste saccharin (CS) followed by a single injection 
of LiCl (US). A two-way ANOVA with repeated measures over the choice tests conducted 48 
h, 72 h and one week after conditioning showed a significant main effect of genotype (F 
(1,36) = 8.167, p < 0.007), choice test (F (4,144) = 8.352, p < 0.001) and genotype x choice 
test interaction (F (4,144) = 3.266, p < 0.013) (Fig. 3.7A). Post-hoc pair-wise comparisons 
revealed that during the first choice test 48 h after conditioning both groups developed a 
strong taste aversion for saccharin (percentage of saccharin consumed: wt: 5.6 ± 1.0%;  
 
0
20
40
60
80
100
%
  f
lu
id
co
ns
um
ed
saccharin
consumption
quinine
consumption
0
10
20
30
40
50
60
%
 s
ac
ch
ar
in
co
ns
um
ed
1 w 5 w
A
B
wt (N=19)
P301L (N=19)
wt (N=11)
P301L (N=11)
48 h  72 h
after conditioning
wt (N=11)
P301L (N=11)
%
  f
lu
id
co
ns
um
ed
%
 s
ac
ch
ar
in
co
ns
um
ed
 
Fig. 3.7 Accelerated extinction of CTA in P301L mice. (A) During the first choice test 48 h after conditioning no 
significant genotype effect was observed (p > 0.094). However, during all subsequent choice tests, 72 h and one 
week after conditioning, P301L mice consumed significantly more saccharin (N=19/group). Additionally, a subset 
of mice (N=11/group) was again tested five weeks after conditioning. P301L mice continued to show a signifi-
cantly accelerated extinction. (B) Basic taste qualities in naive mice were not impaired by the tau pathology. Val-
ues represent the mean ± SEM. 
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P301L: 9.8 ± 2.1%; p > 0.094), indicating that acquisition and consolidation of a taste aver-
sion was not significantly impaired by the tau pathology. However, during the second choice 
test, P301L mice began to consume significantly more saccharin than wild-types (p < 0.017) 
demonstrating a faster extinction of the taste aversion. Repetition of these choice tests on 3 
consecutive days starting 1 week after conditioning showed that CTA memory in wild-type 
mice extinguished slowly, whereas extinction was significantly faster in transgenic mice. A 
subset of mice (N=11/group) was again exposed five weeks after conditioning to three such 
choice tests. P301L mice still continued to show a significantly accelerated extinction (main 
effect of genotype: F (1,20) = 5.404, p < 0.031) (Fig. 3.7A). Neither the amount of water in-
take during the last adaptation day before conditioning (wt: 1.34 ± 0.07 g; P301L: 1.41 ± 0.05 
g; F (1,36) = 0.592, p > 0.447), nor the amount of saccharin consumed on the conditioning 
day itself (wt: 1.27 ± 0.11 g; P301L: 1.35 ± 0.06 g; F (1,36) = 0.339, p > 0.564) revealed a 
significant effect of the transgene. In addition, total liquid intake (water plus saccharin) of 
P301L mice did not differ significantly from wild-type controls at any time point during the 
choice tests (F (1,36) = 0.094, p > 0.761).  
Basic taste qualities were assessed in water-deprived naive mice (N=11/group) by present-
ing saccharin and quinine solutions. This did not reveal any significant differences between 
transgenic and control mice (for saccharin: F (1,20) = 0.147, p > 0.706; and for quinine: F 
(1,20) = 0.002, p > 0.968), indicating that P301L mice possess a normal taste sensitivity (Fig. 
3.7B). 
 
 
3.1.2 Hippocampus-dependent test battery 
 
3.1.2.1 Increased exploratory behavior of P301L mice in the open-field and ele-
vated O-maze 
 
In a second set of experiments P301L mice were used with a calculated > 98% C57Bl/6 
background. To assess levels of spontaneous locomotor activity, anxiety-like behavior and 
exploration, two tasks were performed. 
In the open-field, at 6 months of age (N=12/group), no genotype effect was found for meas-
ures of locomotor activity such as total distance traveled (F (1,22) = 0.088, p > 0.769) (Fig. 
3.8A) and total number of zone transitions (F (1,22) = 0.378, p > 0.545). In contrast, a signifi-
cant genotype effect was detected for measures of anxiety and exploration such as the time 
spent in the inner (exploration) zone (F (1,22) = 9.650, p < 0.005) (Fig. 3.8B), number of vis-
its to the inner zone (F (1,22) = 6.014, p < 0.023) (Fig. 3.8C), and the distance traveled in the 
inner zone (F (1,22) = 6.725, p < 0.017). Evidence that this zone was indeed anxiogenic for 
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the control group was confirmed by the finding that they spent only 70% of the calculated 
expected time in this zone, whereas P301L mice performed at chance level.  
At 11 months of age (N=12 (wt); N=9 (P301L)), a significantly different locomotor behavior 
was revealed between genotypes (total distance traveled (F (1,19) = 8.384, p < 0.009) (Fig. 
3.8A); total number of zone transitions (F (1,19) = 8.452, p < 0.009)), showing enhanced ac-
tivity in P301L mice compared to wild-type controls. In contrast to 6 months old mice, no sig-
nificant differences were found in the time spent in the inner (exploration) zone (F (1,19) = 
0.140, p > 0.712) (Fig. 3.8B). However, P301L mice still performed more visits to the inner 
zone (F (1,19) = 6.365, p < 0.021) (Fig. 3.8C) where they showed higher activity levels (F 
(1,19) = 6.565, p < 0.019). In addition, further analysis revealed that wild-type mice spent sig- 
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Fig.3.8 Increased exploration and reduced anxiety levels of P301L mice in the open-field. (A) Total distance trav-
eled, (B) time spent in the inner (exploration) zone, and (C) total number of visits to the exploration zone. 
N=12/group at 6 months; N=12 (wt); N=9 (P301L) at 11 months. Values represent the mean ± SEM. 
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Fig. 3.9 Increased exploration of P301L mice in the elevated 0-maze. (A) Percentage of time spent in open sec-
tors, (B) total number of head dips, (C) percentage of protected head dips, and (D) total distance traveled. 
N=12/group at 6 months; N=12 (wt); N=10 (P301L) at 11 months. Values represent the mean ± SEM. 
 
 
nificantly more time resting in the exploration zone (periods with >2s with speed <0.025m/s 
(system noise threshold)) than P301L mice (F (1,19) = 5.378, p < 0.032), possibly demon-
strating a more anxiety-like behavior. No differences were found in thigmotaxis (F (1,22) = 
2.533, p > 0.126) at either age. 
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In the elevated O-maze, no significant differences were found for measures of anxiety such 
as the percentage of time spent in open sectors (6 months (N=12/group): F (1,22) = 0.088, p 
> 0.770; 11 months (N=12 (wt); N=10 (P301L)): F (1,20) = 2.407, p > 0.136) (Fig. 3.9A), and 
the percentage of entries into open sectors compared to total entries (6 months: F (1,22) = 
1.226, p > 0.280; 11 months: F (1,20) = 1.948, p > 0.178). Furthermore, the total number of 
head dips (F (1,22) = 2.942, p > 0.100) (Fig. 3.9B) and the percentage of protected head dips 
(F (1,22) = 0.012, p > 0.915) (Fig. 3.9C) did not differ at 6 months of age. In contrast, these 
measures varied significantly at 11 months (Total number of head dips (F (1,20) = 18.075, p 
< 0.001) (Fig. 3.9B); percentage of protected head dips (F (1,20) = 4.890, p < 0.039) (Fig. 
3.9C). Additional exploratory measures in the O-maze such as the total distance traveled (6 
months: F (1,22) = 8.903, p < 0.007; 11 months: F (1,20) = 14.054, p < 0.001) (Fig. 3.9D) 
and the total number of zone transitions (6 months: F (1,22) = 7.180, p < 0.014; 11 months: F 
(1,20) = 16.092, p < 0.001) were significantly increased in P301L mice at both ages tested. 
 
3.1.2.2 No altered spatial working memory in P301L mice 
 
To test spatial working memory, spontaneous alternation behavior was analyzed in the Y-
maze. All groups (6 months: N=12/group; 11 months: N=12 (wt); N=10 (P301L)) expressed a 
reliable spatial working memory by performing above chance level (> 58.9%). P301L mice 
did not differ in their alternation behavior from wild-type controls (6 months: F (1,22) = 0.169, 
p > 0.685; 11 months: F (1,20) = 3.995, p > 0.059) (Fig. 3.10A). They even showed a slightly 
more pronounced alternation behavior at 11 months, which may be due to their higher ex-
ploratory drive. No differences were found in the number of arm entries indicating equivalent 
total activity and motivation states (6 months: F (1,22) = 0.019, p > 0.891; 11 months: F 
(1,20) = 0.825, p > 0.375) (Fig. 3.10B). Together, this shows that P301L mice are not im-
paired in spatial working memory. 
 
3.1.2.3 Deficits in spatial reference memory in P301L mice 
 
To assess spatial reference memory, P301L mice and wild-type littermate controls were 
tested in the Morris water maze paradigm. All groups learned to locate the hidden platform 
position as shown by decreased escape latencies during the acquisition phase (6 months 
(N=12/group): time effect: F (8,176) = 17.779, p < 0.001; genotype effect: F (1,22) = 0.270, p 
> 0.609; genotype x time effect: F (8,176) = 0.466, p > 0.879; 11 months (N=12 (wt); N=10 
(P301L)): time effect: F (8,160) = 4.587, p < 0.001; genotype effect: F (1,20) = 0.036, p > 
0.851; genotype x time effect: F (8,160) = 0.804, p > 0.600) (Fig. 3.11A). The escape laten-
cies increased notably in both genotypes at 6 months of age after replacing the platform for 
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Fig. 3.10 No deficits in spatial working memory of P301L mice in the Y-maze. (A) Percentage of spontaneous 
alternation behavior, and (B) total numbers of arm entries. N=12/group at 6 months; N=12 (wt); N=10 (P301L) at 
11 months. Values represent the mean ± SEM. 
 
 
the reversal phase, confirming that the animals had adapted their escape strategy to the 
specific platform position. Nevertheless, both groups were able to adapt to the new platform 
position (time effect: F (5,110) = 6.951, p < 0.001; genotype effect: F (1,22) = 1.387, p > 
0.252; genotype x time effect: F (5,110) = 1.234, p > 0.298) (Fig. 3.11A). At 11 months, no 
significant improvement in the escape latencies over time was revealed, mostly due to the 
lower escape latencies already at the beginning of the reversal phase (time effect: F (5,100) 
= 1.267, p > 0.284; genotype effect: F (1,20) = 0.730, p > 0.403; genotype x time effect: F 
(5,100) = 0.928, p > 0.466) (Fig. 3.11A), indicating a weaker orientation towards the former 
platform position compared to the younger mice. Additional measures such as percentage of 
time in the current goal quadrant (genotype effect; 6 months: F (1,22) = 1.162, p > 0.293; 11 
months: F (1,20) = 0.364, p > 0.553) (Fig. 3.11B) or total distance traveled (genotype effect; 
6 months: F (1,22) = 0.857, p > 0.365; 11 months: F (1,20) = 0.048, p > 0.829) did not differ 
between genotypes. Average swim speed, floating time and wall hugging (thigmotaxis) were 
also not affected by the mutation (data not shown). 
To test spatial reference memory of the former platform location a probe trial (first 60 s of the 
first reversal trial) was conducted. A two-way ANOVA with repeated measures over the 
quadrant places showed a significant main effect of place (F (2,44) = 9.187, p < 0.001) and 
place x genotype interaction (F (2,44) = 3.201, p < 0.050) at 6 months of age. Post hoc pair-
wise comparisons revealed a significant place effect in wild-type mice (p < 0.001), whereas  
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Fig. 3.11 Acquisition and reversal learning in the Morris water maze. (A) Both P301L mice and wild-type littermate 
controls learn to locate the hidden platform position equally well, as shown by decreasing escape latencies in the 
acquisition phase. The escape latencies raise notably in both genotypes at 6 months of age after replacing the 
platform for the reversal phase, confirming that the animals have adapted their escape strategy to the specific 
platform position. At 11 months of age this effect is slightly less pronounced, indicating lower adaptation to the 
former platform location. However, all groups show a reasonable escape performance for the new platform posi-
tion during the reversal phase. (B) Additional measure: percentage of time spent in the present goal quadrant. 
N=12/group at 6 months; N=12 (wt); N=10 (P301L) at 11 months. Values represent the mean ± SEM. 
 
 
no such place effect was observed in P301L mice (p > 0.277). A further comparison revealed 
that P301L mice spent significantly less time in the former goal quadrant than wild-type con-
trol mice (F (1,22) = 6.820, p < 0.016) (Fig. 3.12A). A similar outcome was revealed by a 
more stringent measure of spatial selectivity when the percentage of time spent in a circular 
target zone (comprising one-eighth of the pool surface) was determined (F (1,22) = 7.831, p 
< 0.010) (Fig. 3.12B). Similarly, a significant difference was found for the annulus crossing (F 
(1,22) = 4.517, p < 0.045) (Fig. 3.12C). At 11 months of age, neither group showed a signifi-
cant preference for the former platform location (main effect of place: F (2,40) = 1.481, p > 
0.240); place x genotype interaction: F (2,40) = 1.117, p > 0.337). Therefore, no significant 
differences between the genotypes could be revealed at this age (time in the former goal 
quadrant: F (1,20) = 0.169, p > 0.685 (Fig. 3.12A); percentage of time spent in the target zo- 
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Fig. 3.12 Probe trial in the Morris water maze reveals deficits in spatial reference memory in P301L mice. (A) A 
two-way ANOVA with repeated measures over the quadrant places shows a significant main effect of place (p < 
0.001) and place x genotype interaction (p < 0.050) at 6 months of age. Post hoc pairwise comparison reveals a 
significant place effect for wild-type mice (p < 0.001), whereas no such place effect is observed in P301L mice (p 
> 0.277). Further comparison reveals that P301L mice spend significantly less time in the former goal quadrant 
than wild-type control mice (p < 0.016). At 11 months of age, neither group shows a significant preference for the 
former platform location (main effect of place: p > 0.240; place x genotype interaction: p > 0.337). Due to a floor 
effect as evidenced by a poor performance of the wild-type control group during the probe trial, with no significant 
preference above chance level for the former platform location, no significant differences could be revealed be-
tween the genotypes at this age (p > 0.685). A similar outcome is revealed by more stringent measures of spatial 
selectivity such as (B) percentage of time spent in a circular target zone (comprising one-eighth of the pool sur-
face) (6 months: p < 0.010; 11 months: p > 0.626 ), and (C) annulus crossing (6 months: p < 0.045; 11 months: p 
> 0.139). N=12/group at 6 months; N=12 (wt); N=10 (P301L) at 11 months. Values represent the mean ± SEM. 
 
 
ne: F (1,20) = 0.245, p > 0.626 (Fig. 3.12B) and annulus crossing F (1,20) = 2.378, p > 0.139 
(Fig. 3.12C)). Together, these results indicate an impaired memory retrieval of P301L mice in 
the water maze paradigm, which is masked in the older group by the poor performance of the 
wild-type control mice. 
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Finally, we analyzed the swim strategy of the mice during acquisition and reversal learning 
by categorizing each individual trial according to the predominant swimming pattern (Fig. 
3.13A). This revealed that the overall distribution of strategies did not differ between geno-
types (6 months: F (1,22) = 1.987, p > 0.173; 11 months: F (1,20) = 0.378, p > 0.546) (Fig. 
3.13B). In addition, no differences in the search strategy were found during reversal learning 
(6 months: F (1,22) = 0.033, p > 0.858; 11 months: F (1,20) = 0.687, p > 0.417) (Fig. 3.13C). 
Together, these data show that P301L mice do not use completely different search strategies 
than wild-type mice to escape from the water. 
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Fig. 3.13 Swim strategy during acquisition and reversal learning in the Morris water maze. (A) Swim strategies of 
the mice were analyzed during acquisition and reversal learning by categorizing each individual trial according to 
the predominant swimming pattern (FL, floating; TH, thigmotaxis; RS, random swim; SC, scanning; CH, chaining; 
FS, focal swim; DS, direct swim). The overall distribution of strategies does not differ between genotypes at any 
age (B) during acquisition (6 months: p > 0.173; 11 months: p > 0.546), and (C) during reversal learning (6 
months: p > 0.858; 11 months: p > 0.417). N=12/group at 6 months; N=12 (wt); N=10 (P301L) at 11 months. Val-
ues represent the mean ± SEM. 
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3.2 Role of different phospho-epitopes and cleavage sites in tau 
filament formation in tissue culture 
 
3.2.1. Analysis of DNA constructs 
 
To map phospho-epitopes of tau involved in filament formation in our human SH-SY5Y tissue 
culture system, the pRc/RSV expression vector containing the longest human 4-repeat tau 
isoform was utilized (Fig 3.14). The following epitopes in tau were mutated by site-directed 
mutagenesis: AT8 (S202A/T205A), AT100 (T212A/S214A) and T231A. The introduction of 
the designated point mutations and the correct orientation of the ligation products were veri-
fied by DNA cycle sequencing (Fig 3.15). In addition, a previously made tau construct bear-
ing the S422A mutation was included in the analysis. Besides the phospho-mutants, an iso-
form of tau truncated at position 421 was generated and analyzed by DNA cycle sequencing 
and restriction digests (Fig. 3.16).  
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Fig. 3.14 Tau plasmid: The longest human 4-repeat tau isoform (htau40) was blunt-end ligated into the multiple 
cloning site of the pRc/RSV expression vector. The total size of the tau bearing vector is ~ 6570 bp! To check for 
plasmid size, HindIII was used. This enzyme has one restriction site on tau (Pos 1021; numbering according to 
the longest tau isoform) and one on the vector (~ Pos 600) which yields two bands of ~ 1050 bp and 5500 bp. To 
release the tau fragment from the plasmid, BamHI and EcoRV can be used: There are three sites for BamHI and 
two for EcoRV on the vector, which yields five bands which can be distinguished by their size (~ 300 bp, ~ 800 bp, 
~ 1150 bp, ~ 1450 bp (the tau fragment), and 2800 bp, respectively). 
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Fig. 3.15 Analysis of single base pair substitutions by DNA cycle sequencing. (A) Mutagenesis of the AT8-epitope 
(Ser-202/Thr-205 mutated to S202A/T205A). (B) Mutagenesis of the AT100-epitope (Thr-212/Ser-214 mutated to 
T212A/S214A). (C) Mutagenesis of the pThr231-epitope (mutated to T231A). 
 
 
 
Fig. 3.16 Restriction analysis of ∆421 truncated tau: Digestion with HindIII yields two fragments for both ∆421 
truncated and wt tau. In contrast, digestion with NotI yields a single cut band only with the wt-tau plasmid as the 
NotI-site has been removed by the truncation procedure.  
 
 
3.2.2. Overexpression of tau constructs in human SH-SY5Y cells 
 
The different tau constructs were stably expressed in human SH-SY5Y neuroblastoma cells 
and their expression was confirmed by immunocytochemistry (Fig. 3.17) and Western blot-
ting (Fig. 3.18). The selective advantage of SH-SY5Y neuroblastoma cells is that they can be 
differentiated into neuron-like cells by sequential treatment with RA and BDNF. Thus, they 
mimic more closely the situation in the brain than other non-neuronal cell-types. As expected, 
sequential RA/BDNF treatment caused a neuron-like phenotype with neurite outgrowth and 
establishment of a complex neuronal network (Fig. 3.19). To elucidate the impact of tau over-
expression on the proliferation rate of SH-SY5Y cells, an MTT assay was performed for dif- 
∆421  wt ∆421  wt 
HindIII NotI
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B: wt-tauA: SH-SY5Y control
C: S202A/T205A-tau D: T212A/S214A-tau
 
Fig. 3.17 Immunofluorescence staining of SH-SY5Y cells with the human tau-specific antibody HT7 (1:200). SH-
SY5Y cells were (A) untransfected or transfected with (B) wt-tau, (C) S202A/T205A-tau and (D) T212A/S214A-tau 
constructs, respectively. 
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Fig. 3.18 Western blot analysis of RAB extracts: (A) Probing with the HT7 antibody (1:1000) reveals a prominent 
overexpression of htau40 in transfected cells compared to untransfected SH-SY5Y control cells independent of 
mutations or Aβ-treatment. (B) In contrast, CP13 antibody (1:50) against tau-phospho-epitope AT8 (Ser-202/Thr-
205) weakly labels wt-tau htau40, whereas the S202A/T205A tau mutant and endogenous tau is not detected. 
 
 
ferent time points of differentiation. During the 5 days of RA treatment, wt-tau overexpressing 
cells proliferated slightly faster than P301L mutant tau expressing and SH-SY5Y control cells 
(Fig. 3.20). Addition of BDNF terminated the proliferation of cells overexpressing tau and cell 
numbers were reduced as the S-type (flat) cells died off during the 5 days with BDNF. In con-
trast, SH-SY5Y control cells continued to proliferate throughout the entire differentiation pe-
riod.  
After ten days of RA/BDNF differentiation, SH-SY5Y cells were exposed for additional five 
days to fibrillar preparations of Aβ42. This treatment was not accompanied by any obvious 
increases in cell death (Ferrari et al., 2003). Once Aβ42 had been added to the cells, the me-
dium was not changed. This, in addition to the stickiness of fibrillar Aβ42, may explain why 
Aβ42 formed large clumps on the cell bodies and processes of differentiated cells (Fig. 3.21).  
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Fig. 3.19 Immunofluorescence staining of neuronally differentiated wt-tau (A+C) and SH-SY5Y control (B+D) cells 
with the human tau-specific antibody HT7 (1:200).  
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Fig. 3.20 Cell proliferation: Wt-tau overexpressing cells proliferate slightly faster than P301L mutant tau express-
ing and SH-SY5Y control cells during the phase of RA-treatment. Addition of BDNF terminates the proliferation of 
tau overexpressing cells, whereas SH-SY5Y control cells continue to proliferate throughout the entire period of 
differentiation. The data represent the mean of three replicates for each time point. 
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B.) +PBS 10x
D.) +PBS 20x
A.) +Aβ 10x
C.) +Aβ 20x
E.) +Aβ
 
Fig. 3.21 (A-D) Light-microscopic and (E) confocal images show that Aβ42 (4G8, green, Ferrari et al., 2003) 
forms large clumps on the cell bodies and processes of differentiated wt-tau expressing SH-SY5Y cells (HT7, 
red).  
 
 
3.2.3. Aβ42-treatment of tau overexpressing SH-SY5Y cells: Western Blot 
analysis and quantification 
 
Our group has shown recently that treatment of wild-type and P301L mutant tau overex-
pressing cells with fibrillar Aβ42 caused a substantial shift of tau from the RAB- and RIPA-
fraction into the FA-fraction, demonstrating increased levels of insoluble tau (Ferrari et al., 
2003).  
To confirm these previous in vitro findings and to determine whether mutating distinct phos-
pho-epitopes of tau will abrogate the β-amyloid-induced decrease in tau solubility, FA-
fractions of different cell extracts were analyzed by Western blotting (Fig. 3.22). As only 
highly insoluble proteins are shifted into the FA-fraction, not enough material is available to 
exactly determine the protein concentration of the solution. Therefore, relative volumes of 
FA-fractions were loaded normalized for the total volumes obtained. The ratio of the intensi-
ties of Aβ- vs. PBS-treated full length tau bands (~ 60 kDa) on the FA-blots was analyzed 
using ImageJ software. In addition to full-length tau, a low-molecular weight band at 28 kDa 
was detected by the HT7 antibody, which was used to detect tau on Western blots. Due to 
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uncertainty of the origin of this band (see chapter 3.2.4 below) it was not included in the 
quantification. At least three independent experiments were performed for each construct. As 
shown in figure 3.23, Aβ42-treatment of SH-SY5Y control cells caused a ~ 5.5 fold decrease 
in tau solubility compared to PBS-treated cells (baseline level), demonstrating the capability 
of endogenous tau to aggregate as well as transfected tau. Overexpressing wt-tau (htau40) 
in these cells led to an additional ~ 2.8 fold increase in Aβ42-mediated tau insolubility com-
pared to baseline induction level (~ 15.5 fold total increase upon treatment with Aβ42). By 
mutating the Ser-422 phospho-epitope into alanine, induction of tau insolubility dropped to 
baseline levels confirming previous findings (Ferrari et al., 2003). Furthermore, mutating the 
phospho-epitopes AT8 and pThr231 of tau prevented the decrease in tau solubility as well 
and may even be inhibitory to aggregation of endogenous tau, as shown by a ~ 60 % de-
crease in tau insolubility compared to baseline. Unfortunately, the data for the AT100 mutant 
had finally to be excluded due to a loss of the tau transgene as revealed by Western blot 
analysis of RAB-fractions. However, taken together, our results indicate a role of different  
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Fig. 3.22 Representative Western blot of FA-fractions: Aβ42 decreases the solubility of wt-tau significantly. Mutat-
ing specific phospho-epitopes of tau prevent this decrease in tau solubility compared to PBS-treated fractions. 
Note that no overexpressed tau was found in the RAB-fraction of T212A/S214A tau extracted cells (AT100 mu-
tant). Hence the data of this mutant cell-line is excluded from the analysis. WB labeled with HT7 (1:500 for FA-
blots). 
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Fig. 3.23 Quantification of tau in FA-fractions. Aβ42-treatment of SH-SY5Y control cells caused a ~ 5.5 fold de-
crease in tau solubility compared to PBS-treated cells (baseline level), demonstrating the capability of endoge-
nous tau to aggregate as well. Overexpressing wt-tau in these cells led to an additional ~ 2.8 fold increase in 
Aβ42-mediated tau insolubility compared to the baseline induction level. In contrast, mutating different phospho-
epitopes of tau (Ser-422, Ser-202/Thr-205 and Thr-231) prevented this decrease in tau solubility. Surprisingly, 
truncation of the C-terminal region of tau at position 421 prevented the Aβ42-mediated decrease in tau solubility as 
well. Bars represent the means ± SEM of at least three independent experiments. 
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epitopes in tau filament formation.  
Tau constructs truncated at Asp-421 assemble much faster than wild-type tau in vitro, dem-
onstrating that the carboxy-terminal tail of the tau molecule inhibits filament formation 
(Abraha et al., 2000; Berry et al., 2003). Surprisingly, truncation of the C-terminal region of 
tau at position 421 prevented the Aβ42-mediated decrease in tau solubility in our SH-SY5Y 
tissue culture system as well (Fig. 3.23).  
 
3.2.4. Characterization of tau isoforms in SH-SY5Y cells: 
 
To better characterize the tau isoforms extracted from SH-SY5Y cells, a Western blot analy-
sis of RAB-fractions with different tau antibodies was carried out (Fig. 3.24). In cells trans-
fected with the longest 4R-tau isoform, at least two bands between ~ 60-65 kDa could be 
detected (e.g. with the exon 10 specific antibody ET2). A faint band was also visible with the 
ET2-antibody in SH-SY5Y control cells, demonstrating the existence of endogenous 4R-tau 
isoforms in these cells, at least upon differentiation. The predominant endogenous tau spe-
cies in SH-SY5Y cells was the shortest 3R isoform (fetal tau) (Zhong et al., 1999). During  
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Fig. 3.24 Western profiling using different tau antibodies (RAB-fractions). (A) 4R-tau overexpressing band. (B) 
During differentiation the endogenous 3R-tau level increases dramatically (not detected with the exon 10 specific 
antibody ET2). (C) Low-molecular tau band (~28kDa), only labeled with antibodies with epitopes in the N-terminal 
half of tau (< aa 200). (D) Weak bands representing caspase-3 cleaved tau.  
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differentiation, endogenous 3R-tau level increased dramatically, due to neurite outgrowth. 
The low molecular weight band of 28 kDa which is detected by the HT7 antibody, was addi-
tionally visualized with Tau-133, an antiserum specific for the N-terminal part of tau. In con-
trast, all other antibodies, reactive with the C-terminal half of tau beyond position 200, did not 
recognize this band. These results may indicate that the 28 kDa band is an N-terminally trun-
cated fragment of tau (cleaved between aa 163 (HT7-epitope) and 200 (Tau5- epitope)) (Fig 
3.24). Moreover, weak bands, possibly representing caspase-3 cleaved tau at position 421, 
were seen with the truncation-specific antibody Tau-C3.  
To get more information about the molecular nature of the 28 kDa band, an immunoprecipita-
tion procedure was carried out. Thereby, an RAB-fraction of wt-tau overexpressing SH-SY5Y 
cells was loaded onto two tau-specific affinity columns, one coupled with HT7 and the other 
with Tau5A6 (directed against tau epitope aa 19-46). The different fractions were analyzed 
by Western blotting using HT7 as primary antibody. The 28 kDa band was only found in the 
flow-through (Fig.3.25; B4-lanes), whereas full-length tau was mainly found in the elution 
fractions (at least for HT7). Thus, the 28 kDa fragment does not bind to the tau antibodies 
including HT7 on the IP-column, while it is detected by HT7 on Western blots. One possible 
explanation for this finding is that HT7 can only recognize the 28 kDa epitope when the frag-
ment is denatured, which is the case after boiling the samples for the Western blotting pro-
cedure.  
To test this hypothesis, a pre-boiled RAB-fraction of wt-tau overexpressing cells was loaded 
onto the columns. Neither in the flow-trough, nor in the eluates was the 28 kDa band found, 
implicating that it is bound to the column. Therefore, the whole column was boiled twice to 
pull down everything, and the fractions were again loaded onto a gel (Fig. 3.26). In the boiled 
column fractions the 28 kDa band appeared once again, together with a slightly lower band 
 
34 kDa
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Fig. 3.25 Immunoprecipitation (IP) of tau. RAB-fraction of wt-tau overexpressing SH-SY5Y cells are loaded onto 
tau-specific IP-columns, generated with HT7 and Tau5A6 antibodies. B4: flow-through; IP1-3: wash steps after 
flow-through, to get rid of every unbound material; C: control fraction before loaded onto the IP-column; E 1-3: 
elution-fractions of the desired antigen. The 28 kDa band is only found in the flow-through and the control lanes 
(WB labeled with HT7 (1:1000)).  
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Fig. 3.26 Immunoprecipitation (IP) of the tau immune complex. To pull down everything which was sticking to the 
agarose gel / antibody complex, the whole column was boiled and fractions were loaded onto a 10-20 % tricine 
gel. In the boiled fraction the 28 kDa band appears again (compare with the B4 flow-through). Slightly below, a 
second band is visible, representing the light chain of the co-precipitated antibody. (WB labeled with HT7 
(1:1000)).  
 
 
(the light chain of the antibodies), indicating an highly hydrophobic structure of this band, but 
a conclusion pro or contra a tau origin can still not be drawn. A schematic overview of the IP-
experiments is illustrated in table 3.1. 
To isolate and analyze the 28 kDa band, IP-fractions were further separated by gel electro-
phoresis. The proteins were silver stained and the indicated bands were cut out (Fig. 3.27). 
After trypsinization, protein digests were identified by matrix-assisted laser desorption ioniza-
tion tandem time-of-flight mass spectrometry (MALDI-TOF / TOF). No tau fragments were 
revealed by this analysis, however, two interesting candidates, the adaptor protein14-3-3γ 
and Rho GDP-dissociation inhibitor (RhoGDI-1) were discovered (for all identified bands see 
table 3.2).  
 
Tab. 3.1: Schematic overview of the tau IP-experiments 
Sample Fraction 60 kDa band 28 kDa band 
Flow-through (+) + 
IP-RAB fractions 
Eluate + - 
Flow-through - - 
IP-Boiled RAB fractions 
Eluate + - 
Column boiled Eluate + + 
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Fig. 3.27 Silver staining of IP-fractions. The bands indicated below the 34 kDa marker band were cut out and 
analyzed by mass spectrometry. The 28 kDa is expected in the first three lanes of each tau-specific antibody 
column. The B4 boiled flow-through lanes served as controls. 
 
 
Tab. 3.2: Mascot search results: MALDI-TOF / TOF analysis 
 
Band number 
 
Protein number 
 
 
Protein name 
 
1 + 5 P01837 Ig kappa chain C region 
2 + 6 + 7 + 14 P52565 Rho GDP-dissociation inhibitor 1 (RhoGDI1) 
3 + 13 - Not detected 
4 + 12 Q15657 Tropomyosin isoform 
8 + 11 +15 P35214 14-3-3 protein gamma (Protein kinase C inhibitor protein-1) 
9 P42655 14-3-3 protein epsilon (Mitochondrial import stimulation factor L subunit) 
10 + 16 Q8TCG3 TPMsk3 (Fragment) 
 
 
To confirm a role of these proteins in our tissue culture system, FA-blots were stripped and 
reprobed with antibodies specific for 14-3-3γ and RhoGDI. Significant amounts of RhoGDI in 
the Aβ42-treated FA-fractions were revealed, whereas no labeling was achieved against 14-3-
3γ on the FA-blot. This indicates a specific effect of Aβ42 on RhoGDI solubility (Fig. 3.28). 
The band migrated with an apparent molecular mass of close to 28 kDa, however, a direct 
comparison with the HT7 blot suggested that the RhoGDI band is not congruent with the HT7 
band. Unfortunately, an IP with the RhoGDI antibody did not work, meaning that a final con-
firmation is still lacking. Nevertheless, RhoGDI is an interesting candidate to follow-up in 
subsequent studies (see discussion part 4.2).  
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Fig. 3.28 FA-blot reprobed with RhoGDI. A FA-blot was stripped and reprobed with a Rho-GDI specific antibody. 
Approximately at 28 kDa strong bands appear in the Aβ-treated fractions, indicating an effect of fibrillar-Aβ on 
RhoGDI. 
 
 
3.2.5 Tet-system 
 
In light of the interaction of Aβ/APP and tau in AD, it is useful to have a system available 
where expression of these genes is tightly regulated in a time- and concentration-dependent 
manner. Therefore, we created a bi-directional (pBI) Tet response system, with co-
expression of both tau and APP expected to provide new insights into the relationship of 
these two proteins. 
First, to be able to select positive clones, a neomycin-resistance sequence was cloned into 
the PvuII-site of the pUHD 29-1 regulator plasmid (Bujard, ZMBH, Heidelberg, Germany) that 
encodes the reverse-tetracycline-controlled transactivator (rtTA) (Fig. 3.29). Two pBI-
constructs were generated: wt-tau/GFP and wt-tau/APPArc (Fig. 2.9). The Arctic mutation was 
chosen, because Aß carrying this mutation forms protofibrils at a much higher rate and in 
larger quantities than wild-type Aß (Nilsberth et al., 2001). To generate these constructs, wt-
htau40-cDNA (cloned into the pRc/RSV expression vector) and a GFP-fragment (located on 
a GFP-expressing plasmid) were first removed by digestion with BamHI/EcoRV and Eco-
RI/NheI, respectively. The fragments were ligated (blunt-ended) into the multiple cloning site 
I (MCSI: EcoRV-site) of the pBI-vector.  
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ColE1
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PPGK
P:     Promoter (CMV)
rtTA: Reverse Tet-controlled 
transactivator
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TetOn: 5986bp
 
Fig. 3.29 Tet-on regulator plasmid pUHD 29-1. A neomycin-resistance sequence is cloned into the PvuII-site of 
the regulator plasmid that encodes the reverse-tetracycline-controlled transactivator (rtTA) under expression of a 
constitutive CMV-promoter.  
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Fig. 3.30 Restriction size analysis of the wt-tau/APPARC response plasmid. Correct orientation of the ligation prod-
uct is checked by double-digestion with BlpI (one restriction site in tau) and XhoI (one restriction site in APP). 
Correct ligation yields two fragments of the approximately sizes of 6820 and 1820 bp, respectively.  
 
 
The APPArc mutation was introduced into the human APP695 cDNA, which was cloned into the 
pGEM-9Zf vector. APP fragments were removed by digestion with HindIII and ligated (end-
blunted) into the MCSII-site (NotI) of the GFP-pBI or wt-tau-pBI vector. Similarly, wt-htau40 
cDNA was ligated into the GFP-pBI vector to obtain the wt-tau/GFP-vector. The correct se-
quence and orientation of all constructs was verified by DNA cycle sequencing and restriction 
enzyme size analysis (Fig. 3.30). 
In a first attempt, a stable founder Tet-On cell line was generated by transfecting SH-SY5Y 
cells with the regulator plasmid encoding the reverse-tetracycline-controlled transactivator 
(rtTA). The pBI-constructs were transfected (together with a pTK-Hyg selection vector) into 
the stably expressing founder Tet-On-SH-SY5Y cells to obtain double-stable Tet-On cell 
lines. However, no overexpression of the proteins of interest was achieved as determined by 
immunocytochemistry, Western blotting and GFP-fluorescence analysis. In addition, co-
transfection of the rtTA-plasmid with the response plasmids led to the same negative result 
(data not shown).  
To check Transfections efficiency and to determine whether the regulator plasmid was func-
tional, SH-SY5Y and HEK 293 cells were co-transfected with the rtTA-plasmid or with a new 
Tet-On regulator plasmid obtained from BD Biosciences and a pBI-GL control vector (BD 
Biosciences Clontech, Palo Alto, CA, USA), which is a response plasmid that can be used to 
express luciferase and β-galactosidase. After doxycycline treatment for 24h, the β-
galactosidase activity was measured by counting numbers of positive cells per visible field 
using light microscopy (Fig. 3.31). In HEK 293 cells a reliable expression of β-galactosidase 
was detected, demonstrating the functionality of the rtTA-plasmid. In contrast, only a few SH- 
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Fig. 3.31 β-galactosidase activity measurement. SH-SY5Y and HEK 293 cells were co-transfected with the rtTA-
plasmid and a pBI-GL-control vector, which express β-galactosidase upon treatment with doxycycline. After 24h 
treatment cells were fixed and incubated with an X-gal staining solution for 3h at 37°C. The numbers of positive 
cells per visible field were counted. Whereas HEK 293 cells show a reliable expression, only a few SH-SY5Y cells 
are labeled. At least three independent fields per cell-line were analyzed. 
 
 
SY5Y cells were labeled, indicating poor transfection efficiencies in these cells which may 
explain our negative findings shown above. A possible reason for this low transfection rate is 
the relatively large size of the plasmids (e.g. ~ 8400 bp for the wt-tau/APPArc construct) caus-
ing difficulties with cells, such as neuroblastoma cells.  
Next, to verify the response constructs (wt-tau/GFP and wt-tau/APPArc), HEK 293 cells were 
transiently transfected and 4h after transfection doxycycline was added for 24h. Transfected 
wt-tau/GFP cells showed a reliable GFP expression as revealed under the fluorescence mi-
croscope (Fig.3.32). Cells were then extracted in RAB-buffer and lysates analyzed by West-
ern blotting (Fig. 3.33). HT7-labelling revealed a strong overexpression of tau (16-30 fold) in 
transfected, non-treated cells compared to untransfected HEK 293 cells, showing an intrinsic 
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Fig. 3.32 Tet-system: HEK 293 cells transiently transfected with rtTA-regulator plasmid and the response wt-
tau/GFP construct (A) GFP-expression upon doxycycline-treatment for 24h. (B) Transfected cells without doxycy-
cline showing some basic background activity.  
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Fig. 3.33 Tet-system: HEK 293 cells transiently transfected with the rtTA-regulator plasmid and the response 
constructs wt-tau/GFP and wt-tau/APPARC, respectively. (A) The HT7 antibody (1:1000) is used to detect tau over-
expression. Background expression of tau is found in transfected cells without Dox-treatment. Upon treatment 
with doxycycline tau expression increase 4-7 fold compared to untreated cells. (B) A similar result is obtained by 
probing with α-GFP (1:1000) against GFP. (C) APP C-terminal antibody (1:2000) against APP revealed only a 
slightly higher APP expression in transfected cells due to high APP expression levels in untransfected cells. 
 
 
basal activity of tau. However, upon doxycycline (Dox) treatment the expression level of tau 
rose further (~ 95 fold compared with untransfected, Dox-treated cells and 4-7 fold compared 
with transfected, untreated cells). GFP expression showed a more regulated pattern, where 
basal levels were 6.5 fold higher than in untransfected cells. Dox treatment increased this 
basal transcription activity significantly (~ 26 fold). APP expression, however, was only 
slightly higher in transfected cells (~ 1.2 fold), since a prominent labeling was already seen in 
untransfected cells.  
Together, these results show that the regulator and response plasmids are functional. How-
ever, several additional experiments and perhaps also modifications of the system are nec-
essary to finally develop a functional TET-system in which the relationship between Aß and 
tau can be properly addressed. Some of these possibilities are brought up in the discussion 
part (4.3). 
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4 DISCUSSION 
 
4.1 Behavioral analysis of P301L tau transgenic mice 
 
I assessed P301L tau transgenic mice as a model for the tau pathology in AD and related 
disorders, first in using an amygdala-dependent test battery (fear conditioning and CTA) and 
secondly, using a hippocampus-dependent test battery (Y-maze and Morris water maze) 
(Table 4.1). Moreover, in both studies exploration, anxiety and locomotor activities were de-
termined, which were independent of the mouse background (Rotarod, open field test, light-
dark test, O-maze) (Table 4.1). Together, the data reveal a behavioral impairment of P301L 
tau transgenic mice, which can be correlated with the expression pattern of the human tau 
transgene. The data of the first study have been published 2004 in Neurobiology of Disease 
(Pennanen et al., 2004) and the results of the second study are in press in Genes, Brain and 
Behavior (Pennanen et al., 2005, in revision). 
 
4.1.1 Amygdala-dependent test battery 
 
The immunohistochemical and behavioral analysis of P301L tau transgenic mice revealed a 
widespread aggregation of tau in the forebrain that is accompanied by selective changes in 
behavior. Behavioral changes include a small increase in exploratory behavior and an accel-
erated extinction of an aversion against a taste that has been previously paired with nausea. 
No changes with respect to wild-types were found in locomotor activity, fear conditioning, 
taste neophobia, and unconditioned natural taste preference for a sweet solution and natural 
taste aversion against a bitter solution. Tau aggregation was found in the forebrain in nuclei 
of the amygdalar complex, the hippocampus and all areas of the neocortex investigated 
(sensory, motor and associative areas). Aggregates were also present in several brain stem 
areas including the red nucleus, ventral tegmental area, and parts of the reticular formation, 
inferior olive, and ambiguus nucleus. NFT formation, as a final stage of tau aggregation, is 
initiated in a subset of amygdaloid neurons at around six months of age, possibly reflecting 
high relative levels of tau expression and/or selective vulnerability of distinct amygdaloid nu-
clei (Gotz et al., 2001a; Gotz and Nitsch, 2001).  
The study also revealed that the body weight of P301L mice was slightly lower than that of 
wild-types already at the beginning of the behavioral testing at 6 months of age. This weight 
difference was even larger during the final (CTA) task of the test battery, when the mice were 
water-deprived. Such a weight loss could be due to disturbances in different brain areas. 
Lesion studies, for instance, established that certain hypothalamic nuclei regulate food intake  
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Tab. 4.1: Behavioral analysis of P301L tau transgenic mice 
TASK TESTING RESULTS 
1st study, amygdala-dependent test battery: P301L mice (B6D2F1 background; starting at 6 mt of age) 
Weight Body weight P301L mice ↓ 
Rotarod Locomotor coordination P301L mice ↑ 
Open-field Locomotor activity, anxiety-like behavior and exploration 
Activity: P301L mice ↔ 
Anxiety: P301L mice ↔ 
Exploration P301L mice ↑ 
Light-dark test Anxiety-like behavior and exploration 
Anxiety: P301L mice ↔ 
Exploration P301L mice ↑ 
Fear condition-
ing 
Conditioned fear response to tone and 
context 
Conditioning:P301L mice ↔ 
Context testing:P301L mice ↔ 
Tone testing:P301L mice ↔ 
Conditioned 
taste aversion 
(CTA) 
Conditioned taste aversion 
Acquisition and consolidation: P301L mice ↔ 
Extinction: P301L mice ↑ 
Basic taste qualities: P301L mice ↔ 
2nd study, hippocampus dependent-test battery: P301L mice backcrossed to C57BL/6 
Open-field Locomotor activity, anxiety-like behavior and exploration 
6 months of age: 
Activity: P301L mice ↔ 
Anxiety: P301L mice ↓ 
Exploration P301L mice ↑ 
11 months of age: 
Activity: P301L mice ↑ 
Anxiety: P301L mice ↓ 
Exploration P301L mice ↑ 
O-maze Locomotor activity, anxiety-like behavior and exploration 
6 months of age: 
Activity: P301L mice ↑ 
Anxiety: P301L mice ↔ 
Exploration P301L mice ↑ 
11 months of age: 
Activity: P301L mice ↑ 
Anxiety: P301L mice ↔ 
Exploration P301L mice ↑ 
Y-maze Spontaneous alternation behavior to test spatial working memory 
6 + 11 months of age: 
Alternation behavior: P301L mice ↔ 
Number of arm entries: P301L mice ↔ 
Morris water 
maze (MWM) 
Spatial reference memory , swimming 
navigation and search strategies 
6 months of age: 
Acquisition learning: P301L mice ↔ 
Reversal learning: P301L mice ↔ 
Probe trial: P301L mice ↓ 
Search strategies: P301L mice ↔ 
11 months of age: 
Acquisition learning: P301L mice ↔ 
Reversal learning: P301L mice ↔ 
Probe trial: P301L mice ↓ (but also wt mice ↓) 
Search strategies: P301L mice ↔ 
↑ = upregulated, ↓ = downregulated; ↔ = no significant differences 
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and body weight (Kishi and Elmquist, 2005). However, no tau aggregates were found in the 
hypothalamus. Damage to amygdaloid nuclei, an area with tau aggregates, has been re-
ported in rats to cause either no change or the opposite, i.e. a gain of weight (Rollins et al., 
2001). However, in our mice an altered emotion caused by amygdala dysfunction, such as 
increased exploratory behavior, could have pronounced effects on food uptake and thereby 
on body weight.  
In the open-field, P301L and wild-type mice moved equal distances, but P301L mice 
changed their activity state somewhat more often from progression to resting to scanning. 
Furthermore, in the light-dark box they were more active and clearly increased the frequency 
of rearing, all of which are signs for greater exploratory behavior. Both, in the open-field and 
light-dark test, measures of anxiety were unchanged. Several brain structures have been 
found to be involved in exploratory behavior including the hippocampus and amygdala. That 
the amygdala might be affected in our transgenic mice is suggested by the observation that 
amygdala lesions increase exploratory behavior (Kelley et al., 1989). Dysfunction of the 
amygdala, however, would not affect unconditioned anxiety as measured with an anxiety test 
(elevated plus-maze) in rats (Treit and Menard, 1997). 
Expression of the transgene and formation of tau aggregates in the forebrain did not impair 
fear conditioning to tone or context. When tested 15 days after conditioning, wild-types as 
well as P301L mice also showed no signs of extinction and froze even more in response to 
the conditioned stimuli (context, auditory cue). The non-significant tendency of reduced 
freezing of P301L mice only during conditioning remains puzzling, and no treatment with a 
similar selective effect has been described. Anyhow, it is difficult to imagine how emotional or 
cognitive changes could affect freezing during conditioning but not during retrieval.  
That P301L mice had no deficits in fear conditioning to a tone is in agreement with the ex-
pression pattern of tau aggregates in their brain (Fig. 4.1). Conditioning to an auditory CS is  
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Behavior: Fear reaction
LA = lateral nucleus of the amygdala
BLA = basolateral nucleus of the amygdala
BM = basomedial nucleus of the amygdala
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Fig. 4.1 Neuroanatomy of fear conditioning. (A) Conditioning to sensory inputs (e.g. tone) is dependent on func-
tionally intact lateral and central nuclei of the amygdala, sites that were free of tau aggregates (B) Context fear 
conditioning depends on an intact hippocampus which projects to the BLA. However, despite a prominent expres-
sion of P301L tau in the hippocampus and the BLA, no deficits were found in context fear conditioning. 
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dependent on functionally intact lateral and central nuclei of the amygdala (LeDoux, 2000), 
sites that were free of tau aggregates in our transgenic mice. The involvement of the baso-
lateral amygdala (BLA), a site with tau aggregates in P301L mice, is less well established 
(but see also (Goosens and Maren, 2001). In contrast to fear conditioning to a tone, success-
ful context fear conditioning depends on an intact hippocampus which projects to the BLA 
(LeDoux, 2000). However, despite a prominent expression of P301L tau in the hippocampus 
and the BLA of P301L mice, no deficits were found in context fear conditioning compared 
with control mice. This may be due to the design of the fear conditioning task that was 
probably not sensitive enough to reveal differences between the two groups. Similar to our 
P301L mice, aged APPSwe mutant mice also showed no deficits in fear conditioning to a tone  
or a context when compared to corresponding wild-types (Corcoran et al., 2002). These 
APPSwe mice had β-amyloid plaques in the hippocampus as well as the amygdala and a re-
duction in function might have been expected. Only when the salience of the context CS was 
reduced, an indication of impairment in APPSwe mice appeared. The general lack of massive 
neurodegeneration in animal models of AD may explain the largely normal performance of 
both P301L and APPSwe mice in fear conditioning, which is in contrast to the reported im-
paired fear conditioning in AD patients (Hamann et al., 2002). This demonstrates the impor-
tance to design highly sensitive protocols for the measurement of different behavioral tasks. 
P301L mice acquired a taste aversion indistinguishable from that of wild-types; that is, when 
given a choice to drink either a saccharin solution or water 2 days after pairing saccharin 
drinking with nausea, both genotypes greatly preferred water and avoided the saccharin so-
lution. However, repeated exposure to such a choice situation attenuated the aversion, and 
this extinction was drastically accelerated in P301L mice compared to wild-types. The possi-
bility has to be considered that a stronger conditioning in wild-type mice might not have 
shown due to a ceiling effect, that is, wild-type mice performed already close to an optimum 
with no further capacity of improvement. 
The CTA deficit in P301L mice cannot be explained by a reduced neophobia, an increased 
sweet preference or a reduced aversion for unpleasantly tasting solutions. With respect to 
these three traits, no genotype differences could be found. P301L, as well as wild-type mice 
reduced their fluid intake, when first exposed to the saccharin solution (neophobia), devel-
oped a strong preference for the sweet solution when drinking was not followed by nausea, 
and avoided a bitter tasting quinine solution to the same degree. Furthermore, despite their 
slightly reduced body weight, P301L mice did not consume less saccharin solution on the 
conditioning day, that is, exposure to the conditioned stimulus was comparable in both 
groups. 
It has been suggested that lesions of the BLA have a general effect on the response to novel 
stimuli (such as food) by decreasing neophobia (Dunn and Everitt, 1988). However, in our 
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study no attenuation of a taste neophobia was found. Thus, the observed formation of tau 
aggregates in the amygdala in P301L mice very unlikely caused a severe functional impair-
ment of this structure.  
Tau was expressed in brain areas which have been shown to be involved in CTA including 
the BLA, the insular cortex and some thalamic nuclei (Welzl et al., 2001). No expression was 
found in other CTA-relevant areas such as the ventral posteromedial nucleus of the thalamus 
(VPM), the parabrachial nucleus (PBN) and the nucleus of the solitary tract (NTS). 
Little is known about what might accelerate extinction of CTA. Several studies implicated 
hormonal systems, neurotransmitter systems or specific brain structures in CTA extinction 
(for review, see (Bures et al., 1998); but in general these studies described retarded, but not 
accelerated, extinction upon treatments. For example, whereas hippocampal lesions affected 
acquisition of CTA only mildly or not at all (Best and Orr, 1973; Yamamoto et al., 1995), they 
slowed extinction of an already conditioned aversion (Kimble et al., 1979). In one study, exci-
totoxic lesions of the VPM had little effect on the acquisition of CTA but markedly accelerated 
its extinction similar to what we observed in our transgenic mice (Yamamoto et al., 1995). 
However, tau is not expressed in the VPM of P301L mice. 
Numerous studies support a critical involvement of the amygdala in CTA (Aja et al., 2000; 
Lamprecht et al., 1997; Yamamoto et al., 1995). Similar to its effect on other aversive memo-
ries, the amygdala could modulate consolidation processes (e.g. of CTA) in other brain areas 
via its projections to these areas (McGaugh et al., 2002). Such a modulation could be 
achieved by pathways from the amygdala to the insular cortex, a structure critical for storage 
of a CTA. Stimulation in the BLA induced LTP in the insular cortex which enhanced retention 
of CTA memory in subsequent extinction trials (Escobar and Bermudez-Rattoni, 2000). 
Overexpression of P301L tau in the BLA could impair this modulatory effect resulting in ac-
celerated extinction, either directly or by weakening the strength of the memory trace.  
Interestingly, a recent study showed that the BLA is essential for extinction of CTA memory 
whereas acquisition is dependent on an intact central nucleus (Bahar et al., 2003). The dif-
ferential effect of tau aggregates on fear conditioning and CTA fits well with their distribution 
pattern in the amygdala. We observed the aggregates in the basolateral but not the lateral 
and central nucleus. In contrast to CTA, fear conditioning is not dependent on an intact BLA, 
but an intact lateral and central nucleus (for review, see (Bures et al., 1998; LeDoux, 2000). It 
also seems noteworthy to mention that, again, APPSwe mice resemble to some degree P301L 
mice. APPSwe mice expressed amyloid plaques in the amygdala and also showed an accel-
erated extinction of the CTA memory. However, in contrast to the P301L mice, the APPSwe 
mice already had deficits in the acquisition of the task (Janus et al., 2004). 
AD patients exhibit an impairment at all levels of gustatory information processing, in line 
with the notion of a dissociation between preservation of olfactory and gustatory thresholds 
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and an alteration in odor identification in patients with mild stage AD, suggesting that the al-
teration is central rather than peripheral (Broggio et al., 2001). Significant losses in the ability 
to detect the taste of glutamic acid and to recognize odorants were found in demented AD 
and non-AD patients when compared with age-matched controls (Schiffman et al., 1990). 
These findings are consistent with our transgenic model as the P301L mice share features of 
AD and FTD. 
In summary, the distribution of mutant tau in P301L mice is widespread and comes close to 
the pattern of tau pathology observed in patients. These mice also lack the motor distur-
bances observed in other tau mutants, disturbances which are not characteristic of AD (see 
below 4.1.3). P301L mice share, however, some characteristics with behavioral disturbances 
observed in APP mutant mice. Furthermore, disturbances can be detected already when 
mice are 6 months old. Thus, we believe that P301L mice are a good model to investigate 
the contribution of tau pathology, as observed in AD and FTDP-17, to behavioral distur-
bances. 
Although this investigation raised a number of questions that have to be addressed in future 
studies, a number of conclusions on the early effects of tau aggregation in transgenic P301L 
mutant tau mice can be drawn. Firstly, in the open field and light-dark box subtle signs for 
increased exploratory behavior were manifest in P301L mice. Secondly, fear conditioning to 
tone or to context remained unaffected, probably due to the specific distribution of tau aggre-
gates in the amygdala. Thirdly, a selective alteration in the extinction of a taste aversion 
could be seen in P301L mice. This, again, resembles data collected in APPSwe mice sub-
jected to a similar paradigm. Thus, CTA suggests itself as a sensitive measure of altered 
brain function in response to the formation of tau aggregates. One possible common factor 
for all these results could be a dysfunction of specific nuclei of the amygdala.  
 
4.1.2 Hippocampus-dependent test battery 
 
As shown in the first study, P301L tau is differentially expressed in cortical areas, in the ba-
solateral (BLA) and the basomedial (BM) nuclei of the amygdala, in the hippocampus (CA1, 
CA3 and dentate gyrus), and in other brain areas. To elucidate the impact of tau aggregation 
on hippocampus-dependent cognition, I used, in a second study, P301L mice backcrossed 
onto a C57Bl/6 background. An immunohistological comparison of brains of transgenic mice 
on a more mixed background (B6D2F1) with transgenic mice onto a C57Bl/6 background at 
both 7 and 13 months of age revealed no obvious differences in the expression pattern and 
phosphorylation of tau (data not shown). Consistent with these findings, in the open-field, 
confirming the previous data obtained with P301L mice on the B6D2F1 background 
(Pennanen et al., 2004), increased exploratory behavior compared to wild-type controls was 
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found for both ages tested. In addition, older P301L mice showed less anxiety and a higher 
locomotor activity than their littermates. In the elevated O-maze the P301L mice showed in-
creased activity at all ages. Anxiety levels were not altered at 6 months, but at 11 months of 
age. These findings are similar to those obtained in the open-field, where P301L mice 
showed a less anxious behavior than wild-types. The increase in activity as observed in the 
O-maze may be taken as additional evidence for an altered exploratory drive. Obviously, 
P301L mice exhibit a modest disinhibition of exploratory behavior which manifests in the 
open field, for example, as more time spent in the inner (exploration) zone and in the O-maze 
as an increase in the total distance traveled. These effects are even more pronounced when 
the mice get older and are accompanied by reduced anxiety levels. Disinhibition of explora-
tory behaviors is not uncommon in rodents with deficits of hippocampal function (Hausheer-
Zarmakupi et al., 1996; Laghmouch et al., 1997; McDaniel et al., 1994; Wright et al., 2004). 
In the Y-maze all groups showed a reliable expression of spatial working memory as demon-
strated by spontaneous alternation behavior above chance level. The two genotypes did not 
differ at either age, suggesting intact spatial working memory of P301L mice.  
This result is supported by the fact that acquisition and reversal learning in the water maze 
was not altered in P301L mice, as illustrated by similar learning curves for all groups. How-
ever, in the probe trial, at 6 months of age, the P301L mice spent less time in the former plat-
form quadrant or in the goal zone indicating impairment in spatial reference memory com-
pared to controls. At least theoretically, less persistent searching may also reflect increased 
exploratory drive. Analysis of a shorter time window during the probe trial yielded a similar 
outcome (data not shown), providing further evidence that the deficits are cognitive in nature. 
The significant difference in spatial retention, which was observed between P301L and con-
trol mice at 6 months, was not seen at 11 months of age. This was due to a floor effect as 
evidenced by a poor performance of the wild-type control group during the probe trial, with no 
significant preference above chance level for the former platform location (Fig. 3.12). Al-
though, in general, C57Bl/6 mice are fairly good learners of swimming navigation (Upchurch 
and Wehner, 1988, 1989), there are reports showing that these mice, as a group, can occa-
sionally perform poor probe trial scores, even when they had learned to adapt a special es-
cape strategy to the former platform location (Wolfer et al., 1997).  
At both ages tested, P301L mice were not capable of developing a significant preference for 
the former platform location as revealed in the probe trial, therefore a further decline at 11 
months of age was not detectable. Only for the annulus crossings as the most sensitive 
measure, a reduced performance was shown which, however, was not statistically significant 
(Fig. 3.12C). 
Triple transgenic mice (APPSWE x P301L x PS1M146V) developed cognitive impairments in the 
MWM as early as 4 months of age (at least homozygous 3xTg mice) which were comparable 
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to the manifested retention/retrieval deficits in our P301L mice, whereas acquisition of the 
hidden platform position was unaffected (Billings et al., 2005). As in our mouse model, these 
deficits occurred prior to the formation of any plaque or tangle pathology.  
In addition, the results obtained in P301L mice are in agreement with findings in rats with 
CA3 lesions (a brain area in P301L mice where tau aggregates are found), which are im-
paired in the retention of spatial memory in the water maze paradigm (Roozendaal et al., 
2001). The observed deficits in spatial reference memory in the P301L mice may be due to 
aggregation of tau in the hippocampus and the BLA. The hippocampus is dependent on the 
BLA in glucocorticoid-induced impairment of spatial memory retrieval (Roozendaal et al., 
2003). Anatomical evidence further indicates a role for the BLA in regulating hippocampal 
processes, as the BLA is known to project extensively to discrete hippocampal subfields 
(Petrovich et al., 2001). For example, electrophysiological data demonstrated that informa-
tion which was processed within the amygdala reached the hippocampal formation, where it 
appeared to modulate synaptic activity. Therefore, the presence of tau aggregates in the BLA 
of our P301L mice may have contributed to the observed spatial memory impairment. 
The results from our P301L mice share some characteristics with behavioral disturbances 
observed in APP mutant mice. Deficits in spatial reference memory have been reported in 
several lines, albeit the onset of cognitive deficits varies between different studies, even 
within the same strain (for a review: (Ashe, 2001)). Deterioration of spatial working memory 
in two different lines of APP transgenic mice could not be detected before 13 -15 months of 
age, although conversion of detergent-soluble into insoluble Aβ and thus plaque formation 
occurred much earlier (~ at 6 months) (Chen et al., 2000; Morgan et al., 2000). Together, it is 
possible that spatial working memory is preserved longer than spatial reference memory and 
is unrelated to the initial conversion into insoluble Aβ-plaques or NFT-formation. However, it 
is also likely that the dynamic ranges of the used paradigms to measure spatial working me-
mory may miss the more subtle abnormalities developing in younger mice.  
The behavioral impairment of P301L tau transgenic mice, which can be correlated with the 
expression pattern of P301L tau, is also consistent with findings in human disease. For ex-
ample, depending on the brain area affected by neuronal loss, the clinical phenotype in 
FTDP-17 patients can differ with variable cognitive and behavioral features (Kramer et al., 
2003). Carriers of the P301L mutation showed significant differences in tasks reflecting the 
relatively focal deficit in frontal systems in these patients (Geschwind et al., 2001). The dec-
rement appeared as early as in the second and third decades of life, many years before neu-
rodegeneration manifests itself clinically. Similarly, in our P301L tau transgenic mice selec-
tive behavioral deficits are observed well before overt NFT formation.  
In summary, we found in the present study that tau aggregation, in the absence of overt NFT 
formation, caused deficits in spatial reference memory as determined in the Morris water 
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maze and a modest disinhibition of exploratory behavior at 6 months of age. The difference 
in the exploratory drive is even more pronounced during aging, whereas no further decline in 
spatial reference memory was detected at 11 months of age. No impairment was found in 
acquisition and reversal learning in the water maze and in spatial working memory as as-
sessed by spontaneous alternation behavior in the Y-maze. These data suggest, together 
with the previous findings, that tau aggregation in distinct brain areas directly affects the per-
formance in memory tests controlled by these brain areas. They also showed that tau aggre-
gation, even in the absence of NFT formation, is sufficient to cause behavioral deficits.  
 
4.1.3 Behavioral analysis of other tau transgenic mouse models 
 
Additional tau transgenic mouse strains have been investigated in a range of behavioral 
tests. For example, transgenic mice which express the same mutant form of tau (P301L), but 
a different tau isoform, under control of the PrP promoter, strongly overexpress the tau 
transgene in several neuronal cell-types, including motor neurons. These mice have been 
analyzed at 5 to 7 months of age as they develop a progressive motor phenotype by 9 to 10 
months of age, thus preventing behavioral testing at this later age (Lewis et al., 2000). Al-
though the transgenic mice were unimpaired as a group in any behavioral measure, when 
numbers of tau-bearing neurons were determined in neocortex and hippocampus, these 
were correlated with a poorer cognitive performance in the individual mice (Arendash et al., 
2004). V337M tau mutant mice which express the transgene only in the hippocampus dis-
played increased locomotor activity and exploratory behavior in the elevated plus maze, in-
creased spontaneous locomotion in the open-field, but no significant impairment in the Morris 
water maze (Tanemura et al., 2002). Transgenic mice expressing human tau with the 
R406W mutation had highest levels of the transgene in the hippocampus and, to a lesser 
extent, in other cortical and subcortical brain areas. In the amygdala, only a few cells strongly 
expressed mutant tau, even in old animals (Tatebayashi et al., 2002). These mice showed a 
slight decrease in locomotor activity in the open field, and a significant impairment in contex-
tual and cued fear conditioning. Obviously, the form of mutant tau expressed and the type of 
promoter controlling its expression, together with the genetic background on which the trans-
gene is expressed have a major impact on the outcome of the behavioral analysis (Wolfer 
and Lipp, 2000). 
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4.2 Tissue culture system 
 
The relationship between Aβ and tau and their relative contribution to the clinical features of 
AD is one of the main topics in AD research. Recently, our group has demonstrated patho-
logical interactions between these two major players in AD. In vivo, stereotaxically injecting 
pre-aggregated Aβ42 fibrils into the somatosensory cortex and the hippocampus (CA1) of 
P301L mice caused a fivefold increase in the numbers of NFT in the amygdala (Gotz et al., 
2001b). In vitro, using tau overexpressing human SH-SY5Y neuroblastoma cells, treatment 
with pre-aggregated Aβ42 lead to the generation of PHF-like tau-containing filaments and 
decreased tau solubility (Ferrari et al., 2003). NFT formation in the Aβ42-injected P301L mice 
was tightly correlated with the pathological phosphorylation of tau at the phospho-epitopes 
pS422 (Ser-422) and AT100 (Thr-212/Ser-214). Congruently, expression of tau mutated at 
the Ser-422 phospho-epitope in SH-SY5Y cells prevented the Aβ42-mediated decrease in 
solubility and the generation of tau filaments, suggesting a pivotal role of this epitope in fibril-
logenesis.  
To confirm the previous in vitro findings and to further map phospho-epitopes and cleavage 
sites of tau involved in the β-amyloid-induced decrease in tau solubility and filament forma-
tion, I have generated several tau mutant constructs and stably expressed them, as well as 
the wild-type tau (htau 40) isoform, in SH-SY5Y neuroblastoma cells. Addition of pre-
aggregated Aβ42 to differentiated wt-tau overexpressing SH-SY5Y cells led to a more than 
15-fold increase in Aβ42-mediated tau insolubility, whereas mutating the Ser-422 phospho-
epitope decreased the level of tau solubility only to baseline levels, comparable to SH-SY5Y 
control cells. These results also show that endogenous tau is capable of aggregating upon 
treatment with Aβ42. Mutating additional phospho-epitopes of tau (the AT8-epitope of Ser-
202/Thr-205 and pT231) prevented the decrease in tau solubility as well. It may even be in-
hibitory to aggregation of endogenous tau, as shown by a ~ 60 % decrease in tau insolubility 
compared to baseline levels.  
These findings correspond with previous reports, pointing out the importance of these phos-
pho-epitopes in filament formation. The AT8-epitope is widely used in neuro-pathological 
stagings (Mercken et al., 1992). Phosphorylation at the AT8-epitope distinguishes PHF tau 
from normal human brain tau (Biernat et al., 1992) and phosphorylation at this site is proba-
bly followed and associated with neuronal apoptosis and apoptotic changes in AD brains 
(Kobayashi et al., 2003).  
Antibodies directed against tau phosphorylated at pThr-231 has also been well documented 
to label filaments in AD brains (Jicha et al., 1997). In addition, this epitope plays an important 
role as it is the only binding site for Pin1, a prolyl isomerase, which catalyzes a conforma-
tional change, restoring tau function and promoting its dephosphorylation (Lu et al., 1999). In 
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addition, Pin1 expression is inversely correlated with neuronal vulnerability and NFT in post-
mortem AD brains. Pin1 knock-out mice show progressive age-dependent neuropathy, tau 
hyperphosphorylation and tau filament formation (Liou et al., 2003).  
Different groups established a hierarchy of tau phosphorylation in AD with varying severity of 
neuropathological changes using a panel of different tau antibodies. Augustinack and co-
workers showed that AT8 intensely stained extraneuronal NFT in advanced cases, whereas 
pre-NFT were rarely labeled (Augustinack et al., 2002). In the same study, TG3, an antibody 
directed against the conformational pThr-231-epitope, stained already pre-NFT, indicating an 
early involvement of this epitope in NFT evolution. However, another study reported contra-
dictionary findings with a prominent labeling of pre-NFT by the AT8 antibody and an exclu-
sive Thr-231 immunoreactivity on extraneuronal NFT (Kimura et al., 1996).  
Unfortunately, the data for the AT100 epitope, which was hyperphosphorylated after Aβ42-
injections in P301L mice (Gotz et al., 2001a) and found to exclusively label AD-filaments (Al-
len et al., 2002; Zheng-Fischhofer et al., 1998), had finally to be excluded from our analysis 
due to a loss of the tau transgene as revealed by Western blot analysis of RAB fractions. We 
encountered a similar problem also with another construct that was stably transfected at the 
beginning. It seems that one of the limitations of the tissue culture system is that transgenes 
may be lost, which may be associated with increased passage numbers during culturing. 
Overall, our results suggest an interplay of different epitopes in tau filament formation.  
Interestingly, the Ser-422 epitope is located next to a putative caspase-3 cleavage site at 
position Asp-421 (Fasulo et al., 2000). That mutagenesis of this epitope prevented tau ag-
gregation could be explained insofar as Ser-422 needs to be phosphorylated such that tau 
can become a substrate for cleavage by caspase-3. ∆421 tau assembles much faster than 
wild-type tau in vitro, demonstrating an inhibitory effect of the carboxy-terminal tail of the tau 
molecule on filament formation (Abraha et al., 2000; Berry et al., 2003). In addition, in neu-
rons treated with Aβ42, tau is rapidly cleaved at this site (Gamblin et al., 2003). Surprisingly, 
truncation of the C-terminal region of tau at position 421 prevented the Aβ42-mediated de-
crease in tau solubility in our tissue culture system similar to the phospho-mutants (Fig. 
3.21). At first sight, comparing these results with the known characteristics of ∆421 tau is 
difficult. However, a recent study suggests that C-terminal truncation at the caspase cleav-
age site Asp-421 occurs only after filament formation from full-length tau in AD-brains 
(Guillozet-Bongaarts et al., 2005). Taken together, our result would support the view that 
filaments form first from full-length tau and therefore truncation is likely not an initial step, but 
rather a subsequent event in tau filament formation. However, obviously additional studies 
are needed to fully resolve the evolution of tau filament formation. 
Wild-type tau transgenic mice develop only a few NFT at very old age, despite high expres-
sion levels of the transgene (Gotz et al., 2001a; Ishihara et al., 1999). Obviously, in the mou-
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se model, a pathogenic tau mutation is required to catalyze tau aggregation and the forma-
tion of PHF-like structures. In the human cell-culture system, however, filament formation 
also occurs with wild-type tau. This may be related to species differences and points to the 
possibility that human cells in culture may be more susceptible to the formation of abnormal 
tau filaments as compared with mouse cells in vivo, probably due to differential gene expres-
sion. Also, in contrast to humans, mice express only four-repeat tau isoforms (Goedert and 
Jakes, 1990), whereas SH-SY5Y cells predominantly express fetal tau (the shortest three-
repeat tau isoform). Thus, a different 4R/3R ratio could also underlie this discrepancy.  
As mentioned above, there are some limitations in the tissue culture system. For instance, 
the expression levels of tau appear to play a critical role, as other research groups, that is, by 
using a viral approach, could detect a shift of tau into the FA-fraction even without Aβ treat-
ment (EVOTEC NeuroSciences GmbH, Hamburg, unpublished data), indicating that if 
enough unbound tau in the cells is available, a self-aggregation process is initialized and tau 
aggregation starts. A tight regulation of gene expression in a time- and concentration de-
pendant manner would clearly help to gain better insight into the process of tau aggregation 
and the relationship of Aβ and tau (see below 4.3).  
Furthermore, the question remains unanswered whether the 28-kDa band is a truncated tau 
isoform and / or a second protein. The finding that the band was also detected by an addi-
tional antibody recognizing the C-terminal part of tau would favor the “tau-hypothesis”. How-
ever, immunoprecipitation experiments failed to detect and isolate this band, as well as mass 
spectrometry analysis, arguing against a tau origin. Therefore, the 28kDa band was not in-
cluded in the phospho-epitope mapping experiments. 
In search of the true nature of the 28kDa band, another interesting protein, the Rho GDP-
dissociation inhibitor (RhoGDI-1), was identified to having a decreased solubility upon Aβ-
treatment. RhoGDI is to be an interesting candidate to follow-up in subsequent studies. First, 
a proteomics analysis of our tissue culture system revealed decreased levels of RhoGDI in 
RAB fractions obtained with cells treated with Aβ42 compared to control cells (David et al., 
unpublished data), confirming the Western blot results discussed above. Secondly, Rho 
GDIs negatively regulate Rho-family GTPases, like Rho, Rac and Cdc42 (Fukumoto et al., 
1990; Ueda et al., 1990). These proteins appear to play a key role in regulating the assembly 
and organization of the actin cytoskeleton in response to extracellular stimuli (Johnson and 
Pringle, 1990; Ridley and Hall, 1992; Ridley et al., 1992). Zhu and colleagues have demon-
strated that Cdc42 and Rac are upregulated in selected neuronal populations of AD brains 
and showed considerable overlap with early cytoskeletal abnormalities (Zhu et al., 2000).  
Cdc42 and Rac are also important upstream regulators of the protein kinase cascade that 
control the SAPK/JNK and p38/Mpk2 activities (Cano and Mahadevan, 1995; Coso et al., 
1995; Minden et al., 1995). SAPK/JNK and p38 are involved in the phosphorylation of tau,  
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Fig. 4.2 Hypothetical schematic overview of Aβ-mediated effects of RhoGDI-aggregation: (A) GDIs inhibit the 
GDP to GTP exchange and thus control the activity state of Rho GTPases like Cdc42 and Rac. (B) Upon treat-
ment with Aβ, RhoGDI-proteins aggregate and lose their inhibitory effects. Cdc42 and Rac upregulation can lead 
to the activation of different protein kinase pathways (SAPK/JNK and p38/Mpk2), which cause tau hyperphos-
phorylation and finally filament formation. 
 
 
and activated phospho-JNK was found to be associated with NFT in AD brains (Goedert et 
al., 1997; Kins et al., 2003; Reynolds et al., 1997; Zhu et al., 2001). 
Thus, Aβ-mediated aggregation of RhoGDIs may lead to the inhibition of these proteins and 
to the activation of Rac and Cdc42 GTPases. Thereby, different protein kinase pathways 
may be activated, which cause tau phosphorylation and aggregation (Fig. 4.2). 
In summary, the human tau-expressing tissue culture system is a suitable tool to address 
aspects of AD and related disorders. Addition of preaggregated Aβ42 to wt-tau expressing 
SH-SY5Y cells decreases the solubility of tau. Mutagenesis of different phospho-epitopes of 
tau prevents this decrease in tau solubility, indicating an interplay of different epitopes in tau 
filament formation. Further adaptation of the SH-SY5Y tissue culture system is likely to pro-
vide mechanistic insight into tauopathies and may allow the screening and validation of com-
pounds designed to prevent PHF formation. 
 
4.2.1 Tet-system 
 
Regarding the above mentioned difficulties of the tissue culture system and the apparent 
discrepancies in the literature concerning the requirements for tau filament formation, it 
would be beneficial to have a system where expression of the tau gene is tightly regulated in 
a time- and concentration dependant manner. Different inducible expression systems were 
generated in the last twenty years that allow genes to be activated or silenced in cells and 
organisms at will (Lewandoski, 2001). The most widely used binary transcription transactiva-
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tion systems are the tetracycline-dependent regulatory systems (Gossen and Bujard, 1992; 
Gossen et al., 1995). For our study, we have chosen the Tet-on system, where transgene 
expression is only induced in the presence of an inducer. Furthermore, to be able to deter-
mine the effects of intracellular β-amyloid on tau pathophysiology a bi-directional (pBI) Tet 
vector was used, where both tau and APP are expressed on the same plasmid. For that, we 
decided to utilize an APP construct containing the Arctic mutation, which leads to enhanced 
Aβ-protofibril formation (Nilsberth et al., 2001). A further advantage of using an inducible sys-
tem is that APP can not be stably expressed by many cell lines at high levels because of its 
toxic effects.  
Unfortunately, no reliable expression was achieved in human SH-SY5Y cells, neither with 
stable nor transient transfection methods. Transient expression in human kidney HEK 293 
cells revealed that the regulator and response plasmids are indeed functional. In addition, 
our findings indicated poor transfection rates of the constructs in the SH-SY5Y cells. A pos-
sible reason for this low transfection rate is the relatively large size of the plasmids (e.g. ~ 
8400 bp for the wt-tau/APPArc construct) causing counterselection in neuroblastoma cells.  
However, an unregulated basal transcription activity was observed in the transient trans-
fected HEK 293 cells. This is one of the disadvantages of the system, which occurs when-
ever the transcription units are not integrated into the chromosome or when the two plasmids 
are integrated in relative proximity to each other (Gossen and Bujard, 1992). The main rea-
sons for this background activity are the absence of chromatin repression and the high copy 
number of the template in the cells. Several attempts of stable transfections may help to di-
minish this problem by embedding the templates into chromatin where the minimal CMV-
promoter is actively repressed. An additional solution to efficiently repress such background 
activities can be the use of tetracycline controlled transcriptional silencers (tTS). These are 
fusions between a transcription factor (rtTA) variant and domains known to function as rep-
ressors of transcription (Freundlieb et al., 1999). In the absence of an inducer, tTS binds to 
the Tet-response element (TRE) and represses the residual activity of the minimal promoter. 
Another point to deal with is the poor transcription efficiency of the SH-SY5Y cells. Initially, 
this neuroblastoma cell line was chosen, because they can be differentiated into neuron-like 
cells by sequential treatment with RA and BDNF (Encinas et al., 2000). Thus, they mimic 
more closely the situation in the brain than other non-neuronal cell-types, like the human kid-
ney HEK 293 cells. The use of other transfection methods, such as calcium-phosphate trans-
fection (Graham and van der Eb, 1973) or electroporation (Neumann et al., 1982) may in-
crease the rate of transfection. 
In summary, a functional TET-system in which the expression of APP and tau can be regu-
lated in a time- and concentration-dependant manner within the same cell would be very 
helpful to elucidate the relationship between Aß and tau. 
5 REFERENCES 
89 
5 REFERENCES 
 
Abraha, A., Ghoshal, N., Gamblin, T.C., Cryns, V., Berry, R.W., Kuret, J., and Binder, L.I. (2000) C-
terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113: 3737-
3745. 
Aja, S., Sisouvong, S., Barrett, J.A., and Gietzen, D.W. (2000) Basolateral and central amygdaloid 
lesions leave aversion to dietary amino acid imbalance intact. Physiol Behav 71: 533-541. 
Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, 
M., Emson, P.C., Atzori, C., Migheli, A., Crowther, R.A., Ghetti, B., Spillantini, M.G., and 
Goedert, M. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic 
mice expressing human P301S tau protein. J Neurosci 22: 9340-9351. 
Alzheimer, A. (1907) About a peculiar disease of the cerebral cortex. Allgemeine Zeitschrift für Psy-
chiatrie und Psychisch-Gerichtliche Medizin 64: 146-148. 
Anderton, B.H., Dayanandan, R., Killick, R., and Lovestone, S. (2000) Does dysregulation of the Notch 
and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol Med To-
day 6: 54-59. 
Arendash, G.W., Lewis, J., Leighty, R.E., McGowan, E., Cracchiolo, J.R., Hutton, M., and Garcia, M.F. 
(2004) Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's dis-
ease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012: 
29-41. 
Arnold, S.E., Hyman, B.T., Flory, J., Damasio, A.R., and Van Hoesen, G.W. (1991) The topographical 
and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral 
cortex of patients with Alzheimer's disease. Cereb Cortex 1: 103-116. 
Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., and Hyman, B.T. (1992) Neurofibrillary tangles 
but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42: 
631-639. 
Ashe, K.H. (2001) Learning and memory in transgenic mice modeling Alzheimer's disease. Learn 
Mem 8: 301-308. 
Augustinack, J.C., Schneider, A., Mandelkow, E.M., and Hyman, B.T. (2002) Specific tau phosphoryla-
tion sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neu-
ropathol (Berl) 103: 26-35. 
Bahar, A., Samuel, A., Hazvi, S., and Dudai, Y. (2003) The amygdalar circuit that acquires taste aver-
sion memory differs from the circuit that extinguishes it. Eur J Neurosci 17: 1527-1530. 
Balschun, D., Wolfer, D.P., Gass, P., Mantamadiotis, T., Welzl, H., Schutz, G., Frey, J.U., and Lipp, 
H.P. (2003) Does cAMP response element-binding protein have a pivotal role in hippocampal 
synaptic plasticity and hippocampus-dependent memory? J Neurosci 23: 6304-6314. 
Barghorn, S., Zheng-Fischhofer, Q., Ackmann, M., Biernat, J., von Bergen, M., Mandelkow, E.M., and 
Mandelkow, E. (2000) Structure, microtubule interactions, and paired helical filament aggrega-
tion by tau mutants of frontotemporal dementias. Biochemistry 39: 11714-11721. 
Barnham, K.J., Masters, C.L., and Bush, A.I. (2004) Neurodegenerative diseases and oxidative stress. 
Nat Rev Drug Discov 3: 205-214. 
Behl, C., Davis, J.B., Lesley, R., and Schubert, D. (1994) Hydrogen peroxide mediates amyloid beta 
protein toxicity. Cell 77: 817-827. 
Bergeron, C., Pollanen, M.S., Weyer, L., and Lang, A.E. (1997) Cortical degeneration in progressive 
supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol 
Exp Neurol 56: 726-734. 
Berry, R.W., Abraha, A., Lagalwar, S., LaPointe, N., Gamblin, T.C., Cryns, V.L., and Binder, L.I. (2003) 
Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochem-
istry 42: 8325-8331. 
5 REFERENCES 
90 
Best, P.J., and Orr, J., Jr. (1973) Effects of hippocampal lesions on passive avoidance and taste aver-
sion conditioning. Physiol Behav 10: 193-196. 
Bierer, L.M., Hof, P.R., Purohit, D.P., Carlin, L., Schmeidler, J., Davis, K.L., and Perl, D.P. (1995) 
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. 
Arch Neurol 52: 81-88. 
Biernat, J., Mandelkow, E.M., Schroter, C., Lichtenberg-Kraag, B., Steiner, B., Berling, B., Meyer, H., 
Mercken, M., Vandermeeren, A., Goedert, M., and et al. (1992) The switch of tau protein to an 
Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the 
microtubule binding region. Embo J 11: 1593-1597. 
Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L., and Laferla, F.M. (2005) Intraneuronal Abeta 
causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. 
Neuron 45: 675-688. 
Binder, L.I., Guillozet-Bongaarts, A.L., Garcia-Sierra, F., and Berry, R.W. (2005) Tau, tangles, and 
Alzheimer's disease. Biochim Biophys Acta 1739: 216-223. 
Bird, T.D., Nochlin, D., Poorkaj, P., Cherrier, M., Kaye, J., Payami, H., Peskind, E., Lampe, T.H., Ne-
mens, E., Boyer, P.J., and Schellenberg, G.D. (1999) A clinical pathological comparison of 
three families with frontotemporal dementia and identical mutations in the tau gene (P301L) 
[published erratum appears in Brain 1999 Jul;122(Pt 7):1398]. Brain 122: 741-756. 
Blum, H., Beier, H., and Gross, H.J. (1987) Improved silver staining of plant proteins , RNA and DNA 
in polyacrylamide gels. Electrophoresis 8: 93-99. 
Braak, H., and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neu-
ropathol (Berl) 82: 239-259. 
Braak, H., and Braak, E. (1995) Staging of Alzheimer's disease-related neurofibrillary changes. 
Neurobiol Aging 16: 271-278; discussion 278-284. 
Brion, J.P., Tremp, G., and Octave, J.N. (1999) Transgenic expression of the shortest human tau af-
fects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's 
disease [see comments]. Am J Pathol 154: 255-270. 
Broggio, E., Pluchon, C., Ingrand, P., and Gil, R. (2001) [Taste impairment in Alzheimer's disease]. 
Rev Neurol (Paris) 157: 409-413. 
Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P.R. (2000) Tau protein isoforms, 
phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-
130. 
Bugiani, O., Murrell, J.R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M., Morbin, M., Prima-
vera, A., Carella, F., Solaro, C., Grisoli, M., Savoiardo, M., Spillantini, M.G., Tagliavini, F., 
Goedert, M., and Ghetti, B. (1999) Frontotemporal dementia and corticobasal degeneration in 
a family with a P301S mutation in tau. J Neuropathol Exp Neurol 58: 667-677. 
Bures, J., Bermudez-Rattoni, F., and Yamamoto, T. (1998) Conditioned taste aversion - memory of a 
special kind. Oxford University Press, Inc., New York. 
Cano, E., and Mahadevan, L.C. (1995) Parallel signal processing among mammalian MAPKs. Trends 
Biochem Sci 20: 117-122. 
Cao, X., and Sudhof, T.C. (2001) A transcriptionally [correction of transcriptively] active complex of 
APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115-120. 
Carmel, G., Mager, E.M., Binder, L.I., and Kuret, J. (1996) The structural basis of monoclonal antibody 
Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 271: 32789-32795. 
Check, E. (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415: 462. 
Chen, F., David, D., Ferrari, A., and Gotz, J. (2004a) Posttranslational modifications of tau - Role in 
human tauopathies and modeling in transgenic animals. Curr Alz Res 5: 503-515. 
Chen, G., Chen, K.S., Knox, J., Inglis, J., Bernard, A., Martin, S.J., Justice, A., McConlogue, L., 
Games, D., Freedman, S.B., and Morris, R.G. (2000) A learning deficit related to age and 
beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-979. 
5 REFERENCES 
91 
Chen, Y., Wollmer, M.A., Hoerndli, F., Münch, G., Kuhla, B., Rogaev, E.I., Tsolaki, M., Papassotiro-
poulos, A., and Gotz, J. (2004b) Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad 
Sci U S A 101: 7687-7692. 
Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., 
Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., 
Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., and Bush, A.I. (2001) Treatment with a 
copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's 
disease transgenic mice. Neuron 30: 665-676. 
Chin, S.S., and Goldman, J.E. (1996) Glial inclusions in CNS degenerative diseases. J Neuropathol 
Exp Neurol 55: 499-508. 
Corcoran, K.A., Lu, Y., Turner, R.S., and Maren, S. (2002) Overexpression of hAPPswe impairs re-
warded alternation and contextual fear conditioning in a transgenic mouse model of Alz-
heimer's disease. Learn Mem 9: 243-252. 
Coso, O.A., Chiariello, M., Yu, J.C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J.S. 
(1995) The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK 
signaling pathway. Cell 81: 1137-1146. 
Crowther, R.A., and Wischik, C.M. (1985) Image reconstruction of the Alzheimer paired helical fila-
ment. Embo J 4: 3661-3665. 
Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, 
M., and Wolfson, L. (1988) Clinico-pathologic studies in dementia: nondemented subjects with 
pathologically confirmed Alzheimer's disease. Neurology 38: 1682-1687. 
Cummings, J.L. (2004) Alzheimer's disease. N Engl J Med 351: 56-67. 
David, D.C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., Ravid, R., Drose, S., 
Brandt, U., Muller, W.E., Eckert, A., and Gotz, J. (2005) Proteomic and functional analysis re-
veal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem in press. 
De, F., Gv, and Inestrosa, N.C. (2000) Wnt signaling function in Alzheimer's disease [In Process Cita-
tion]. Brain Res Brain Res Rev 33: 1-12. 
Delacourte, A., Sergeant, N., Wattez, A., Gauvreau, D., and Robitaille, Y. (1998) Vulnerable neuronal 
subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution 
and phosphorylation. Ann Neurol 43: 193-204. 
Delacourte, A., David, J.P., Sergeant, N., Buee, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-
Bianco, C., Pasquier, F., Lebert, F., Petit, H., and Di Menza, C. (1999) The biochemical path-
way of neurofibrillary degeneration in aging and Alzheimer's disease [see comments]. Neurol-
ogy 52: 1158-1165. 
Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C.A., Lebert, F., Pasquier, F., and 
David, J.P. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alz-
heimer's disease. Neurology 59: 398-407. 
Delobel, P., Flament, S., Hamdane, M., Mailliot, C., Sambo, A.V., Begard, S., Sergeant, N., Dela-
courte, A., Vilain, J.P., and Buee, L. (2002) Abnormal Tau phosphorylation of the Alzheimer-
type also occurs during mitosis. J Neurochem 83: 412-420. 
D'Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M., Bird, T.D., and Schellenberg, G.D. (1999) 
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-
chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc 
Natl Acad Sci U S A 96: 5598-5603. 
Dunn, L.T., and Everitt, B.J. (1988) Double dissociations of the effects of amygdala and insular cortex 
lesions on conditioned taste aversion, passive avoidance, and neophobia in the rat using the 
excitotoxin ibotenic acid. Behav Neurosci 102: 3-23. 
Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. (1998) Over-
expression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and 
endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143: 777-794. 
Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., and Haass, C. (2003) Reconstitution of 
gamma-secretase activity. Nat Cell Biol 5: 486-488. 
5 REFERENCES 
92 
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Cena, V., Gallego, C., and Comella, J.X. 
(2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotro-
phic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like 
cells. J Neurochem 75: 991-1003. 
Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., and 
Ward, P.J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its pre-
cursor. Science 248: 1122-1124. 
Escobar, M.L., and Bermudez-Rattoni, F. (2000) Long-term potentiation in the insular cortex enhances 
conditioned taste aversion retention. Brain Res 852: 208-212. 
Fasulo, L., Ugolini, G., Visintin, M., Bradbury, A., Brancolini, C., Verzillo, V., Novak, M., and Cattaneo, 
A. (2000) The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an 
effector of apoptosis. J Neurochem 75: 624-633. 
Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R.M., and Gotz, J. (2003) Beta-amyloid induces PHF-like 
tau filaments in tissue culture. J Biol Chem 278: 40162-40168. 
Ferrer, I., Boada Rovira, M., Sanchez Guerra, M.L., Rey, M.J., and Costa-Jussa, F. (2004) Neuropa-
thology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's 
disease. Brain Pathol 14: 11-20. 
Flanagan, L.A., Cunningham, C.C., Chen, J., Prestwich, G.D., Kosik, K.S., and Janmey, P.A. (1997) 
The structure of divalent cation-induced aggregates of PIP2 and their alteration by gelsolin 
and tau. Biophys J 73: 1440-1447. 
Forman, M.S., Lal, D., Zhang, B., Dabir, D.V., Swanson, E., Lee, V.M., and Trojanowski, J.Q. (2005) 
Transgenic mouse model of tau pathology in astrocytes leading to nervous system degenera-
tion. J Neurosci 25: 3539-3550. 
Freundlieb, S., Schirra-Muller, C., and Bujard, H. (1999) A tetracycline controlled activation/repression 
system with increased potential for gene transfer into mammalian cells. J Gene Med 1: 4-12. 
Fukumoto, Y., Kaibuchi, K., Hori, Y., Fujioka, H., Araki, S., Ueda, T., Kikuchi, A., and Takai, Y. (1990) 
Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho 
proteins, ras p21-like small GTP-binding proteins. Oncogene 5: 1321-1328. 
Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Gar-
cia-Sierra, F., LaPointe, N., Miller, R., Berry, R.W., Binder, L.I., and Cryns, V.L. (2003) Cas-
pase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc 
Natl Acad Sci U S A 100: 10032-10037. 
Geschwind, D.H., Robidoux, J., Alarcon, M., Miller, B.L., Wilhelmsen, K.C., Cummings, J.L., and Nas-
reddine, Z.S. (2001) Dementia and neurodevelopmental predisposition: cognitive dysfunction 
in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Ann 
Neurol 50: 741-746. 
Giannakopoulos, P., Herrmann, F.R., Bussiere, T., Bouras, C., Kovari, E., Perl, D.P., Morrison, J.H., 
Gold, G., and Hof, P.R. (2003) Tangle and neuron numbers, but not amyloid load, predict 
cognitive status in Alzheimer's disease. Neurology 60: 1495-1500. 
Glenner, G.G., and Wong, C.W. (1984) Alzheimer's disease: initial report of the purification and char-
acterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 
885-890. 
Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., 
Irving, N., James, L., and et al. (1991) Segregation of a missense mutation in the amyloid pre-
cursor protein gene with familial Alzheimer's disease. Nature 349: 704-706. 
Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E., and Klug, A. (1988) Cloning and sequencing 
of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identi-
fication as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 85: 4051-4055. 
Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., and Crowther, R.A. (1989) Multiple isoforms 
of human microtubule-associated protein tau: sequences and localization in neurofibrillary 
tangles of Alzheimer's disease. Neuron 3: 519-526. 
Goedert, M., and Jakes, R. (1990) Expression of separate isoforms of human tau protein: correlation 
with the tau pattern in brain and effects on tubulin polymerization. Embo J 9: 4225-4230. 
5 REFERENCES 
93 
Goedert, M., Spillantini, M.G., Cairns, N.J., and Crowther, R.A. (1992) Tau proteins of Alzheimer 
paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8: 159-
168. 
Goedert, M., Spillantini, M.G., Jakes, R., Crowther, R.A., Vanmechelen, E., Probst, A., Gotz, J., Burki, 
K., and Cohen, P. (1995) Molecular dissection of the paired helical filament. Neurobiol Aging 
16: 325-334. 
Goedert, M., Hasegawa, M., Jakes, R., Lawler, S., Cuenda, A., and Cohen, P. (1997) Phosphorylation 
of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409: 57-
62. 
Goedert, M., Jakes, R., and Crowther, R.A. (1999a) Effects of frontotemporal dementia FTDP-17 mu-
tations on heparin-induced assembly of tau filaments. FEBS Lett 450: 306-311. 
Goedert, M., Spillantini, M.G., Crowther, R.A., Chen, S.G., Parchi, P., Tabaton, M., Lanska, D.J., Mar-
kesbery, W.R., Wilhelmsen, K.C., Dickson, D.W., Petersen, R.B., and Gambetti, P. (1999b) 
Tau gene mutation in familial progressive subcortical gliosis. Nat Med 5: 454-457. 
Goosens, K.A., and Maren, S. (2001) Contextual and auditory fear conditioning are mediated by the 
lateral, basal, and central amygdaloid nuclei in rats. Learn Mem 8: 148-155. 
Gossen, M., and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracy-
cline-responsive promoters. Proc Natl Acad Sci U S A 89: 5547-5551. 
Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995) Transcriptional 
activation by tetracyclines in mammalian cells. Science 268: 1766-1769. 
Gotz, J., Probst, A., Spillantini, M.G., Schafer, T., Jakes, R., Burki, K., and Goedert, M. (1995) Soma-
todendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing 
the longest human brain tau isoform. Embo J 14: 1304-1313. 
Gotz, J. (2001) Tau and transgenic animal models. Brain Res Brain Res Rev 35: 266-286. 
Gotz, J., Chen, F., Barmettler, R., and Nitsch, R.M. (2001a) Tau Filament Formation in Transgenic 
Mice Expressing P301L Tau. J Biol Chem 276: 529-534. 
Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R.M. (2001b) Formation of neurofibrillary tangles in 
P301L tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495. 
Gotz, J., and Nitsch, R.M. (2001) Compartmentalized tau hyperphosphorylation and increased levels 
of kinases in transgenic mice. Neuroreport 12: 2007-2016. 
Gotz, J., Tolnay, M., Barmettler, R., Chen, F., Probst, A., and Nitsch, R.M. (2001c) Oligodendroglial 
tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci 13: 2131-
2140. 
Gotz, J., Schild, A., Hoerndli, F., and Pennanen, L. (2004a) Amyloid-induced neurofibrillary tangle 
formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int 
J Dev Neurosci 22: 453-465. 
Gotz, J., Streffer, J.R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., and Chen, F. 
(2004b) Transgenic animal models of Alzheimer's disease and related disorders: Histopathol-
ogy, behavior and therapy. Mol Psychiatry 9: 664-683. 
Graham, F.L., and van der Eb, A.J. (1973) A new technique for the assay of infectivity of human ade-
novirus 5 DNA. Virology 52: 456-467. 
Grover, A., Houlden, H., Baker, M., Adamson, J., Lewis, J., Prihar, G., Pickering-Brown, S., Duff, K., 
and Hutton, M. (1999) 5' splice site mutations in tau associated with the inherited dementia 
FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol 
Chem 274: 15134-15143. 
Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Reynolds, M.R., Horowitz, P.M., Fu, Y., Wang, T., Cahill, 
M.E., Bigio, E.H., Berry, R.W., and Binder, L.I. (2005) Tau truncation during neurofibrillary 
tangle evolution in Alzheimer's disease. Neurobiol Aging 26: 1015-1022. 
Hall, G.F., Lee, V.M., Lee, G., and Yao, J. (2001) Staging of neurofibrillary degeneration caused by 
human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol 158: 
235-246. 
5 REFERENCES 
94 
Hall, G.F., Lee, S., and Yao, J. (2002) Neurofibrillary degeneration can be arrested in an in vivo cellu-
lar model of human tauopathy by application of a compound which inhibits tau filament forma-
tion in vitro. J Mol Neurosci 19: 253-260. 
Hamann, S., Monarch, E.S., and Goldstein, F.C. (2002) Impaired fear conditioning in Alzheimer's dis-
ease. Neuropsychologia 40: 1187-1195. 
Hanger, D.P., Brion, J.P., Gallo, J.M., Cairns, N.J., Luthert, P.J., and Anderton, B.H. (1991) Tau in 
Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Bio-
chem J 275 ( Pt 1): 99-104. 
Hardy, J.A., and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 
256: 184-185. 
Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B., and Selkoe, 
D.J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiologi-
cal changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884. 
Hasegawa, M., Smith, M.J., and Goedert, M. (1998) Tau proteins with FTDP-17 mutations have a 
reduced ability to promote microtubule assembly. FEBS Lett 437: 207-210. 
Hausheer-Zarmakupi, Z., Wolfer, D.P., Leisinger-Trigona, M.C., and Lipp, H.P. (1996) Selective breed-
ing for extremes in open-field activity of mice entails a differentiation of hippocampal mossy fi-
bers. Behav Genet 26: 167-176. 
Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., and Evans, D.A. (2003) Alzheimer disease in 
the US population: prevalence estimates using the 2000 census. Arch Neurol 60: 1119-1122. 
Higuchi, M., Ishihara, T., Zhang, B., Hong, M., Andreadis, A., Trojanowski, J., and Lee, V.M. (2002) 
Transgenic mouse model of tauopathies with glial pathology and nervous system degenera-
tion. Neuron 35: 433-446. 
Hock, C., Konietzko, U., Papassotiropoulos, A., Wollmer, A., Streffer, J., von Rotz, R.C., Davey, G., 
Moritz, E., and Nitsch, R.M. (2002) Generation of antibodies specific for beta-amyloid by vac-
cination of patients with Alzheimer disease. Nat Med 8: 1270-1275. 
Hock, C., Konietzko, U., Streffer, J.R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, U., Henke, 
K., Moritz, E., Garcia, E., Wollmer, M.A., Umbricht, D., de Quervain, D.J., Hofmann, M., Mad-
dalena, A., Papassotiropoulos, A., and Nitsch, R.M. (2003) Antibodies against beta-Amyloid 
Slow Cognitive Decline in Alzheimer's Disease. Neuron 38: 547-554. 
Hoerndli, F.J., Toigo, M., Schild, A., Gotz, J., and Day, P.J. (2004) Reference genes identified in SH-
SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain 
reaction. Anal Biochem 335: 30-41. 
Hof, P.R., Bouras, C., Perl, D.P., and Morrison, J.H. (1994) Quantitative neuropathologic analysis of 
Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's dis-
ease. Acta Neuropathol 87: 115-124. 
Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chak-
raverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., Davies, 
P., Petersen, R.C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., 
Joosse, M., Kwon, J.M., Nowotny, P., Heutink, P., and et al. (1998) Association of missense 
and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705. 
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M.K., Trojanowski, J.Q., and Lee, V.M. (1999) 
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing 
the shortest human tau isoform. Neuron 24: 751-762. 
Ishihara, T., Zhang, B., Higuchi, M., Yoshiyama, Y., Trojanowski, J.Q., and Lee, V.M. (2001) Age-
Dependent Induction of Congophilic Neurofibrillary Tau Inclusions in Tau Transgenic Mice. Am 
J Pathol 158: 555-562. 
Jackson, G.R., Wiedau-Pazos, M., Sang, T.-K., Wagle, N., Brown, C.A., Massachi, S., and Gesch-
wind, D.H. (2002) Human wild-type tau interacts with wingless pathway components and pro-
duces neurofibrillary pathology in Drosophila. Neuron 34: 509-519. 
Janus, C., Welzl, H., Hanna, A., Lovasic, L., Lane, N., St George-Hyslop, P., and Westaway, D. (2004) 
Impaired conditioned taste aversion learning in APP transgenic mice. Neurobiol Aging 25: 
1213-1219. 
5 REFERENCES 
95 
Jenkins, S.M., and Johnson, G.V. (1998) Tau complexes with phospholipase C-gamma in situ. Neu-
roreport 9: 67-71. 
Jicha, G.A., Lane, E., Vincent, I., Otvos, L., Jr., Hoffmann, R., and Davies, P. (1997) A conformation- 
and phosphorylation-dependent antibody recognizing the paired helical filaments of Alz-
heimer's disease. J Neurochem 69: 2087-2095. 
Johnson, D.I., and Pringle, J.R. (1990) Molecular characterization of CDC42, a Saccharomyces cere-
visiae gene involved in the development of cell polarity. J Cell Biol 111: 143-152. 
Kelley, A.E., Cador, M., and Stinus, L. (1989) Exploration and its measurement - A psychopharma-
cological perspective. Neuromethods; Volume 13 (Psychopharmacology) Boulton, A. A., 
Baker, G. B. & Greenshaw, A. J. (Eds.), The Humana Press, Inc. Clifton, NJ 13. 
Kerr, M.L., and Small, D.H. (2005) Cytoplasmic domain of the beta-amyloid protein precursor of Alz-
heimer's disease: Function, regulation of proteolysis, and implications for drug development. J 
Neurosci Res 80: 151-159. 
Kimble, D.P., Bremiller, R., Schroeder, L., and Smotherman, W.P. (1979) Hippocampal lesions slow 
extinction of a conditioned taste aversion in rats. Physiol Behav 23: 217-222. 
Kimura, T., Ono, T., Takamatsu, J., Yamamoto, H., Ikegami, K., Kondo, A., Hasegawa, M., Ihara, Y., 
Miyamoto, E., and Miyakawa, T. (1996) Sequential changes of tau-site-specific phosphoryla-
tion during development of paired helical filaments. Dementia 7: 177-181. 
Kishi, T., and Elmquist, J.K. (2005) Body weight is regulated by the brain: a link between feeding and 
emotion. Mol Psychiatry 10: 132-146. 
Kins, S., Kurosinski, P., Nitsch, R.M., and Gotz, J. (2003) Activation of the ERK and JNK signaling 
pathways caused by neuron specific inhibition of PP2A in transgenic mice. Am J Pathol 163: 
833-843. 
Kobayashi, K., Nakano, H., Hayashi, M., Shimazaki, M., Fukutani, Y., Sasaki, K., Sugimori, K., and 
Koshino, Y. (2003) Association of phosphorylation site of tau protein with neuronal apoptosis 
in Alzheimer's disease. J Neurol Sci 208: 17-24. 
Komori, T. (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degen-
eration and Pick's disease. Brain Pathol 9: 663-679. 
Kraemer, B.C., Zhang, B., Leverenz, J.B., Thomas, J.H., Trojanowski, J.Q., and Schellenberg, G.D. 
(2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans 
model of tauopathy. Proc Natl Acad Sci U S A 100: 9980-9985. 
Kramer, J.H., Jurik, J., Sha, S.J., Rankin, K.P., Rosen, H.J., Johnson, J.K., and Miller, B.L. (2003) 
Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and 
Alzheimer disease. Cogn Behav Neurol 16: 211-218. 
Ksiezak-Reding, H., Binder, L.I., and Yen, S.H. (1990) Alzheimer disease proteins (A68) share epi-
topes with tau but show distinct biochemical properties. J Neurosci Res 25: 420-430. 
Laghmouch, A., Bertholet, J.Y., and Crusio, W.E. (1997) Hippocampal morphology and open-field 
behavior in Mus musculus domesticus and Mus spretus inbred mice. Behav Genet 27: 67-73. 
Lahiri, D.K., Farlow, M.R., Sambamurti, K., Greig, N.H., Giacobini, E., and Schneider, L.S. (2003) A 
critical analysis of new molecular targets and strategies for drug developments in Alzheimer's 
disease. Curr Drug Targets 4: 97-112. 
Lamprecht, R., Hazvi, S., and Dudai, Y. (1997) cAMP response element-binding protein in the amyg-
dala is required for long- but not short-term conditioned taste aversion memory. J Neurosci 17: 
8443-8450. 
LeDoux, J.E. (2000) Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184. 
Lee, G., and Rook, S.L. (1992) Expression of tau protein in non-neuronal cells: microtubule binding 
and stabilization. J Cell Sci 102: 227-237. 
Lee, V.M., Goedert, M., and Trojanowski, J.Q. (2001) Neurodegenerative tauopathies. Annu Rev Neu-
rosci 24: 1121-1159. 
Lee, V.M., Kenyon, T.K., and Trojanowski, J.Q. (2005) Transgenic animal models of tauopathies. Bio-
chim Biophys Acta 1739: 251-259. 
5 REFERENCES 
96 
Lewandoski, M. (2001) Conditional control of gene expression in the mouse. Nat Rev Genet 2: 743-
755. 
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-
Hardy, K., Murphy, P.M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W.L., Yen, S.H., 
Dickson, D.W., Davies, P., and Hutton, M. (2000) Neurofibrillary tangles, amyotrophy and pro-
gressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 
402-405. 
Lewis, J., Dickson, D.W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skip-
per, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., and McGowan, E. (2001) Enhanced 
neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293: 
1487-1491. 
Lichtenberg, B., Mandelkow, E.M., Hagestedt, T., and Mandelkow, E. (1988) Structure and elasticity of 
microtubule-associated protein tau. Nature 334: 359-362. 
Liou, Y.C., Sun, A., Ryo, A., Zhou, X.Z., Yu, Z.X., Huang, H.K., Uchida, T., Bronson, R., Bing, G., Li, 
X., Hunter, T., and Lu, K.P. (2003) Role of the prolyl isomerase Pin1 in protecting against age-
dependent neurodegeneration. Nature 424: 556-561. 
Loo, D.T., Copani, A., Pike, C.J., Whittemore, E.R., Walencewicz, A.J., and Cotman, C.W. (1993) 
Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl 
Acad Sci U S A 90: 7951-7955. 
Lu, P.J., Wulf, G., Zhou, X.Z., Davies, P., and Lu, K.P. (1999) The prolyl isomerase Pin1 restores the 
function of Alzheimer-associated phosphorylated tau protein. Nature 399: 784-788. 
Maas, T., Eidenmuller, J., and Brandt, R. (2000) Interaction of tau with the neural membrane cortex is 
regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 
275: 15733-15740. 
Mandelkow, E.M., Schweers, O., Drewes, G., Biernat, J., Gustke, N., Trinczek, B., and Mandelkow, E. 
(1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad 
Sci 777: 96-106. 
Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., 
and Schenk, D. (2005) Abeta vaccination effects on plaque pathology in the absence of en-
cephalitis in Alzheimer disease. Neurology 64: 129-131. 
Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., and Beyreuther, K. (1985) 
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U 
S A 82: 4245-4249. 
Mattson, M.P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R.E. (1992) beta-Amyloid 
peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to 
excitotoxicity. J Neurosci 12: 376-389. 
McDaniel, W.F., Compton, D.M., and Smith, S.R. (1994) Spatial learning following posterior parietal or 
hippocampal lesions. Neuroreport 5: 1713-1717. 
McGaugh, J.L., McIntyre, C.K., and Power, A.E. (2002) Amygdala modulation of memory consolida-
tion: interaction with other brain systems. Neurobiol Learn Mem 78: 539-552. 
Mercken, M., Vandermeeren, M., Lubke, U., Six, J., Boons, J., Van de Voorde, A., Martin, J.J., and 
Gheuens, J. (1992) Monoclonal antibodies with selective specificity for Alzheimer Tau are di-
rected against phosphatase-sensitive epitopes. Acta Neuropathol (Berl) 84: 265-272. 
Minden, A., Lin, A., Claret, F.X., Abo, A., and Karin, M. (1995) Selective activation of the JNK signaling 
cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 
1147-1157. 
Mirra, S.S., Murrell, J.R., Gearing, M., Spillantini, M.G., Goedert, M., Crowther, R.A., Levey, A.I., 
Jones, R., Green, J., Shoffner, J.M., Wainer, B.H., Schmidt, M.L., Trojanowski, J.Q., and 
Ghetti, B. (1999) Tau pathology in a family with dementia and a P301L mutation in tau. J Neu-
ropathol Exp Neurol 58: 335-345. 
 
5 REFERENCES 
97 
Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., 
DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G.W. 
(2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's 
disease. Nature 408: 982-985. 
Morishima-Kawashima, M., and Kosik, K.S. (1996) The pool of map kinase associated with micro-
tubules is small but constitutively active. Mol Biol Cell 7: 893-905. 
Morris, R.G., Garrud, P., Rawlins, J.N., and O'Keefe, J. (1982) Place navigation impaired in rats with 
hippocampal lesions. Nature 297: 681-683. 
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, L. (1992) A 
pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of 
beta-amyloid. Nat Genet 1: 345-347. 
Mullis, K.B. (1990) Target amplification for DNA analysis by the polymerase chain reaction. Ann Biol 
Clin (Paris) 48: 579-582. 
Nacharaju, P., Lewis, J., Easson, C., Yen, S., Hackett, J., Hutton, M., and Yen, S.H. (1999) Acceler-
ated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 
447: 195-199. 
Nagy, Z., Jobst, K.A., Esiri, M.M., Morris, J.H., King, E.M., MacDonald, B., Litchfield, S., Barnetson, L., 
and Smith, A.D. (1996) Hippocampal pathology reflects memory deficit and brain imaging 
measurements in Alzheimer's disease: clinicopathologic correlations using three sets of patho-
logic diagnostic criteria. Dementia 7: 76-81. 
Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B.A., and Yuan, J. (2000) Caspase-12 
mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 
403: 98-103. 
Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., 
Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., and Benson, D.F. (1998) Fron-
totemporal lobar degeneration: a consensus on clinical diagnostic criteria [see comments]. 
Neurology 51: 1546-1554. 
Neumann, E., Schaefer-Ridder, M., Wang, Y., and Hofschneider, P.H. (1982) Gene transfer into 
mouse lyoma cells by electroporation in high electric fields. Embo J 1: 841-845. 
Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R.O. (2003) Neuropathol-
ogy of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. 
Nat Med 9: 448-452. 
Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, 
C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J., and Lannfelt, L. (2001) The 'Arctic' 
APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. 
Nat Neurosci 4: 887-893. 
Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., 
Mattson, M.P., Akbari, Y., and LaFerla, F.M. (2003) Triple-transgenic model of Alzheimer's 
disease with plaques and tangles. Intracellular abeta and synaptic dysfunction. Neuron 39: 
409-421. 
Paxinos, K.B.J.F.a.G. (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic Press 
Inc. 
Pennanen, L., Welzl, H., D'Adamo, P., Nitsch, R.M., and Gotz, J. (2004) Accelerated extinction of 
conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis 15: 500-509. 
Pennanen, L., Wolfer, D., Nitsch, R.M., and Gotz, J. (2005) Impaired spatial reference memory in 
P301L tau transgenic mice. Genes Brain Behav in revision. 
Petrovich, G.D., Canteras, N.S., and Swanson, L.W. (2001) Combinatorial amygdalar inputs to hippo-
campal domains and hypothalamic behavior systems. Brain Res Brain Res Rev 38: 247-289. 
Poorkaj, P., Bird, T.D., Wijsman, E., Nemens, E., Garruto, R.M., Anderson, L., Andreadis, A., Wieder-
holt, W.C., Raskind, M., and Schellenberg, G.D. (1998) Tau is a candidate gene for chromo-
some 17 frontotemporal dementia. Ann Neurol 43: 815-825. 
5 REFERENCES 
98 
Probst, A., Gotz, J., Wiederhold, K.H., Tolnay, M., Mistl, C., Jaton, A.L., Hong, M., Ishihara, T., Lee, 
V.M., Trojanowski, J.Q., Jakes, R., Crowther, R.A., Spillantini, M.G., Burki, K., and Goedert, 
M. (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. 
Acta Neuropathol (Berl) 99: 469-481. 
Puglielli, L., Tanzi, R.E., and Kovacs, D.M. (2003) Alzheimer's disease: the cholesterol connection. 
Nat Neurosci 6: 345-351. 
Reed, L.A., Grabowski, T.J., Schmidt, M.L., Morris, J.C., Goate, A., Solodkin, A., Van Hoesen, G.W., 
Schelper, R.L., Talbot, C.J., Wragg, M.A., and Trojanowski, J.Q. (1997) Autosomal dominant 
dementia with widespread neurofibrillary tangles [see comments]. Ann Neurol 42: 564-572. 
Reszka, A.A., Seger, R., Diltz, C.D., Krebs, E.G., and Fischer, E.H. (1995) Association of mitogen-
activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci U S A 92: 
8881-8885. 
Reynolds, C.H., Utton, M.A., Gibb, G.M., Yates, A., and Anderton, B.H. (1997) Stress-activated protein 
kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 68: 1736-1744. 
Ridley, A.J., and Hall, A. (1992) The small GTP-binding protein rho regulates the assembly of focal 
adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399. 
Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D., and Hall, A. (1992) The small GTP-binding 
protein rac regulates growth factor-induced membrane ruffling. Cell 70: 401-410. 
Rocchi, A., Pellegrini, S., Siciliano, G., and Murri, L. (2003) Causative and susceptibility genes for 
Alzheimer's disease: a review. Brain Res Bull 61: 1-24. 
Roher, A.E., Chaney, M.O., Kuo, Y.M., Webster, S.D., Stine, W.B., Haverkamp, L.J., Woods, A.S., 
Cotter, R.J., Tuohy, J.M., Krafft, G.A., Bonnell, B.S., and Emmerling, M.R. (1996) Morphology 
and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alz-
heimer's disease. J Biol Chem 271: 20631-20635. 
Rollins, B.L., Stines, S.G., McGuire, H.B., and King, B.M. (2001) Effects of amygdala lesions on body 
weight, conditioned taste aversion, and neophobia. Physiol Behav 72: 735-742. 
Roozendaal, B., Phillips, R.G., Power, A.E., Brooke, S.M., Sapolsky, R.M., and McGaugh, J.L. (2001) 
Memory retrieval impairment induced by hippocampal CA3 lesions is blocked by adrenocorti-
cal suppression. Nat Neurosci 4: 1169-1171. 
Roozendaal, B., Griffith, Q.K., Buranday, J., De Quervain, D.J., and McGaugh, J.L. (2003) The hippo-
campus mediates glucocorticoid-induced impairment of spatial memory retrieval: dependence 
on the basolateral amygdala. Proc Natl Acad Sci U S A 100: 1328-1333. 
Sanger, F., Nicklen, S., and Coulson, A.R. (1977) DNA sequencing with chain-terminating inhibitors. 
Proc Natl Acad Sci U S A 74: 5463-5467. 
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-
Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., 
Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., 
Games, D., and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-
disease-like pathology in the PDAPP mouse. Nature 400: 173-177. 
Schenk, D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat 
Rev Neurosci 3: 824-828. 
Schiffman, S.S., Clark, C.M., and Warwick, Z.S. (1990) Gustatory and olfactory dysfunction in demen-
tia: not specific to Alzheimer's disease. Neurobiol Aging 11: 597-600. 
Schweers, O., Schonbrunn-Hanebeck, E., Marx, A., and Mandelkow, E. (1994) Structural studies of 
tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol 
Chem 269: 24290-24297. 
Senior, K. (2002) Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 1: 3. 
Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, 
G., Holman, K., and et al. (1995) Cloning of a gene bearing missense mutations in early-onset 
familial Alzheimer's disease. Nature 375: 754-760. 
Shulman, J.M., and Feany, M.B. (2003) Genetic modifiers of tauopathy in Drosophila. Genetics 165: 
1233-1242. 
5 REFERENCES 
99 
Sinha, S., and Lieberburg, I. (1999) Cellular mechanisms of beta-amyloid production and secretion. 
Proc Natl Acad Sci U S A 96: 11049-11053. 
Sisodia, S.S., and St George-Hyslop, P.H. (2002) gamma-Secretase, Notch, Abeta and Alzheimer's 
disease: where do the presenilins fit in? Nat Rev Neurosci 3: 281-290. 
Sobrido, M.J., Miller, B.L., Havlioglu, N., Zhukareva, V., Jiang, Z., Nasreddine, Z.S., Lee, V.M., Chow, 
T.W., Wilhelmsen, K.C., Cummings, J.L., Wu, J.Y., and Geschwind, D.H. (2003) Novel tau 
polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. 
Arch Neurol 60: 698-702. 
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J., White, C.L., 3rd, 
Mumby, M.C., and Bloom, G.S. (1999) Molecular interactions among protein phosphatase 2A, 
tau, and microtubules. Implications for the regulation of tau phosphorylation and the develop-
ment of tauopathies. J Biol Chem 274: 25490-25498. 
Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M., and Frangione, B. (1998) Beta-
sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications 
for Alzheimer's therapy. Nat Med 4: 822-826. 
Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A., and Ghetti, B. (1998) Mutation in 
the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci 
U S A 95: 7737-7741. 
Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, 
H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R., and Van Leuven, F. (1999) Prominent 
axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human 
tau protein. Am J Pathol 155: 2153-2165. 
Sumi, S.M., Bird, T.D., Nochlin, D., and Raskind, M.A. (1992) Familial presenile dementia with psy-
chosis associated with cortical neurofibrillary tangles and degeneration of the amygdala. Neu-
rology 42: 120-127. 
Tanemura, K., Akagi, T., Murayama, M., Kikuchi, N., Murayama, O., Hashikawa, T., Yoshiike, Y., Park, 
J.M., Matsuda, K., Nakao, S., Sun, X., Sato, S., Yamaguchi, H., and Takashima, A. (2001) 
Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. 
Neurobiol Dis 8: 1036-1045. 
Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., Yamaguchi, H., 
and Takashima, A. (2002) Neurodegeneration with tau accumulation in a transgenic mouse 
expressing V337M human tau. J Neurosci 22: 133-141. 
Tatebayashi, Y., Miyasaka, T., Chui, D.H., Akagi, T., Mishima, K., Iwasaki, K., Fujiwara, M., Tane-
mura, K., Murayama, M., Ishiguro, K., Planel, E., Sato, S., Hashikawa, T., and Takashima, A. 
(2002) Tau filament formation and associative memory deficit in aged mice expressing mutant 
(R406W) human tau. Proc Natl Acad Sci U S A 99: 13896-13901. 
Thal, D.R., Rub, U., Orantes, M., and Braak, H. (2002) Phases of A beta-deposition in the human 
brain and its relevance for the development of AD. Neurology 58: 1791-1800. 
Treit, D., and Menard, J. (1997) Dissociations among the anxiolytic effects of septal, hippocampal, and 
amygdaloid lesions. Behav Neurosci 111: 653-658. 
Ueda, T., Kikuchi, A., Ohga, N., Yamamoto, J., and Takai, Y. (1990) Purification and characterization 
from bovine brain cytosol of a novel regulatory protein inhibiting the dissociation of GDP from 
and the subsequent binding of GTP to rhoB p20, a ras p21-like GTP-binding protein. J Biol 
Chem 265: 9373-9380. 
Upchurch, M., and Wehner, J.M. (1988) Differences between inbred strains of mice in Morris water 
maze performance. Behav Genet 18: 55-68. 
Upchurch, M., and Wehner, J.M. (1989) Inheritance of spatial learning ability in inbred mice: a classi-
cal genetic analysis. Behav Neurosci 103: 1251-1258. 
Van Broeckhoven, C., Backhovens, H., Cruts, M., De Winter, G., Bruyland, M., Cras, P., and Martin, 
J.J. (1992) Mapping of a gene predisposing to early-onset Alzheimer's disease to chromo-
some 14q24.3. Nat Genet 2: 335-339. 
5 REFERENCES 
100 
van Swieten, J.C., Stevens, M., Rosso, S.M., Rizzu, P., Joosse, M., de Koning, I., Kamphorst, W., 
Ravid, R., Spillantini, M.G., Niermeijer, M.F., and Heutink, P. (1999) Phenotypic variation in 
hereditary frontotemporal dementia with tau mutations. Ann Neurol 46: 617-626. 
Varani, L., Hasegawa, M., Spillantini, M.G., Smith, M.J., Murrell, J.R., Ghetti, B., Klug, A., Goedert, M., 
and Varani, G. (1999) Structure of tau exon 10 splicing regulatory element RNA and destabili-
zation by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. 
Proc Natl Acad Sci U S A 96: 8229-8234. 
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., 
Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., 
Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G., and Cit-
ron, M. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the trans-
membrane aspartic protease BACE. Science 286: 735-741. 
Welzl, H., D'Adamo, P., and Lipp, H.P. (2001) Conditioned taste aversion as a learning and memory 
paradigm. Behav Brain Res 125: 205-213. 
Wischik, C.M., Crowther, R.A., Stewart, M., and Roth, M. (1985) Subunit structure of paired helical 
filaments in Alzheimer's disease. J Cell Biol 100: 1905-1912. 
Wittmann, C.W., Wszolek, M.F., Shulman, J.M., Salvaterra, P.M., Lewis, J., Hutton, M., and Feany, 
M.B. (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Sci-
ence 293: 711-714. 
Wolfer, D.P., Muller, U., Stagliar, M., and Lipp, H.P. (1997) Assessing the effects of the 129/Sv genetic 
background on swimming navigation learning in transgenic mutants: a study using mice with a 
modified beta-amyloid precursor protein gene. Brain Res 771: 1-13. 
Wolfer, D.P., and Lipp, H.P. (2000) Dissecting the behaviour of transgenic mice: is it the mutation, the 
genetic background, or the environment? Exp Physiol 85: 627-634. 
Wolfer, D.P., Madani, R., Valenti, P., and Lipp, H.P. (2001) Extended analysis of path data from mu-
tant mice using the public domain software Wintrack. Physiol Behav 73: 745-753. 
Wright, J.W., Murphy, E.S., Elijah, I.E., Holtfreter, K.L., Davis, C.J., Olson, M.L., Muhunthan, K., and 
Harding, J.W. (2004) Influence of hippocampectomy on habituation, exploratory behavior, and 
spatial memory in rats. Brain Res 1023: 1-14. 
Yamamoto, T., Fujimoto, Y., Shimura, T., and Sakai, N. (1995) Conditioned taste aversion in rats with 
excitotoxic brain lesions. Neurosci Res 22: 31-49. 
Yasuda, M., Kawamata, T., Komure, O., Kuno, S., D'Souza, I., Poorkaj, P., Kawai, J., Tanimukai, S., 
Yamamoto, Y., Hasegawa, H., Sasahara, M., Hazama, F., Schellenberg, G.D., and Tanaka, 
C. (1999) A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degen-
eration. Neurology 53: 864-868. 
Zheng-Fischhofer, Q., Biernat, J., Mandelkow, E.M., Illenberger, S., Godemann, R., and Mandelkow, 
E. (1998) Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein 
kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 
and requires a paired-helical-filament-like conformation. Eur J Biochem 252: 542-552. 
Zhong, J., Iqbal, K., and Grundke-Iqbal, I. (1999) Hyperphosphorylated tau in SY5Y cells: similarities 
and dissimilarities to abnormally hyperphosphorylated tau from Alzheimer disease brain. 
FEBS Lett 453: 224-228. 
Zhu, X., Raina, A.K., Boux, H., Simmons, Z.L., Takeda, A., and Smith, M.A. (2000) Activation of onco-
genic pathways in degenerating neurons in Alzheimer disease. Int J Dev Neurosci 18: 433-
437. 
Zhu, X., Raina, A.K., Rottkamp, C.A., Aliev, G., Perry, G., Boux, H., and Smith, M.A. (2001) Activation 
and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating 
neurons in Alzheimer's disease. J Neurochem 76: 435-441. 
ABBREVIATIONS 
101 
ABBREVIATIONS 
 
aa    Amino acids 
ACo   Anterior cortical amygdaloid nucleus 
AD    Alzheimer's disease 
AIP   Agranular insular cortex 
Amb    Ambiguus nucleus 
ANOVA  One-way analysis of variance 
AP   Anteroposterior 
ApoE   Apolipoprotein E 
APP    Amyloid precursor protein 
APPα   Soluble extracellular fragment of APP generated by α-cleavage 
APPβ   Soluble extracellular fragment of APP generated by β-cleavage 
Aβ   β-amyloid 
BACE   β-site APP cleaving enzyme 
BDNF   Brain-derived neurotrophic factor 
BLA   Basolateral nucleus of the amygdala 
BM   Basomedial nucleus of the amygdala 
bp    Base pair 
BSA   Bovine serum albumin 
C83   C-terminal fragment of APP generated by a α-secretase 
C99   C-terminal fragment of APP generated by a β-secretase 
CBD   Corticobasal degeneration 
CE    Central nucleus of the amygdala 
CNS    Central nervous system 
CS    Conditioned stimulus 
CTA   Conditioned taste aversion 
ddH2O   Double deionised water 
DEn   Dorsal endopiriform nucleus  
DMEM   Dulbecco’s modified Eagle medium 
DMSO   Dimethylsulfoxid 
DNA    Deoxyribonucleic acid 
dNTP    Deoxynucleoside triphosphate 
Dox   Doxycycline 
DTT    DiThioThreitol 
E. coli    Escherichia coli 
ECIC   External cortex of the inferior colliculus 
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EDTA    Ethylenediamine tetraacetic acid 
FA   Formic acid 
FAD    Familial Alzheimer's disease 
FCS    Fetal calf serum 
FTDP-17  Frontotemporal dementia with Parkinsonism linked to chromosome 17  
GFAP    glial fibrillary acidic protein 
HEK 293   Human embryonal kidney cells 
HS   Horse serum 
IC   Insular cortex 
IO    Inferior olive 
IP   Immunoprecipitation 
i.p.   Intraperitoneal 
L/D    Light-dark test 
LA    Lateral nucleus of the amygdala 
LB-medium   Luria-Bertani medium 
LiCl   Lithium chlorid 
MALDI-TOF Matrix-assisted laser desorption/ionization tandem time-of-flight mass 
spectrometry 
MWM   Morris water maze 
NFT    Neurofibrillary tangles 
ORF    Open reading frame 
PBS   Phosphate buffered saline 
PCR    Polymerase chain reaction 
PFA   Paraformaldehyde 
PHF   Paired helical filaments 
PiD    Pick’s disease 
PMCo   Posteromedial cortical amygdaloid nucleus 
PMSF   Phenyl-methyl-sulfonyl-fluoride 
PnO   Oral pontine reticular nucleus 
PS 1+2   Presenilin 1+2 
PSP   Progressive supranuclear palsy  
RA   Retinoic acid 
RAB   High-salt reassembly buffer 
RIPA   Radioimmunoprecipitation buffer 
RNA    Ribonucleic acid 
RPC   Red nucleus (parvocellular part) 
rpm    Rotations per minute 
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RPO    Rostral periolivary region 
rtTA    Transactivator 
RtTG    Reticulotegmental nucleus pons 
SAD   Sporadic Alzheimer’s disease 
SDS    Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamid gel electrophoresis 
SEM   Standard error of the mean 
SF   Straight filaments  
SH-SY5Y   Human neuroblastoma cell line 
TET   Tetracycline 
Tg   Transgenic 
TRE    Tet-response element 
Tris   Tris(hydroxymethyl)-amino-methane 
US    Unconditioned stimulus 
VTA    Ventral tegmental area 
WB   Western blot 
wt    Wild-type 
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Accelerated extinction of conditioned taste aversion
in P301L tau transgenic mice
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Neurofibrillary tangles, insoluble protein deposits composed of filamen-
tous tau aggregates, are neuropathological hallmarks of Alzheimer’s
disease and familial frontotemporal dementia (FTDP-17). Transgenic
mice expressing the FTDP-17 mutation P301L of tau recapitulate key
features of the human pathology, that is, tau proteins aggregate and
neurofibrillary tangles begin to appear in the amygdala at 6 months of
age. To detect early signs of tau aggregate-associated changes, we
investigated behavioral alterations and cognitive deficits in such mice
using an amygdala-specific test battery for anxiety-related and cognitive
behavior. P301L mice had anxiety levels not different from wild-types,
but their exploratory behavior was significantly increased. Acquisition
of a fear response to tone and context as well as taste aversion was
comparable to wild-types. However, extinction of a conditioned taste
aversion was significantly accelerated. We conclude that already
aggregation of tau proteins not yet accompanied by massive formation
of neurofibrillary tangles causes selective behavioral deficits.
D 2004 Elsevier Inc. All rights reserved.
Keywords: Alzheimer’s disease; Frontotemporal dementia; Tau; Transgenic
mice; Conditioned taste aversion; Amygdala; Neurofibrillary tangles;
Extinction
Introduction
Alzheimer’s disease (AD) and frontotemporal dementia with
Parkinsonism linked to chromosome 17 (FTDP-17) are common
forms of age-related dementing diseases. Whereas AD is charac-
terized by extracellular h-amyloid-containing plaques and intracel-
lular neurofibrillary tangles (NFT), in neurodegenerative diseases
such as FTDP-17, NFT form in the absence of amyloid plaques
(Gotz, 2001; Lee et al., 2001). In cells affected in these tauopathies,
the microtubule-associated protein tau is abnormally phosphory-
lated and relocalized from axonal to somatodendritic compartments
where it accumulates in pretangle, filamentous aggregates that
eventually assemble into NFT (Buee et al., 2000; Goedert et al.,
1995). The discovery of mutations in the tau gene in FTDP-17
established that dysfunction of tau alone can cause neurodegenera-
tion and lead to dementia (Hutton et al., 1998; Poorkaj et al., 1998;
Spillantini et al., 1998).
Expression of FTDP-17 mutant tau in transgenic mice caused
NFT formation both in neurons (Allen et al., 2002; Gotz et al.,
2001a; Lewis et al., 2000; Tanemura et al., 2001; Tatebayashi et al.,
2002) and in glial cells (Gotz et al., 2001b; Higuchi et al., 2002;
Lin et al., 2003). Whereas extensive behavioral studies have been
performed in h-amyloid-forming APP transgenic mice (Chapman
et al., 1999; Chen et al., 2000; Dodart et al., 1999; Hsiao et al.,
1996; Janus et al., 2000; Morgan et al., 2000; Routtenberg et al.,
1997), less information is available for tau mutant mice (Tanemura
et al., 2002; Tatebayashi et al., 2002). We investigated our P301L
(FTDP-17) mutant mice in several amygdala-dependent tasks
because tau aggregates mainly formed in the amygdala (Gotz et
al., 2001c). This brain area is involved in mediating effects of
emotion and stress on learning and memory as determined in fear
conditioning and conditioned taste aversion (CTA) tests (LeDoux,
2000; Welzl et al., 2001). It plays a role in modulating consolida-
tion processes which involve other brain areas (McGaugh et al.,
2002). To correlate behavior with tau expression, we determined
the distribution of P301L tau in more detail with special emphasis
on brain areas shown to be involved in CTA.
We found that the P301L mice showed increased exploratory
behavior but normal anxiety levels and no impairment in fear
conditioning. CTA is a well-established learning and memory
paradigm in which subjects learn to associate a novel taste with
nausea and, as a consequence, avoid consumption of this specific
taste at the next presentation. Acquisition and consolidation of
CTA memory were not significantly affected by the transgene.
However, transgenic mice extinguished the CTA more rapidly than
wild-type mice. Together, our data show that tau aggregation, as
found in particular in the basolateral and basomedial nucleus of the
amygdala, has functional consequences for specific forms of
learning and memory.
Materials and Methods
Animals
The transgenic mice used in this study express the human
pathogenic mutation P301L of tau together with the longest
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human brain tau isoform (htau40) under control of the neuron-
specific mThy1.2 promoter. Pronuclear injections were done into
C57Bl/6  DBA/2 F2 oocytes to obtain founder animals that were
back-crossed with C57Bl/6 mice to establish transgenic lines (Gotz
et al., 2001a). Line pR5-183 expressed mutant human tau in many
brain areas; however, NFT formation was mainly confined to the
amygdala (Gotz et al., 2001c). Here, male wild-type (wt) and
P301L mice were sequentially analyzed in two sets, which were
balanced for the genotype and subjected to behavioral tests at the
age of 6 months when NFT began to form. Data were pooled, as no
statistically significant differences were found between sets.
Group-housed mice were transferred to individual cages at 6
months of age when testing began. They were kept under an
inverted 12 h light/dark cycle with a room temperature of 22jC.
Food pellets and water were available ad libitum unless otherwise
noted. Thirty minutes before each test session, the mice were
transferred to the behavioral room.
Histology
Coronal 4-Am paraffin brain sections were immunohistologi-
cally stained as previously described (Gotz and Nitsch, 2001;
Gotz et al., 2001a) and brain areas were mapped based on the
mouse atlas by Paxinos (1997). Sections were dehydrated in an
ascending series of ethanol, stained and flat-embedded between
glass slides and coverslips in Eukitt (Kindler, Germany). For
signal enhancement, sections were microwave-treated in citrate-
buffer pH 5.8 at 70jC for 15 min. They were stained with the
human tau-specific antibody HT7 (Innogenetics Inc, diluted
1:200) and the phosphorylation-dependant anti-tau antibody
CP13 (Dr. Peter Davies, diluted 1:200) directed against phosphor-
ylated S202/T205. For the peroxidase/DAB stainings, secondary
antibodies were obtained from Vector Laboratories (Vectastain
ABC kits PK-6101 and PK-6102).
Motor coordination on the Rotarod
The body weight was determined at 6 and again at 8 months of
age, when the CTA test was performed. To test locomotor
coordination, the accelerating Rotarod (Udo Basile, Milano, Italy)
was used which consists of a rotating drum with a diameter of 3 cm
covered with knurled Perspex to provide an adequate grip. The
mice were first placed on the rod at the lowest speed of 4 rpm for 2
min. Only then the rod was switched to acceleration mode and the
time on the rod was recorded for up to 5 min when the speed
reached the maximum of 40 rpm. Mice were assessed daily in two
trials on three consecutive days, with an intertrial interval of at least
3 h.
Open-field test
The open-field test analyzes spontaneous locomotor activity,
exploratory behavior, and anomalies of locomotion patterns. Mice
were placed at the border of a dimly lit (50 lx) circular arena
(diameter of 150 cm) for 10 min followed by a second session on
the following day. The arena was divided into an outer zone
(within 7 cm of the wall), an inner zone (inner circle with a
diameter of 110 cm), and an intermediate zone. Paths were tracked
with an electronic imaging system (EthoVision 1.96, Noldus
Information Technology, Wageningen, The Netherlands) at a
frequency of 4.2 Hz and a spatial resolution of 256  256 pixels.
Raw data were analyzed with the Wintrack 2.3 software (Wolfer et
al., 2001). Locomotor activity was assessed by measuring the total
distance traveled and the total number of zone transitions. Thig-
motaxis, that is, moving along the wall, was quantified by
measuring the time spent in the outer zone. To determine measures
of anxiety and exploratory behavior, the following parameters were
assessed: number of visits to the inner zone, average distance to
inner zone, and the number of activity state changes. Three activity
states were distinguished: progression (periods with a locomotion
speed above the progression threshold of 0.085 m/s and a minimal
distance moved exceeding 0.05 m), resting (periods lasting at least
2 s with a speed below 0.025 m/s) and scanning (periods meeting
neither resting nor progression criteria).
Light–dark (L–D) test
Unconditioned anxiety-like behavior was tested in the light–
dark (L–D) test. The mice were placed into the 30  20 cm area
of a Perspex L–D box that was illuminated with an average of
700 lx. A dark compartment of 15  20 cm was attached opposite
to the releasing site with an opening facing the center of the
illuminated part. Movements were tracked in the illuminated part
over a 5-min trial as described above. Anxiety was measured by
the latency to enter the dark compartment and the time spent in it.
Exploration was defined by the number of rearings in the
illuminated part, and the percentage of visited tiles/total of 36
tiles (5  3.3 cm) entered with all four paws, defined as
exploration index.
Fear conditioning test
The conditioning chamber consisted of a gray opaque box
(16.5  25 cm) with a grid floor through which shocks could be
delivered (0.15 mA) as the unconditioned stimulus (US). The
chamber was placed into a dimly lit sound-attenuating box with a
speaker on top delivering a 92 dB/2000 Hz tone as the conditioned
stimulus (CS). Two measures were used to quantify freezing as the
conditioned reaction: a grid of photobeams (1  1 cm) detected the
inactivity of the mice, which was defined as no photobeam breaks
for at least 2 s. Freezing was also detected manually while
observing the animal and was defined as no movement except
for respiration (as defined and applied by the experimenter). The
two measures correlated well with each other. However, we finally
used the manually detected measurement due to technical prob-
lems with the photobeams during cue testing: sawdust was used in
the new environment and unfortunately, from time to time, the
photobeams were concealed, which caused a higher, inappropriate
measurement of inactivity. During the conditioning session, a 1-
min adaptation period in the box was followed by three identical
conditioning trials, each trial consisting of 30-s CS presentation,
with the US being applied during the last 2 s of the CS, separated
by an intertrial interval of 30 s.
Retrieval tests for context conditioning and, 2 h later, for
conditioning to tone were carried out 24 h and 15 days after the
conditioning session by recording freezing as mentioned above. To
evaluate context conditioning, mice were placed for 2 min in the
conditioning chamber. To evaluate conditioning to tone, the
physical characteristics of the chamber were changed (shape, light,
smell, and bedding material). Each mouse was then placed for 2
min into this new chamber, and the CS was presented throughout
the second minute.
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Conditioned taste aversion test (CTA)
For the first 4 days of the experiment, water-deprived mice
were adapted to obtain water only during two daily drinking
sessions, a morning session lasting 20 min and an afternoon
session lasting 10 min, with a 4-h intertrial interval. Water was
presented in two 15-ml bottles that were weighed before and after
the test to measure fluid intake. During the morning session on the
conditioning day, mice were only allowed to drink a 0.5%
saccharin solution (CS) (saccharin sodium salt hydrate, Fluka
Chemie, Buchs, Switzerland) from one bottle. 40 min later, the
mice were injected intraperitoneally with a 0.14 M LiCl solution
(at 2% of body weight) as the nausea-inducing agent (US). Two
days after conditioning, during the 20-min morning session, all
mice could drink either tap water from one bottle or a 0.5%
saccharin solution from another bottle (two-bottle choice test). The
percentage of saccharin consumption per total fluid intake was
calculated. Extinction was determined by repeating the choice
tests 3 days after conditioning and on 3 consecutive days,
beginning 1 week after conditioning. The mice of the second
set were analyzed in three additional choice tests starting 5 weeks
following conditioning.
To determine whether P301L mice were able to discriminate
basic taste qualities, a separate group of water-deprived naive mice
was adapted to the drinking schedule as described above. Then,
they were tested for their natural preference for a 0.5% saccharin
solution in a choice test with the second bottle filled with tap water.
Finally, to determine the natural aversion towards a bitter taste, a
choice test between a 0.02% quinine solution (quinine hydrochlo-
ride dihydrate, Fluka, Buchs, Switzerland) and water was carried
out.
Data analysis
For statistical analysis, the SPSS software was used. Between-
group comparisons were analyzed using a one-way analysis of
variance (ANOVA) or a two-way ANOVAwith repeated measures.
Significant effects were analyzed post hoc using Fisher’s PLSD
(protected least significant difference) for pairwise comparison. All
data are represented as mean F SEM with a statistical significance
given at P < 0.05.
Results
Expression pattern of P301L tau
To determine the expression pattern of human P301L tau in
more detail, with special emphasis on brain areas involved in the
CTA task, we analyzed frontal sections of four P301L tau
expressing mice by immunohistochemistry using the human tau-
specific antibody HT7 and the phosphorylation-dependant anti-tau
antibody CP13 (Fig. 1). We found expression of human tau in the
motor, somatosensory and insular cortex (IC) and in the claustrum
at position AP +1.1 mm. At AP 0.82, tau was present in cortical
motor and somatosensory neurons, and to a variable degree in the
posterior part of the agranular insular cortex (AIP), in the anterior
cortical amygdaloid nucleus (ACo) and different regions of the
thalamus. At position AP 1.34, expression was found in the
cortex, in the basolateral (BLA) and the basomedial nucleus of the
amygdala (BM), in the dorsal endopiriform nucleus (DEn) and in
Fig. 1. Expression pattern of tau in P301L tau transgenic mice. (A) Areas
involved in CTA are shown in gray: IC, insular cortex; VPM, ventral
posteromedial nucleus of the thalamus; LH, lateral hypothalamus; Am,
amygdala; PbN, parabrachial nucleus and NTS, nucleus of the solitary tract.
(B) Tau was expressed in the cortex, hippocampus and adjacent brain areas.
(C) Higher magnification of tau expression in the IC and CL (claustrum),
(D) the hippocampus, (E) the DEn (dorsal endopiriform nucleus), the BLA
(basolateral nucleus), and BM (basomedial nucleus) of the amygdala, the
Astr (amygdalostriatal transition area), but not in the lateral nucleus (LA)
and the central nucleus of the amygdala (CE). (F) Tau was expressed in the
brain stem. (G) Higher magnification of (F) shows high tau expression in
motor neurons of the brain stem. (H) The amygdala of a wild-type mouse is
shown as a negative control. The sections were stained with the human tau-
specific antibody HT7 (B, D, F, G, H) and the phospho-tau specific
antibody CP13 (C, E).
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the ACo. No tau expression was found in the lateral nucleus (LA)
and the central nucleus of the amygdala (CE). HT7 staining
revealed also a strong expression of human tau in the hippocam-
pus (CA1, CA3, and dentate gyrus), whereas staining of these
brain areas with the CP13 antibody was very weak. However,
both antibodies strongly stained the posterior part of these
hippocampal regions at position AP 2.92 (where human tau
was also expressed in cortical neurons), the posterior part of the
basolateral amygdala, and to a variable degree, neurons in the red
nucleus (parvocellular part, RPC), the ventral tegmental area
(VTA) and the posteromedial cortical amygdaloid nucleus
(PMCo). At AP 4.60, tau was present in cortical neurons,
especially in the lateral entorhinal cortex and the external cortex
of the inferior colliculus (ECIC) and to a variable degree in the
oral pontine reticular nucleus (PnO), the rostral periolivary region
(RPO) and the reticulotegmental nucleus pons (RtTG). Particularly
high levels of expression were found in the brain stem (AP 7.20),
predominantly in the inferior olive (IO), the ambiguus nucleus
(Amb), and in various parts of the reticular formation and medulla.
In contrast to the tau expression in the BLA, IC, and some
thalamic nuclei, no expression was found in CTA-relevant areas
such as the ventral posteromedial nucleus of the thalamus (VPM),
the parabrachial nucleus (PBN), and the nucleus of the solitary
tract (NTS).
Weight reduction and motor coordination of P301L tau transgenic
mice
At the beginning of experiments, body weights of wild-types
(38.2 F 2.2 g) were significantly higher than that of P301L tau
transgenic mice (33.0 F 1.2 g; P < 0.04) (wt: N = 21; P301L: N =
20). This difference was even more pronounced during the CTA
task (wt: 36.4F 1.2 g; P301L: 30.2F 0.8 g; P < 0.001) (Fig. 2). To
test whether expression of the transgene affected locomotor coor-
dination, the accelerating Rotarod test was performed (N = 11/
group). P301L mice stayed significantly longer on the Rotarod than
wt mice (wt: 124.3 F 14.2 s; P301L: 178.2 F 17.5 s; F(1,20) =
5.316, P < 0.032) and therefore reached a significantly higher
average speed (wt: 18.7 F 2.0 rpm; P301L: 25.3 F 2.3 rpm;
F(1,20) = 4.647, P < 0.043) before slipping off the rod. However,
when the data were normalized for weight (by calculating a weight
coefficient), the differences between the two groups disappeared
(F(1,20) = 0.364, P > 0.553), demonstrating a correlation between
weight and performance on the Rotarod.
Slightly increased exploration of P301L mice in the open-field and
light–dark test
Levels of spontaneous locomotor activity, anxiety-like behavior
and exploration were assessed in the open-field and light–dark
(L–D) tests. In the open-field test (N = 21/group), no genotype
Fig. 2. Weight reduction of P301L mice. The weight of the P301L mice was
significantly reduced at the onset of the experiment ( P < 0.04) and, more
pronounced, during the CTA task ( P < 0.001). The values represent the
mean F SEM.
Fig. 3. No altered activity levels of P301L mice in the open-field test but
slightly increased exploratory behavior. (A) Total distance moved; (B)
average distance to exploration zone; and (C) total number of activity state
changes. Values represent the mean F SEM.
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effect was found for measures of locomotor activity [total distance
traveled: F(1,40) = 2.587, P > 0.116; total number of zone
transitions: F(1,40) = 0.003, P > 0.956]. Similarly, no differences
were found for measures of anxiety such as thigmotaxis (F(1,40) =
0.119, P > 0.732), the time spent in the inner zone (F(1,40) =
0.473, P > 0.496), and the average distance to the inner zone
(F(1,40) = 0.347, P > 0.559). Only for the total number of activity
state changes a significant genotype effect was detected (F(1,40) =
6.469, P < 0.015) (Fig. 3).
No significant differences were found in the L–D test (wt: N =
20; P301L: N = 21) for measures of anxiety such as the latency to
enter the dark compartment (F(1,39) = 0.082, P > 0.776) and the
time spent in the dark compartment (F(1,39) = 0.040, P > 0.843).
In contrast, additional parameters for exploration such as the
number of rearings ( F(1,39) = 4.624, P < 0.038), and the
exploration index (F(1,39) = 4.078, P < 0.050) were significantly
increased in P301L tau transgenic mice (Fig. 4).
No altered fear conditioning in P301L mice
To test the ability of P301L mice to acquire a conditioned fear
response, freezing was recorded during the conditioning session as
well as the retrieval sessions for conditioning to context or tone.
During conditioning, freezing increased significantly in both groups
after the first US has been delivered (F(7,273) = 38.022, P < 0.001;
wt: N = 21; P301L: N = 20; Fig 5A). Neither genotype nor genotype
 interval significantly affected freezing during conditioning (ge-
notype: F(1,39) = 2.857, P > 0.099; genotype  interval: F(7,273)
= 1.436, P > 0.191), although freezing levels of transgenic mice
consistently were below that of wild-type mice (Fig. 5A).
During the retrieval test for context conditioning, no significant
differences between transgenic and wild-type mice could be found
24 h (F(1,39) = 0.344, P > 0.561) (wt: N = 21; P301L: N = 20) as
well as 15 days (F(1,19) = 0.242, P > 0.629) (wt: N = 11; P301L:
N = 10) post-conditioning (Fig. 5B). No significant genotype
Fig. 4. No altered anxiety levels of P301L mice in the light–dark test but slightly increased exploratory behavior. (A) Latency to enter the dark compartment;
(B) time spent in the dark compartment; (C) number of rearings; and (D) exploration index. Values represent the mean F SEM.
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effect was observed in freezing during the retrieval test for
conditioning to tone, neither at 24 h (F(1,39) = 0.013, P >
0.911) nor at 15 days ( F(1,19) = 0.068, P > 0.798) post-
conditioning. Freezing significantly increased in response to tone
presentation (second minute of the test) in both groups (24 h:
F(3,117) = 34.287, P < 0.001, 15 days: F(3,57) = 112.458, P <
0.001) demonstrating that wild-type as well as P301L mice learned
to associate the tone with the US. Tone presentation elicited a
similar increase of freezing in both groups (genotype  interval
interaction: 24 h: F(3,117) = 0.776, P > 0.510, 15 days: F(3,57) =
0.512, P > 0.676) (Fig. 5C).
Enhanced extinction of CTA in P301L mice
To test the ability to develop a taste aversion, P301L mice and
wild-type littermate controls (N = 19/group) were exposed to the
novel taste saccharin (CS) followed by a single injection of LiCl
(US). A two-way ANOVAwith repeated measures over the choice
tests conducted 48, 72 h and 1 week after conditioning showed a
significant main effect of genotype (F(1,36) = 8.167, P < 0.007),
choice test (F(4,144) = 8.352, P < 0.001), and genotype  choice
test interaction (F(4,144) = 3.266, P < 0.013) (Fig. 6A). Post hoc
Fig. 5. No altered fear conditioning in P301L mice. (A) Genotype did not
significantly affect freezing during conditioning ( P > 0.099). Base, baseline
activity; CS, tone presentation; ITI, inter-trial interval. (B) In the context
test, no significant differences between genotypes were detected, neither at
24 h ( P > 0.561) nor at 15 days ( P > 0.629) post-conditioning. (C)
Conditioning to tone also revealed no significant differences between
genotypes, neither at 24 h (P > 0.911) nor at 15 days (P > 0.798) post-
conditioning. The values represent the mean F SEM.
Fig. 6. Accelerated extinction of CTA in P301L mice. (A) During the first
choice test 48 h after conditioning no significant genotype effect was
observed ( P > 0.094). However, during all subsequent choice tests, 72 h and
1 week after conditioning, P301L mice consumed significantly more
saccharin (N = 19/group). Additionally, a subset of mice (N = 11/group) was
again tested 5 weeks after conditioning. P301L mice continued to show a
significantly accelerated extinction. (B) Basic taste qualities in naive mice
were not impaired by the tau pathology. Values represent the mean F SEM.
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pairwise comparisons revealed that during the first choice test 48
h after conditioning both groups developed a strong taste aversion
for saccharin (percentage of saccharin consumed: wt: 5.6 F 1.0%;
P301L: 9.8 F 2.1%; P > 0.094), indicating that acquisition and
consolidation of a taste aversion was not significantly impaired by
the tau pathology. However, during the second choice test, P301L
mice began to consume significantly more saccharin than wild-
types (P < 0.017), demonstrating a faster extinction of the taste
aversion. Repetition of these choice tests on 3 consecutive days
starting 1 week after conditioning showed that CTA memory in
wild-type mice extinguished slowly, whereas extinction was sig-
nificantly faster in transgenic mice. A subset of mice (N = 11/
group) was again exposed 5 weeks after conditioning to three such
choice tests. P301L mice still continued to show a significantly
accelerated extinction (main effect of genotype: F(1,20) = 5.404,
P < 0.031) (Fig. 6A). Neither the amount of water intake during the
last adaptation day before conditioning (wt: 1.34 F 0.07 g; P301L:
1.41 F 0.05 g; F(1,36) = 0.592, P > 0.447), nor the amount of
saccharin consumed on the conditioning day itself (wt: 1.27F 0.11
g; P301L: 1.35 F 0.06 g; F(1,36) = 0.339, P > 0.564) revealed a
significant effect of the transgene. In addition, total liquid intake
(water plus saccharin) of P301L mice did not differ significantly
from wild-type controls at any time point during the choice tests
(F(1,36) = 0.094, P > 0.761).
Basic taste qualities were assessed in water-deprived naive mice
(N = 11/group) by presenting saccharin and quinine solutions. This
did not reveal any significant differences between transgenic and
control mice (for saccharin: F(1,20) = 0.147, P > 0.706; and for
quinine: F(1,20) = 0.002, P > 0.968), indicating that P301L mice
possess a normal taste sensitivity (Fig. 6B).
Discussion
Our immunohistochemical and behavioral analysis of P301L
tau transgenic mice revealed a widespread aggregation of tau in the
forebrain that is accompanied by selective changes in behavior.
Behavioral changes include a small increase in exploratory behav-
ior and an accelerated extinction of an aversion against a taste that
has been previously paired with nausea. No changes, with respect
to wild-types, were found in locomotor activity, fear conditioning,
taste neophobia, and unconditioned natural taste preference for a
sweet solution and natural taste aversion against a bitter solution.
Extending previously published data, we found tau aggregation in
the forebrain in nuclei of the amygdalar complex, the hippocampus
and all areas of the neocortex investigated (sensory, motor, and
associative areas). Aggregates were also present in several brain
stem areas including the red nucleus, ventral tegmental area, and
parts of the reticular formation, inferior olive, and ambiguus
nucleus. At 6 months of age, NFT began to form in a subset of
amygdaloid neurons, possibly reflecting high relative levels of tau
expression and/or a selective vulnerability of distinct amygdaloid
nuclei (Gotz and Nitsch, 2001; Gotz et al., 2001c).
Our study also revealed that body weights of P301L mice were
slightly lower than that of wild-types already at the beginning of
behavioral testing. This weight difference was even larger during
the final (CTA) task of the test battery. Such a weight loss could be
due to disturbances in several different brain sites. In light of the
widespread appearance of tau aggregates in the brain, it would be
difficult to pinpoint the structure(s) responsible for the weight loss.
However, a defect that very unlikely contributes to the observed
weight loss is diminished amygdalar function since damage to
amygdaloid nuclei has been reported to cause either no change or
just the opposite, that is, weight gain in rats (Rollins et al., 2001).
In the open-field, P301L and wild-type mice moved equal
distances, but P301L mice changed their activity state somewhat
more often from progression to resting to scanning. Furthermore,
in the light–dark box they were more active and clearly increased
the frequency of rearing, all of which are signs for greater
exploratory behavior. In both the open-field and light–dark test,
measures of anxiety were unchanged. Several brain structures have
been found to be involved in exploratory behavior including the
hippocampus and amygdala. That the amygdala might be affected
in our transgenic mice is suggested by the observation that
amygdala lesions increase exploratory behavior (Kelley et al.,
1989). Dysfunction of the amygdala, however, would not affect
unconditioned anxiety as measured with an anxiety test (elevated
plus-maze) in rats (Treit and Menard, 1997).
Expression of the transgene and formation of tau aggregates in
the forebrain did not impair fear conditioning to tone or context.
When tested 15 days after conditioning, wild-types as well as
P301L mice also showed no signs of extinction and froze even
more in response to the conditioned stimuli (context, auditory cue).
The non-significant tendency of reduced freezing of P301L mice
only during conditioning remains puzzling, and to our knowledge,
no treatment with a similar selective effect has been described.
Anyhow, it is difficult to imagine how emotional or cognitive
changes could affect freezing during conditioning but not during
retrieval.
That P301L mice had no deficits in fear conditioning to a tone
is in agreement with the expression pattern of tau aggregates in
their brains. Conditioning to an auditory CS is dependent on
functionally intact lateral and central nuclei of the amygdala
(LeDoux, 2000), sites that were free of tau aggregates in our
transgenic mice. The involvement of the basolateral amygdala
(BLA), a site with tau aggregates in P301L mice, is less well
established (but see also Goosens and Maren, 2001). In contrast to
fear conditioning to a tone, successful context fear conditioning
depends on an intact hippocampus which projects to the BLA
(LeDoux, 2000). However, despite a prominent expression of
P301L tau in the hippocampus and the BLA of P301L mice, no
deficits were found in context fear conditioning compared with
control mice. This may be due to the design of the fear condition-
ing task that was probably not sensitive enough to reveal differ-
ences between the two groups. Similar to our P301L mice, aged
APPSwe mutant mice also showed no deficits in fear conditioning
to a tone or a context when compared to corresponding wild-types
(Corcoran et al., 2002). These APPSwe mice had h-amyloid plaques
in the hippocampus as well as the amygdala and a reduction in
function might have been expected. Only when the salience of the
context CS was reduced, an indication of impairment in APPSwe
mice appeared. The general lack of massive neurodegeneration in
animal models of AD may explain the largely normal performance
of both P301L and APPSwe mice in fear conditioning, which is in
contrast to the reported impaired fear conditioning in AD patients
(Hamann et al., 2002). This demonstrates the importance to design
highly sensitive protocols for the measurement of different behav-
ioral tasks.
P301L mice acquired a taste aversion indistinguishable from
that of wild-types; that is, when given a choice to drink either a
saccharin solution or water 2 days after pairing saccharin drinking
with nausea, both genotypes greatly preferred water and avoided
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the saccharin solution. However, repeated exposure to such a
choice situation attenuated the aversion, and this extinction was
drastically accelerated in P301L mice compared to wild-types. The
possibility has to be considered that a stronger conditioning in
wild-type mice might not have shown due to a flooring effect, that
is, wild-type mice performed already close to an optimum with no
further capacity of improvement.
The CTA deficits in P301L mice cannot be explained by a
reduced neophobia, an increased sweet preference or a reduced
aversion for unpleasantly tasting solutions. With respect to these
three traits, no genotype differences could be found. P301L, as well
as wild-type mice reduced their fluid intake, when first exposed to
the saccharin solution (neophobia) developed a strong preference
for the sweet solution when drinking was not followed by nausea,
and avoided a bitter-tasting quinine solution to the same degree.
Further, despite their slightly reduced body weight, P301L mice
did not consume less saccharin solution on the conditioning day,
that is, exposure to the conditioned stimulus was comparable in
both groups.
It has been suggested that lesions of the BLA have a general
effect on the response to novel stimuli (such as food) by decreasing
neophobia (Dunn and Everitt, 1988). However, in our study, no
attenuation of a taste neophobia was found. Thus, the observed
formation of tau aggregates in the amygdala in P301L mice very
unlikely caused a severe functional impairment of this structure.
Tau was expressed in brain areas which have been shown to be
involved in CTA including the BLA, the insular cortex, and some
thalamic nuclei (Welzl et al., 2001). No expression was found in
other CTA-relevant areas such as the ventral posteromedial nucleus
of the thalamus (VPM), the parabrachial nucleus (PBN), and the
nucleus of the solitary tract (NTS).
Little is known about what might accelerate extinction of CTA.
Several studies implicated hormonal systems, neurotransmitter
systems, or specific brain structures in CTA extinction (for review,
see Bures et al., 1998); but in general, these studies described
retarded, but not accelerated, extinction upon treatments. For
example, whereas hippocampal lesions affected acquisition of
CTA only mildly or not at all (Best and Orr, 1973; Yamamoto et
al., 1995), they slowed extinction of an already conditioned
aversion (Kimble et al., 1979). In one study, excitotoxic lesions
of the VPM had little effect on the acquisition of CTA but
markedly accelerated its extinction similar to what we observed
in our transgenic mice (Yamamoto et al., 1995). However, tau is
not expressed in the VPM of P301L mice.
Numerous studies support a critical involvement of the amyg-
dala in CTA (Aja et al., 2000; Lamprecht et al., 1997; Yamamoto et
al., 1995). Similar to its effect on other aversive memories, the
amygdala could modulate consolidation processes (e.g., of CTA) in
other brain areas via its projections to these areas (McGaugh et al.,
2002). Such a modulation could be achieved by pathways from the
amygdala to the insular cortex, a structure critical for storage of a
CTA. Stimulation in the BLA induced LTP in the insular cortex
which enhanced retention of CTA memory in subsequent extinc-
tion trials (Escobar and Bermudez-Rattoni, 2000). Overexpression
of P301L tau in the BLA could impair this modulatory effect
resulting in accelerated extinction, either directly or by weakening
the strength of the memory trace.
Interestingly, a recent study showed that the BLA is essential
for extinction of CTA memory whereas acquisition is dependent on
an intact central nucleus (Bahar et al., 2003). The differential effect
of tau aggregates on fear conditioning and CTA fits well with their
distribution pattern in the amygdala. We observed the aggregates in
the basolateral but not the lateral and central nucleus. In contrast to
CTA, fear conditioning to a tone is not dependent on an intact
BLA, but an intact lateral and central nucleus (for review, see
Bures et al., 1998; LeDoux, 2000). It also seems noteworthy to
mention that, again, APPSwe mice resemble to some degree P301L
mice. APPSwe mice expressed amyloid plaques in the amygdala
and were drastically impaired in the acquisition of a CTA and,
therefore, also in the extinction of this task (Janus et al., 2002).
AD patients exhibit an impairment at all levels of gustatory
information processing, in line with the notion of a dissociation
between preservation of olfactory and gustatory thresholds and an
alteration in odor identification in patients with mild stage AD,
suggesting that the alteration is central rather than peripheral
(Broggio et al., 2001). Significant losses in the ability to detect
the taste of glutamic acid and to recognize odorants were found in
demented AD and non-AD patients when compared with age-
matched controls (Schiffman et al., 1990). These findings are
consistent with our transgenic model as the P301L mice share
features of AD and FTD.
A range of behavioral tasks that did not include a test for CTA
have been performed with other transgenic mouse strains express-
ing a mutated form of tau. PrP promoter-driven P301L tau
transgenic mice strongly overexpress mutant tau in the brain and
in motor neurons of the spinal cord. They develop a progressive
motor phenotype commonly not observed in AD (Lewis et al.,
2000). V337M tau mutant mice, on the other hand, express mutant
tau only in the hippocampus, which is in contrast to our mice that
develop a more widespread tau pathology similar to the human tau
pathology. V337M mice show an increased locomotor activity and
memory deficits in the elevated plus maze, increased spontaneous
locomotion in the open-field, but no significant impairments in the
Morris water maze (Tanemura et al., 2002). R406W tau mutant
mice express tau at highest levels in the hippocampus and to a
lesser extent in other cortical and subcortical brain areas. However,
in the amygdala, only few cells strongly expressed mutant tau,
even in 16- to 23-month-old animals (Tatebayashi et al., 2002). Not
unexpectedly, the form of mutant tau and the type of promotor
controlling its expression in transgenic mice determines the ex-
pression pattern of tau pathology and, as a consequence, results in
very different behavioral phenotypes. The distribution of mutant
tau in P301L mice investigated in the present study is widespread
and comes close to the pattern of tau pathology observed in
patients. These mice also lack the motor disturbances observed
in other tau mutants, disturbances that are not characteristic of AD.
P301L mice share, however, some characteristics with behavioral
disturbances observed in APP mutant mice. Furthermore, distur-
bances can be detected already when mice are 6 months old. Thus,
we think that P301L mice are a good model to investigate the
contribution of tau pathology, as observed in AD and FTDP-17, to
behavioral disturbances.
In summary, although this investigation raised several questions
that have to be addressed in future studies, several conclusions on
the early effects of tau aggregation in transgenic P301L mutant tau
mice can be drawn. Firstly, in the open-field and light–dark box,
subtle signs for increased exploratory behavior were manifest in
P301L mice. Other behaviors indicative of general activity or
anxiety, however, were unaffected by the transgene. Secondly, fear
conditioning to tone or to context remained unaffected, probably
due to the specific distribution of tau aggregates in the amygdala,
and/or the design for this task that was probably not sensitive
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enough to detect differences. Thirdly, a selective alteration in the
extinction of a taste aversion could be seen in P301L mice. This,
again, resembles data collected in APPSwe mice submitted to a
similar paradigm. Thus, CTA suggests itself as a sensitive measure
of altered brain function in response to the formation of tau
aggregates. One possible common factor for all these results could
be a dysfunction of specific nuclei of the amygdala.
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